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ABSTRACT 
This thesis focuses on outcomes in hypertension in pregnancy, and the role of ambulatory 
blood pressure monitoring (ABPM). Overviews of blood pressure measurement and 
hypertension in pregnancy are followed by discussion of ABPM in non-pregnant and 
pregnant individuals. A literature review of research in ABPM in pregnancy is presented, 
revealing good prediction of certain outcomes. ABPM is recommended in chronic 
hypertension, identifying white coat hypertension and targeting intervention appropriately in 
pregnancy. An extensive database of hypertensive pregnancies is then analysed to assess 
outcomes in a local multi-ethnic population. Women with chronic hypertension are examined 
separately. Very high rates of stillbirth are evident, especially in women of Asian and Black 
ethnicity with growth-restricted babies.  
 
ABPM is then compared with sphygmomanometer measurements in 100 women using 
regression analysis, assessing prediction of perinatal outcomes. ABPM is superior in 
predicting low birth weight, prematurity and proteinuria. Finally, the first randomized 
controlled trial (RCT) of ABPM in pregnancy is presented. Hypertensive pregnant women 
were randomized to revealed or concealed ABPM results. Fewer women in the „revealed‟ 
group underwent induction of labour for hypertension. However, the reduction in overall 
rates of induction did not reach significance. Patient satisfaction was high. Randomized trials 
of ABPM in pregnancy are viable. Further RCTs particularly in chronic hypertensives are 
recommended. 
 
 
  
 
DEDICATION 
I dedicate this thesis to my family, with thanks and love: 
To my husband Matthew for his patience and support over the years,  
and my children Sam and Ellen. 
 
  
 
ACKNOWLEDGEMENTS 
This work was undertaken while I was a clinical research fellow at Good Hope Hospital 
from April 2002 to February 2004.  
 
I would like to acknowledge and thank:  
-Mr David Churchill, my supervisor, for formulating the protocols for the two ambulatory 
blood pressure monitoring studies, providing ongoing support and advice, and obtaining 
funding for the first year of research. 
-Professor Gareth Beevers, for permission to use his prospectively gathered database of 
women with hypertension in pregnancy under his care at City Hospital, Birmingham. 
-Dr Tim Marshall, Dept of Statistics at the University of Birmingham, for statistical advice  
-Library staff at Good Hope Hospital Education Centre for assistance with the literature 
search and obtaining articles 
-Medical and midwifery staff at Good Hope Hospital for supporting the trial of ABPM in 
pregnancy, especially the consultants for entering their patients into the trial and the 
midwives on the antenatal day unit. 
-All the women who agreed to participate in the trial 
-NHS Research and Development Fund for funding the first year of my research post. 
-John Dallas, rare books librarian at the Royal College of Physicians of Edinburgh, for 
permission to use images included in Chapter One.  
 
  
 
TABLE OF CONTENTS 
   
CHAPTER 1: INTRODUCTION                                          Page no. 
1.1 INTRODUCTION………….……………………………...………………………. 1 
1.1.1 General Introduction………………………………………………………… 2 
1.1.2 Literature search……………………………………………………………... 3 
1.2 BLOOD PRESSURE MEASUREMENT………………………………………….. 5 
1.2.1 History of blood pressure measurement……………………………………... 5 
1.2.2 Blood pressure measurement today………………………………………….. 9 
1.2.3 Possible sources of error……………………………………………………..11 
1.3  HIGH BLOOD PRESSURE IN PREGNANCY………........................................... 13 
1.3.1 Classification………………………………………………………………… 13 
1.3.2 Incidence and implications of high blood pressure in pregnancy…………… 16 
1.4  AMBULATORY BLOOD PRESSURE MONITORING ……… ………………... 18 
1.4.1 Ambulatory blood pressure monitoring: an overview……………………….. 18 
1.4.2 Review of ambulatory blood pressure monitoring  devices used  in  
pregnancy…………………………………………………………………………... 21 
1.4.3 Ambulatory blood pressure monitoring  in pregnancy………………………. 33 
1.5 AIMS AND OBJECTIVES OF THIS THESIS………………..…………………... 83 
 
CHAPTER 2: PERINATAL OUTCOMES IN A MULTI-ETHNIC HYPERTENSIVE, 
PREGNANT POPULATION 
2.1 ABSTRACT………………………………………………………………………... 85 
2.2 INTRODUCTION…………………………………………………………………. 87 
2.3 METHODS………………………………………………………………………… 87 
  
 
2.4 RESULTS………………………………………………………………………….. 91 
2.5 DISCUSSION ……………………………………………………………………...105 
 
CHAPTER 3: A RETROSPECTIVE ANALYSIS OF THE USE AND PREDICTIVE 
VALUE OF AMBULATORY BLOOD PRESSURE MONITORING IN 100 
PREGNANT HYPERTENSIVE WOMEN 
3.1 ABSTRACT………………………………………………………………………..117 
3.2 INTRODUCTION………………………………………………………………….118 
3.3 OBJECTIVES………………………………………………………………………118 
3.4 METHODS…………………………………………………………………………118 
3.5 RESULTS…………………………………………………………………………..119 
3.6 DISCUSSION …………………………………………………………………..….124 
 
CHAPTER 4: A RANDOMIZED COMPARISON OF AMBULATORY BLOOD 
PRESSURE MONITORING VERSUS CONVENTIONAL OFFICE BLOOD 
PRESSURE MEASUREMENT IN THE MANAGEMENT OF PREGNANT 
HYPERTENSIVE WOMEN 
4.1 ABSTRACT………………………………………………………………………..127 
4.2 INTRODUCTION………………………………………………………………….128 
4.3 METHODS…………………………………………………………………………128 
4.4 RESULTS……………………………………………………..................................137 
4.5 DISCUSSION ……………………………………………………………………...145 
 
CHAPTER 5: CONCLUSIONS AND RECOMMENDATIONS  
5.1 SUMMARY OF FINDINGS…………………………………………….…………154 
5.2 RECOMMENDATIONS FOR FUTURE RESEARCH…………………………...158    
 
 
 
  
 
APPENDICES 
APPENDIX 1: LITERATURE SEARCH……………………………………………….160 
APPENDIX 2: PROFORMA FOR CHAPTER 3……………………………………….165 
APPENDIX 3: POSTER FOR TRIAL…………………………………………………..167 
APPENDIX 4: DAY UNIT STAFF: DETAILED INSTRUCTIONS FOR ABPM TRIAL   
PATIENTS………………………………………………………………………………168 
APPENDIX 5: PATIENT INFORMATION SHEET…………………………………. .169 
APPENDIX`6: PATIENT CONSENT FORM………………………………………….174 
APPENDIX 7: CONSULTANT LETTERS…………………………………………….175 
APPENDIX 8: PROFORMA FOR CHAPTER 4……………………………………….177 
APPENDIX 9: PATIENT QUESTIONNAIRE AND COVERING LETTER………….181 
APPENDIX 10: ETHICS COMMITTEE APPROVAL………………………………...183 
APPENDIX 11: CONSORT FLOWCHART……………………………………………186 
 
LIST OF REFERENCES………………………….……………………..……………….188 
 
 
 
  
 
LIST OF FIGURES 
Chapter 1 Page  
1.1 
1.2 
1.3 
Harvey „De motu cordis.’ 
Hales „Statical (sic) Essays, containing haemastaticks‟ 
Mercury and aneroid sphygmomanometers 
5 
6 
9 
Chapter 4 
4.1 ABPM monitor in situ 132 
4.2 Flow diagram of participants in trial 138 
 
 
 
  
 
LIST OF TABLES 
Chapter 1 Page 
1.1 Sources of error in measurement of blood pressure using standard 
sphygmomanometer. 
12, 13 
1.2 Clinical scenarios where ABPM is recommended in non-pregnant patients 20 
1.3 Publications relating to ambulatory blood pressure devices used in 
pregnancy, grouped by monitor 
22-27 
1.4 Studies of normal values and patterns of ABPM in normal pregnancy 35-38 
1.5 Studies of ABPM patterns in hypertensive pregnant women 40-43 
1.6 Studies of ABPM as a screening test/predictor of hypertension in 
pregnancy 
45-49 
1.7 Studies of ABPM as a predictor of perinatal outcome in hypertensive 
pregnancies 
52-57 
1.8 Studies of ABPM to evaluate anti-hypertensive medication or as a research 
tool 
59 
1.9 Studies of ABPM values compared to conventional BP values, including 
white coat hypertension 
65-70 
1.10 Classification schemes for interpreting evidence for guidelines 71 
1.11 Guidelines and Society recommendations for ABPM in pregnancy 72-73 
1.12 Reviews, overviews and commentaries on ABPM in pregnancy 75-79 
Chapter 2 
2.1 Definitions of hypertensive disorders in pregnancy 90 
2.2 Diagnosis in 627 pregnancies in 509 women 91 
2.3 Maternal characteristics in pregnancies in total study population and 
different diagnostic groups 
93 
2.4 Obstetric and neonatal data 94, 95 
2.5 Perinatal outcomes 97 
2.6 Details of stillbirths in 18 of 317 chronic hypertensive pregnancies 99 
2.7 Characteristics of 316 pregnancies with chronic hypertension by ethnicity 101, 
102 
 
  
 
2.8 Stillbirths and caesarean section rates in pregnancies with chronic 
hypertension by time period. 
104 
Chapter 3 
3.1 Pregnancy data and obstetric/neonatal outcomes 121 
3.2 ABPM results 122 
3.3 Regression analysis of conventional vs. ambulatory blood pressure 
monitoring for perinatal outcomes 
123 
Chapter 4 
4.1 Outcome measures 133 
4.2 Power calculations  136 
4.3 Baseline characteristics of trial groups 139 
4.4 Summary results: Primary outcomes and induction of labour (overall) 140 
4.5 Summary results. Secondary outcome measures: neonatal data 141 
4.6 Summary results. Secondary outcomes: attendance/length of stay data 141 
4.7 Summary of responses to participant questionnaire 143 
4.8 Sample of free-text responses to participant questionnaire 144 
  
  
 
 LIST OF ABBREVIATIONS  
ABPM  Ambulatory blood pressure monitoring 
ANOVA Analysis of variance 
CBP(M) Conventional blood pressure (monitoring) 
CDBP  Conventional diastolic blood pressure 
CH  Chronic hypertension 
CI  Confidence intervals 
CS  Caesarean section 
CSBP  Conventional systolic blood pressure 
DBP  Diastolic blood pressure 
GH  Gestation hypertension 
HELLP Haemolysis elevated liver enzymes low platelets 
IOL  Induction of labour 
ISSHP  International Society for the Study of Hypertension in Pregnancy 
IQR  Interquartile range 
IUGR   Intrauterine growth restriction 
mmHg  Millimetres of mercury 
NK  Not known 
PE  Pre-eclampsia  
PIH   Pregnancy induced hypertension  
PPV  Positive predictive value 
RCT  Randomized controlled trial 
SBP  Systolic blood pressure 
SD  Standard deviation 
 
 
 
 
  
 
SH  Secondary hypertension 
SPE  Superimposed pre-eclampsia  
TRH  Thyrotophin releasing hormone 
WCH   White coat hypertension 
 
  
 
PRESENTATIONS AND PUBLICATIONS  
FROM THIS THESIS 
British Maternal and Fetal Medicine Society, Annual Conference, York University, 2003:  
Poster presentation: „A comparison of ambulatory and conventional blood pressure 
monitoring as predictors of obstetric and neonatal outcomes‟. CA Rhodes, D Churchill, T 
Marshall. 
 
Rhodes CA, Churchill D, Marshall T. A comparison of ambulatory conventional blood 
pressure monitoring as predictors of obstetric and neonatal outcomes. J Obstet Gynaecol 
2003;23 (suppl 1):S73. 
 
International Society for Study of Hypertension in Pregnancy: British Meeting, Glasgow 
2003: 
Oral presentation: „Obstetric and neonatal outcomes in 645 women attending an antenatal 
hypertension clinic.‟ CA Rhodes, D Churchill, DG Beevers. 
 
Birmingham and Midland Obstetrics and Gynaecology Society, Prague Meeting, 2004:  
Oral presentation: „Obstetric and neonatal outcomes in 645 women attending an antenatal 
hypertension clinic.‟ CA Rhodes, D Churchill, DG Beevers. 
 
British Maternal and Fetal Medicine Society, Annual Conference, Nottingham University, 
2005:  
Oral presentation: „A randomized comparison of ambulatory blood pressure measurement 
versus conventional blood pressure measurement for the management of pregnant 
hypertensive women.‟ CA Rhodes, D Churchill. 
  
 
Rhodes C, Churchill D. „A randomized comparison of ambulatory blood pressure 
measurement (ABPM), versus conventional blood pressure measurement, for the 
management of pregnant hypertensive women.‟ J Obstet Gynaecol 2005;25 (suppl 1):S16.  
  
 
 1 
 
CHAPTER 1:  
INTRODUCTION 
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1.1 INTRODUCTION 
1.1.1 General Introduction 
Blood pressure measurement is embedded in the care of pregnant women. It is a standard test 
used globally to screen for hypertension. The burden of morbidity and mortality related to 
increased blood pressure in pregnancy for both mothers and babies is well-documented. 
More recent research has suggested long-term health implications for babies born to women 
with hypertension. Raised blood pressure in pregnancy may reflect failure of maternal 
cardiovascular adaptations to the pregnant state, resulting in an undernourished fetus of low 
birth weight at subsequent risk of coronary heart disease, stroke and hypertension.
1
 The 
longer term implications for mothers are also becoming evident: women with pre-eclampsia 
have a raised long term risk of cardiovascular disease, occurring at an earlier age.
2
  
 
Much effort has been directed to improving the detection, prevention and management 
strategies for this common pregnancy complication. In spite of this, controversies remain 
concerning defining the problem, technical aspects of measuring blood pressure, the nature 
of the underlying patho-physiology, and how best to manage the various presentations of 
hypertension in pregnancy. 
 
This thesis has five chapters, all related to issues in hypertension in pregnancy. A 
background section will discuss the history of blood pressure measurement, hypertension in 
pregnancy and the use of ambulatory blood pressure monitoring (ABPM) generally and in 
pregnancy. The second chapter concerns outcomes in women with raised blood pressure. 
Prospectively recorded details of women from a multi-ethnic population, attending a 
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specialist antenatal hypertension clinic over a 22-year period, will be reviewed with 
particular reference to obstetric and neonatal outcomes. In the third chapter, the notes of 100 
pregnant women will be reviewed to assess the predictive value of ABPM for obstetric and 
neonatal outcomes in comparison with conventional blood pressure monitoring. Following 
this, the results of a prospective randomized trial of the use of ABPM in pregnancy will be 
presented in the fourth chapter. Finally, the fifth chapter summarises the conclusions and 
recommendations. 
1.1.2 Literature search 
An initial Medline search was performed for background information and to write the 
research protocol, using search terms „Hypertension‟ „Pregnancy‟ „Ambulatory blood 
pressure monitoring‟ „ABPM‟ „chronic hypertension‟ and „pre-eclampsia‟, with appropriate 
alternate spellings and truncated terms. Full text articles were then obtained from the Good 
Hope Hospital Library, British Medical Association, Royal College of Obstetricians and 
Gynaecologists (RCOG) libraries or via the National Electronic Library for Health 
(NELH)/RCOG where available electronically. 
 
Following this, a formal systematic search was conducted with the aid of a clinical librarian, 
with the aim of identifying publications in two fields. The first search was for reviews, meta-
analyses and clinical trials relating to hypertension in pregnancy, to identify recent advances 
and important studies. This was to provide background information for the thesis. The 
second search related to any type of publication on the use of ABPM in pregnancy, to access 
all publications relevant to this thesis. The exact search terms are listed in Appendix 1. 
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In the general „hypertension in pregnancy‟ search, 974 citations were identified. Citations 
were reviewed by the research fellow with advice from the clinical librarian. The abstracts of 
every identified publication were read if available. If the abstract was not published, the full 
papers were obtained. Publications which focused on classification of hypertension in 
pregnancy, pregnancy outcomes, and updates on pathophysiology and management were 
ordered in full text from the libraries above.  
 
In the „ABPM in pregnancy‟ search, 106 citations were found. All abstracts were reviewed; 
if the abstract was unavailable the full text article was requested. Relevance was agreed with 
the research supervisor, and the full text article obtained for all publications deemed as 
relevant. If there was uncertainty on relevance on reading the abstract, the full text article 
was obtained for review. Reference lists of all articles retrieved were hand searched to check 
for further papers.  
 
Articles on automated or self-initiated blood pressure measurement which were not strictly 
related to ABPM were excluded. At the end of the search process, all 91 relevant papers 
were classified by subject or publication type, and are reviewed in sections 1.4.2 and 1.4.3. 
No randomized controlled trials were found.  
 
 All publications relating to the database reported in Chapter Two were available from the 
previous research fellow Dr H Bayliss, and research supervisor. Once relevant articles were 
obtained and read, a database of references to use for the thesis was compiled. 
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1.2 BLOOD PRESSURE MEASUREMENT 
1.2.1 History of blood pressure measurement 
In 1628, William Harvey noted that when an artery is cut, the blood spurts out as if under 
pressure. In his seminal work, De motu cordis (Figure 1.1), Harvey proposed that the heart 
did not continuously produce blood, but circulated it around the body in one direction.
3
  
Figure 1.1 Harvey ‘De motu cordis.’  
 
Image by courtesy of the Royal College of Physicians of Edinburgh 
In 1733, the Reverend Stephen Hales performed the first direct blood pressure measurement 
by cannulating the femoral artery of a conscious horse 
4
 (Figure 1.2). He described how „in 
December I caused a mare to be tied down alive on her back…having laid open the left cruel 
artery about three inches from her belly, I inserted into it a brass tube whose bore was one 
sixth of an inch in diameter…to this I fixed a glass tube of nearly the same diameter which 
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was nine feet in length. Then, untying the ligature of the artery the blood rose in the tube to 
eight feet in length, three inches perpendicular above the level of the left ventricle of the 
heart.‟ The tubing was used to measure the mean pressure, its pulsatile nature, and changes 
due to respiration. Hales suggested human blood pressure would measure seven feet (176 
mmHg). However, he ceased experiments quoting „the disagreeableness of anatomical 
dissection.‟ 5  
Figure 1.2. Hales ‘Statical (sic) Essays, containing haemastaticks’  
 
Image by courtesy of the Royal College of Physicians of Edinburgh 
In 1828 Poiseuille was the first to use a mercury sphygmomanometer, measuring direct 
arterial pressure in a dog.
6
 This reduced the height of the column by a factor of 13.6. The 
units for measuring BP (millimetres of mercury: mmHg) originate in this study.  The first 
direct blood pressure measurement in a human was taken around 1850 when Faivre inserted 
a tube into an artery after amputation of an arm.
7
 The impracticability of direct methods in a 
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clinical setting led to the development of indirect methods of blood pressure measurement. 
Ritter von Basch, an Austrian, invented the first sphygmomanometer which did not puncture 
the blood vessel. Initial systems used counter pressure on a distal artery, observing the 
pressure when the pulse distal to this disappeared and reappeared, loss and return of colour to 
the skin occurred, or appearance of oscillation in the mercury column.
8-10
 
 
The arm-occluding cuff and mercury sphygmomanometer were described by Riva Rocci in 
Italy in 1896
11
 and Hill and Barnard reported its use in the United Kingdom one year later.
12
 
The technique involved cuff inflation with recording of the pressures at which the palpated 
radial pulse disappeared and reappeared. However, it was not universally well received, with 
the British Medical Journal stating „by using the sphygmomanometer we pauperise our 
senses and weaken clinical acuity.‟ 5 The final contribution to the modern technique of blood 
pressure measurement occurred when Korotkoff used a stethoscope, publishing the 
auscultatory method in 1905.
13
 
 
Doctors had assumed that high blood pressure occurred in eclampsia by the characteristic 
hard bounding pulse, and the availability of machines to measure blood pressure confirmed 
this in the late 19
th
 century.
14
 In 1874 Mahomed presented „sphygmograms‟ from pregnant 
women, describing high „tension‟ in the pulse returning to normal in one to three weeks.15 
Schedoff and Porockjakoff in 1884 also described high blood pressure with eclampsia,
16
 and 
there followed an increasing number of reports of the measurement of blood pressure in 
pregnancy. Cook and Briggs used the Riva-Rocci sphygmomanometer at Johns Hopkins 
Hospital in 1903 to measure blood pressure in pregnancy, reporting raised readings 
preceding the onset of eclampsia.
17
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One of the first reliable longitudinal studies was carried out by MacGillivray et al in 1969.
18
 
They studied blood pressure throughout pregnancy in 226 primigravid women using the 
London School of Hygiene sphygmomanometer. Blood pressure was low in the first two 
trimesters and rose in the third trimester, with the highest levels occurring at six weeks 
postpartum. Increases in systolic pressure as pregnancy advanced were substantially less than 
those for diastolic pressure. They made several recommendations on standardisation of blood 
pressure measurement in pregnancy; however they did not make allowance for arm 
circumference, and used Korotkoff Phase IV for the diastolic pressure. These and other 
issues of blood pressure measurement technique are discussed below. 
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1.2.2 Blood pressure measurement today 
Mercury and aneroid sphygmomanometers are commonly-used devices with similar features: 
a manually-operated inflation-deflation system connected by rubber tubing to an occluding 
bladder placed on the arm.
19
 Inflation occurs with a bulb compressed by hand, and deflation 
using a hand-controlled release valve. The pump and control valve are connected to the 
sphygmomanometer by rubber tubing. The mercury reservoir is connected to a calibrated 
column where the blood pressure is read. In the aneroid sphygmomanometer, this is replaced 
by a more complex bellows and lever system and a „clock-face‟ dial giving the reading. 
 
Figure 1.3 Mercury and aneroid sphygmomanometers 
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There is concern about the possible toxic effect of mercury on the environment. In some 
European countries mercury is no longer permitted in hospitals and it is likely that this will 
become the case in the United Kingdom.
20, 21
 Technical problems with cracked or perished 
rubber, and defective control valves making controlled pressure release difficult should be 
addressed with regular servicing of equipment. The aneroid manometer is vulnerable to 
damage over time with loss of accuracy, and should be regularly calibrated against a mercury 
sphygmomanometer. 
 
Newer devices are now available which use oscillometric techniques. These calculate the 
blood pressure from changes in the amplitude of intra-oscillatory pressure waves, which are 
detected by the pressure cuff during deflation.
22
 As the cuff deflates below the systolic blood 
pressure, blood begins to flow through the artery and a detectable vibration starts in the 
arterial wall. As cuff pressure falls below the diastolic pressure, blood flows easily and the 
vibrations cease. Detected vibrations are transferred through the cuff into a transducer in the 
monitor, which converts them into electrical signals, producing a digital readout. An 
oscillometric device is now available which measures blood pressure by detecting 
oscillations on inflation rather than deflation of a cuff.
23
 There are also auscultatory 
monitors, which detect the Korotkoff sounds using an attached microphone in the pressure 
cuff. 
 
Hundreds of blood pressure measuring devices are now available and these must be validated 
to set criteria to assess accuracy. The European Society of Hypertension has published 
recommendations in this area, including an international protocol.
24, 25
 Validation standards 
have also been set by the US Association for the Advancement of Medical Instrumentation 
(AAMI) and the British Hypertension Society (BHS).
26, 27
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1.2.3 Possible sources of error 
As well as the need for validation and regular maintenance of devices, there are other areas 
where errors may occur in BP measurement. The need to minimize these is paramount, as 
patients may undergo unnecessary investigations and receive medication which they do not 
need for many years, if readings are overestimated. Conversely, those needing further 
monitoring and treatment may be missed if readings are incorrectly thought to be in the 
normal range. Studies surveying staff measuring BP in pregnant women have shown 
considerable variation in practice.
28,
 
29
 Table 1.1 illustrates the main sources of error in BP 
measurement. 
6,
 
30-37
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Table 1.1. Sources of error in measurement of blood pressure using standard 
sphygmomanometer 
Source Notes 
Variation due to intrinsic rhythms 
of respiratory fluctuation,  periodic 
waves mediated by chemoreceptors, 
posture, external/internal factors 
(exercise, bladder distension, 
emotion, meals, tobacco, caffeine, 
alcohol, pain, temperature, and 
mental activity) & diurnal variation 
BP is inherently variable: 80,000 to 140,000 tensions 
take place beat-to-beat over 24 hrs in a pregnant 
woman. 
Equipment error: 
-Mercury 
-Glass tube 
 
-Air vent 
 
 
-Rubber tubing 
-Incorrect cuff size 
Regular calibration and maintenance is needed 
-May leak causing underestimation of BP 
-Interior may be dirty due to oxidation of mercury, 
mercury can adhere giving overestimation of BP 
-Blockage due to clogging with mercury may inhibit 
entry of air when pressure released, upward drag on 
mercury when cuff deflated with overestimation of BP 
-Cracked/perished rubber: problems with deflation 
-If bladder too small pressure may not be fully 
transmitted to artery, giving overestimation. Use large 
cuff if mid-bicep arm circumference over 32 cm. 
Observer bias: 
-Terminal digit preference 
 
-Threshold avoidance 
 
-Rounding BP to zero or five. In one study ~50% of 
values by clinic staff had terminal digit zero.
38
 
-Prejudice in favor of „normal values‟, or to fit 
preconceived ideas 
Observer error  Fatigue, poor memory/concentration/reaction time, 
impaired auditory/visual acuity can effect readings 
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Table 1.1. (cont.) Sources of error in measurement of blood pressure using standard 
sphygmomanometer  
Source Notes  
Poor observer technique:  
-Poor patient posture and position 
of manometer 
-Incorrect rate of deflation 
-Incorrect interpretation of 
Korotkoff sounds 
Recommendations: training of observers 
35 
 
-Patient sitting with arm supported at level of heart 
  
-Deflate at 2-3 mmHg per second 
-Use K5 (disappearance of sound), not K4 (muffling)
 
39,
 
40
 and palpate to find systolic pressure to avoid 
auscultatory gap. 
White-coat effect Note distinction between white coat hypertension (see 
section 1.4), and white coat effect which can occur in 
people with established hypertension 
 
The limitations of conventional BP measurement described in Table 1.1 have led to 
exploration of alternative methods. These include automatic blood pressure measurement 
devices and ambulatory blood pressure monitoring, which is discussed further in section 1.4 
below.  
1.3 HIGH BLOOD PRESSURE IN PREGNANCY 
1.3.1   Classification 
As outlined above, the diagnosis of hypertension depends on measuring blood pressure 
accurately. Pregnant women as a group have special characteristics, and must be considered 
separately. Blood pressure is the product of cardiac output and peripheral resistance. In 
pregnancy, reduction in systemic vascular resistance mediated by local factors results in a 
reduction of BP by 5-10 mmHg. In the third trimester the peripheral vascular resistance 
increases, and BP also rises towards term.
41
  Pregnancy may be the first time a BP reading 
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has been taken, with no prior readings for reference. There may be pre-existing disease 
brought to light, or exacerbated by pregnancy, or hypertensive disease purely related to the 
pregnant state. There is a short window of time during the gestation when appropriate 
management must be instituted. The final diagnosis is confirmed only in retrospect when 
postnatal blood pressure is available. Therefore, definitions and classification of hypertensive 
disease in pregnancy must be clear and consistent. 
 
Unfortunately, this has not been the case. Historically, research in hypertension in pregnancy 
has been dogged by variations in diagnostic thresholds for blood pressure and proteinuria, a 
plethora of classification systems and varied terminologies.
42
 In large epidemiological 
population-based studies, ICD coding (International Classification of Diseases) in this 
„vexing and enigmatic group of disorders‟ is notoriously unreliable: one study reported that 
one in four codings for pre-eclampsia was incorrect.
43
  
 
An important and universally agreed change over recent years is the abandonment of oedema 
as a criterion for the diagnosis of pre-eclampsia. Also, relative increases of 15 mmHg and 30 
mmHg diastolic BP (DBP) and systolic BP (SBP), respectively, are no longer recognized as 
defining hypertension by the relevant bodies in Australasia, the United States and the 
International Society for the Study of Hypertension in Pregnancy (ISSHP).
44-46 
The same 
guidelines use a SBP ≥ 140 mmHg and/or a DBP ≥ 90 mmHg for the definition of raised BP 
in pregnancy. The use of absolute thresholds for „abnormal‟ systolic and diastolic BP is not 
arbitrary; there is evidence supporting their use from studies of outcomes at different levels 
of BP.
47, 48
 These cut-off points alert clinicians and patients to hypertensive disease and are 
established in clinical and research practice. Finally, the use of „muffling‟ of sounds 
(Korotkoff IV) is no longer recommended, and Korotkoff V (disappearance of sounds), must 
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be recorded as the diastolic blood pressure.
39, 40 
This removes important areas of potential for 
variation in research and practice that have confounded consistency and standardization. 
 
Proteinuria is a classic prerequisite to diagnose pre-eclampsia, but the exact definition has 
varied.
49
 A protein reagent dipstick placed in a random urine sample is widely used, 
measuring concentration of protein and vulnerable to error/variation due to contamination, 
specific gravity, pH, posture and observer error.
50, 51
 A value of 1+ or more, which ideally 
correlates with a 24-hour urinary protein value of 300 mg in 24 hours, is considered 
abnormal. In a study of accuracy of dipstick techniques Waugh et al found the 1+ threshold 
had poor accuracy in predicting significant proteinuria as defined by 24-hour urine, and was 
of limited use.
52
 Therefore although dipstick urine is widely used for initial assessment, the 
gold standard remains the 24-hour urine. There has been recent interest in the random urine 
protein/creatinine ratio. However, the wide variations in protein excretion hour-to-hour in 
pre-eclampsia have meant „this test has not been universally endorsed for evaluating 
proteinuria when pre-eclampsia is suspected.‟ 49 It has however been recommended by 
ISSHP that the order of preference for urinalysis is 24-hour urine collection, followed by 
protein/creatinine ratio (cut-off 30 mg/mmol), and dipstick urine if it is the only test 
available.
46 
 
 
The definitions above are combined by ISSHP to give four main hypertensive disorders in 
pregnancy: gestational hypertension (isolated hypertension after 20 weeks), chronic 
hypertension (diagnosed before 20 weeks and/or not resolving postpartum), pre-eclampsia-
eclampsia, and pre-eclampsia superimposed on chronic hypertension.
46
 Clinical diagnosis of 
pre-eclampsia is defined as de novo hypertension after 20 weeks gestation with one or more 
findings, including proteinuria and several other clinical/laboratory parameters. For research 
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purposes proteinuria must be present and properly documented. This is consistent with 
recommendations that clinical definitions should be „as loose as practical for patient safety, 
whereas research definitions should be stringent.‟ 37 The research definition and categories 
are based on those proposed in an important paper by Davey and McGillivray in 1988 and 
endorsed by ISSHP, which are used in this thesis.
53
 All definitions must be used with the 
caveat that pre-eclampsia in particular is a complex maternal syndrome with varying 
presentations. Hypertension or proteinuria is reported as absent in 38% of women with 
eclampsia
54
 and 10-15% of patients with HELLP syndrome.
55
  
 
It is thus important to note that even an accurate assignation of „diagnosis‟ simply signifies 
the woman meeting a „definition‟ according to the clinical presentation alone. There are no 
reliable and specific disease markers. Research to establish the patho-physiology behind 
these disorders of pregnancy continues, and is vital to improve prediction of perinatal 
outcomes and optimise patient care. Hypertension in pregnancy has been aptly described as 
„a disorder begging for pathophysiological support.‟ 56 
1.3.2  Incidence and implications of high blood pressure in pregnancy 
Hypertensive disorders in pregnancy are consistently one of the top three causes of direct 
maternal mortality in both the United Kingdom and the United States, causing approximately 
15% of maternal deaths and significant morbidity.
45, 57-59 
Eclampsia, intracerebral 
haemorrhage and end-organ dysfunction all contribute to maternal morbidity and mortality. 
Ethnic origin and age are also relevant: in a 2001 report on mortality from pre-
eclampsia/eclampsia in the United States, black women were 3.1 times more likely to die 
than white women, and women aged over 40 years were 5.3 times more likely to die than 
those aged 25-29 years.
60
 Maternal deaths due to hypertension reach epidemic proportions in 
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developing countries, with death rates 100-200 times greater than Europe and North 
America.
61
  
 
The overall reported rates of hypertension in pregnancy range from 6-10%.
45, 62, 63
 Chronic 
hypertension occurs in 1-5% of pregnant women, with a higher incidence in women who are 
older, obese and of black ethnic origin.
64
 The remainder have pre-eclampsia/eclampsia, 
which may be superimposed on chronic hypertension, and gestational hypertension.
45, 53 
The 
rate of pre-eclampsia in the US increased by 40% between 1990-99, probably due to older 
mothers (with an increased rate of chronic hypertension) and more multiple pregnancies.
65
 
  
Numerous studies have examined the effect of maternal hypertension on fetal outcome, with 
many demonstrating increased rates of pre-term delivery, growth restriction, and perinatal 
mortality.
66-87 
Varied definitions of  hypertensive disorders and perinatal outcomes lead to 
some difficulty in comparing results, but there is general consensus that women with pre-
eclampsia, especially when superimposed on pre-existing chronic hypertension, have the 
worst outcomes. There is also evidence that racial factors are important in perinatal 
outcomes, with pregnancies in black women being at increased risk, particularly when 
chronic hypertension is present.
66, 76, 79, 88 
A 2006 WHO study of 7993 pregnancies in 6 
developing countries found 24% of perinatal deaths were secondary to hypertensive 
disorders, second only to preterm delivery.
89
 
 
Much recent work in the area of hypertension in pregnancy has focussed on screening 
women for pre-eclampsia with the hope of preventing it and reducing adverse outcomes. As 
stated above, the underlying patho-physiology of pre-eclampsia is still unclear. There is 
consensus that there is inadequate trophoblast invasion, with poor placental perfusion, 
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general endothelial dysfunction, platelet and clotting system activation, and an abnormal 
immune response with inflammation.
90
 Oxidative stress has been proposed as important, 
leading to trials of preventative Vitamins C and E, but early optimism has not been supported 
by randomized trials, and a systematic review confirmed the evidence available discouraged 
this treatment.
91
 Similarly, initial hopes for anti-platelet agents, hypothesised to correct the 
imbalance between prostacycline and thromboxane, were not confirmed when large studies 
showed only modest reductions in adverse outcomes. However, analysis of individual patient 
data has suggested that the 10% reduction in relative risk of pre-eclampsia would be 
important at a population level, and use of prophylactic aspirin should be discussed with 
women at risk.
92
  
 
Community screening for risk factors and early detection of pre-eclampsia is recommended, 
with better evidence now available.
93,
 
94
 Uterine artery Doppler screening has also been 
investigated, possibly in conjunction with biochemical markers.
95
 One important advance is 
in the now routine use of magnesium sulphate to prevent and treat eclampsia,
96
 but there are 
still many areas of controversy and uncertainty in the management of hypertension in 
pregnancy. 
 
1.4 AMBULATORY BLOOD PRESSURE MONITORING  
1.4.1 Ambulatory Blood Pressure Monitoring: an overview 
Interest in “ambulatory” medicine has grown during the last two decades.  The driving force 
behind much of the change has been financial.  However, the demonstrable cost benefit of 
outpatient monitoring and treatment might not be matched in terms of clinical benefit.  It is 
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important that new techniques of monitoring be rigorously examined for clinical 
effectiveness as well as cost effectiveness.   
 
The inconsistent relationship between degree of hypertension and associated complications 
was noted in the 1950s by Sokolow.
6
 To investigate if clinic BP was equivalent to overall BP 
he used a home monitor designed by Remler, which was manually inflated. Reports of the 
technique of non-invasive ambulatory blood pressure monitoring (ABPM) appeared in 
1962,
97, 98
 and NASA developed a miniaturised version of the Remler device to record the 
blood pressure of astronauts. In 1966 Sokolow‟s group published an important study, the 
first to show that end-organ damage was more closely related to mean daytime ABPM 
measurements than office BP.
99
 In the 1970s Thorton  designed an automatic non-invasive 
monitor, which he later wore himself on an early Space Shuttle flight.
6
  
 
National guidelines on managing hypertension now include the use of ABPM in non-
pregnant patients.
100-102 
Although clinic readings remain fundamental, they may not represent 
the true situation for three reasons: variability of BP with a small number of readings, poor 
technique (section 1.2.3) and the „white coat effect.‟ 103 Overall there are several clinical 
areas where ABPM is recommended in general medical practice (Table 1.2) 
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Table 1.2. Clinical scenarios where ABPM is recommended in non-pregnant patients 
Use Notes 
Identification of white-coat hypertension (see 
below)   
Useful in newly diagnosed patients with no 
end-organ damage 
Monitoring and adjustment of drug 
treatment, and any related side-effects 
Timing of medication can be adjusted 
especially for morning „surges‟,104 and to 
minimise unwanted side-effects 
Diagnosis of postural hypotension, 
investigation of syncope, episodic 
hypertension and resistant hypertension 
Autonomic neuropathy and panic disorder 
can be diagnosed 
Prediction of end-organ damage, 
cardiovascular events and mortality, 
including as related to nocturnal „dip‟ 105-107 
Improved detection of high-risk patients 
allowing targeted intervention, better 
prediction demonstrated 
Suspected observer error and bias  
 
In spite of national recommendations about the use of ABPM, there are still areas of 
uncertainty and difficulty. Acceptability of the technique is variable (10-25% of patients 
prefer not to repeat it due to „inconvenience‟).108 There is also lack of consensus on which 
measures should be used by the clinician. Several methods of analysis have been described 
of varying complexity including the blood pressure load (percentage of the area under the 
curve above certain limits), „hyperbaric index‟ based on time-specified tolerance and 
prediction intervals,
109
 a Bayesian approach using restricted cubic splines and heterogeneous 
within-subject variances,
110
 analysis of Circadian rhythm by multiple-component analysis, 
111
 and chronobiological analysis using MESOR (midline estimating statistic of rhythm), 
amplitude and acrophase.
112
 In clinical practice the mean 24-hour, and day and night 
systolic/diastolic BP are most often used. 
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For all these indices normal ranges are needed for different populations. Values in normal 
populations for ABPM data have been established, revealing readings to be lower than 
„office‟ BP.113 There is still some controversy surrounding levels of „abnormal‟ ABPM, but 
generally <135/85 mmHg (day), <120/75 mmHg (night) and <130/80 mmHg (24 hours) are 
used as cut-off points for non-pregnant populations.
98 
 
 
As referred to in section 1.2.2, devices must be validated for use in varying clinical 
situations, as reviews of studies show only „about two thirds of ABPM devices tested can be 
recommended.‟ 98  To pass a device needs to be given Grade A or B by British Hypertension 
Society (BHS) Guidelines,
24  and to be awarded a „pass‟ by the American Association for the 
Advancement of Medical Instrumentation (AAMI) criteria.
26 
The website 
www.dableducational.com has full details of guidelines, devices and their ratings, and there 
is more discussion below.  
1.4.2 Review of ambulatory blood pressure monitoring devices used in pregnancy 
The need for objective validation of ambulatory monitors has been referred to above. 
Relevant publications on device validation in pregnant women are presented in Table 1.3 
below. The literature search to identify these studies is described in section 1.1.2. Where 
details are available in the publication they are included, but in some papers few details are 
available on (for example) the parity or gestation of women in the study, and descriptions 
such as „mild hypertension‟ are not defined. See the end of section 1.4.3 for further 
discussion of this issue. 
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Table 1.3. Publications relating to ambulatory blood pressure devices used in pregnancy, grouped by monitor. 
Reference 
First author 
Year 
Monitor(s) Study design 
 
Sample 
size 
Subjects Description Findings Recommendation 
114 O‟Brien 
1993 
SpaceLabs 90207 
monitor 
Validation study 86 
   
Normotensive 
pregnant women. 
Accuracy assessed by 
British Hypertension 
Society (BHS) protocol 
& Association for the 
Advancement of 
Medical Instrumentation 
(AAMI) criteria vs 
mercury device 
BHS 1990:  
Systolic: Grade A  
Diastolic phase V: Grade 
C 
AAMI:  
Systolic: passed  
Diastolic: failed 
More information is 
needed on the 
performance of BP 
measuring devices in 
pregnancy. 
115 Shennan 
1993 
SpaceLabs 90207 
monitor 
Validation study 98 Pregnant women 
with range of BP 
<130/80 to 
>140/100 
Accuracy assessed by 
BHS protocol & AAMI 
criteria vs mercury 
device 
BHS 1990:  
Systolic: Grade B  
Diastolic phase V: Grade 
B  
AAMI: 
passed criteria 
Device accurate in 
determining systolic 
and diastolic blood 
pressure by BHS/ 
AAMI protocols in 
pregnancy. 
116 Shennan 
1996 
SpaceLabs 90207 
monitor 
Validation study 30 Nulliparous 
pregnant women 
with severe pre-
eclampsia (BP 
>170/110 and 
proteinuria >500 
mg /24 hours) 
Accuracy assessed by 
BHS protocol vs 
mercury device 
BHS 1990:  
Systolic: Grade C  
Diastolic phase V: Grade 
C 
Added to reference 115  
(same authors) grading 
remains B/B. 
Within acceptable 
limits in severe pre-
eclampsia. 
Recommend future 
studies include women 
with pre-eclampsia 
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Table 1.3. (cont.) Publications relating to ambulatory blood pressure devices used in pregnancy, grouped by monitor  
Reference 
First author 
Year 
Monitor(s) Study design 
 
Sample 
size 
Subjects Description Findings Recommendation 
117 Brown 
1995 
SpaceLabs 90207 
(oscillometric) 
monitor 
 
Accutracker II 
(auscultatory) 
monitor 
Validation study 
using direct 
intra-arterial 
readings 
compared with 
both ABPM 
devices 
39 Pregnant women in 
third trimester with 
mild hypertension 
(not defined). 
SpaceLabs (25 women) 
and Accutracker (14 
women) accuracy 
assessed by BHS 
protocol & AAMI 
criteria vs intra-arterial 
pressures as reference 
-SpaceLabs: BHS 1993: 
Systolic: Grade D 
Diastolic: Grade D 
AAMI: Failed 
-Accutracker: 
BHS 1993: 
Systolic: Grade D 
Diastolic: Grade C 
AAMI: Failed 
Poor gradings in both 
devices, but is similar 
to comparisons to 
mercury devices, „does 
not mean devices are 
unsuitable for use in 
pregnancy‟. 
118 Franx 
1997 
SpaceLabs 90207 
(oscillometric) 
Monitor 
 
Profilomat 
(auscultatory) 
monitor 
Validation study 55 Pregnant women: 
-21 normotensive,  
-22 diastolic 
BP>90  
-12 diastolic 
BP>90 & 
proteinuria 
>300mg/24 hours  
-2 in 1
st
 trimester 
-9 in 2
nd
 trimester 
-44 in 3
rd
 trimester 
SpaceLabs & Profilomat 
accuracy assessed by 
BHS protocol vs 
mercury device on all 
women 
-SpaceLabs: 
BHS 1990:  
Systolic: Grade B 
Diastolic: Grade C 
-Profilomat: 
BHS 1990: 
Systolic: Grade B 
Diastolic: Grade C 
Large differences with 
mercury readings in 
individuals, which 
increased with BP. 
Ambulatory devices 
need to be evaluated at 
the extremes of BP 
range where maternal 
morbidity is more 
likely. 
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Table 1.3. (cont.) Publications relating to ambulatory blood pressure devices used in pregnancy, grouped by monitor  
Reference 
First author 
Year 
Monitor(s) Study design Sample 
size 
Subjects Description Findings Recommendation 
119 Brown 
1998 
SpaceLabs 90207  
Monitor 
 
OMRON HEM 
705 CP portable 
(non ABPM) 
device  
 
Comparative 
study 
79 Normotensive  
pregnant women 
„at risk‟ of pre-
eclampsia 
(undefined) or with 
„mild 
hypertension‟ 
(undefined) 
Three BP readings on 
each device averaged 
and compared with 
average of three 
readings on mercury 
device, tested with 
Student‟s paired t-test 
and Bland Altman plots. 
SpaceLabs tended to 
overestimate systolic BP 
by mean of 11: Standard 
Deviation (SD) 8 and 
diastolic BP by mean of 
5 (SD 7) mmHg. 
Considerable patient 
variability in accuracy.  
Recommend if record a 
limited number of 
readings, must compare 
with mercury readings. 
Do note that ABPM 
devices are designed for 
usage over 24-hour 
period. 
120 Livi 
1998 
SpaceLabs 90207 
Monitor 
 
Takeda TM2420 
model 7 
Cohort study of 
reproducibility 
159 Pregnant women 
gestation 6-39 
weeks 
-95 normotensive 
-42 previous 
gestational 
hypertension 
-10 previous pre-
eclampsia 
-12 hypertensive in 
current pregnancy 
SpaceLabs (19 women) 
and Takeda (140 
women) used over two 
consecutive 24-hour 
periods in hospital. Two 
periods compared using 
reproducibility index (2 
x standard deviation of 
differences between 
individual means.) 
At group level the mean 
observed differences 
were not significantly 
different except the first 
2 hours of readings. 
„High overall 
reproducibility‟ 
supports use of the 
technique. 
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Table 1.3. (cont.) Publications relating to ambulatory blood pressure devices used in pregnancy, grouped by monitor  
Reference 
First author 
Year 
Monitor(s) Study design Sample 
size 
Subjects Description Findings Recommendation 
121 
Natarajan 
1999 
SpaceLabs 90207  
Oscillometric 
monitor 
 
QuietTrak 
auscultatory  
monitor 
Validation study 37 30 pregnant 
women  with pre-
eclampsia 
(diastolic BP>90 
and >2+ 
proteinuria) 
7 women (3 
postpartum) with 
severe pre-
eclampsia on high 
dependency unit 
with pulmonary 
oedema 
SpaceLabs and 
QuietTrak accuracy 
assessed by BHS 
protocol & AAMI 
criteria vs mercury 
device in women with 
pre-eclampsia. Also 
assessed vs intra-arterial 
readings in 6 women 
with severe pre-
eclampsia: device failed 
in one woman, excluded. 
SpaceLabs/QuietTrak: 
BHS 1993:  
Systolic BP: Grade D 
Diastolic BP: Grade D  
AAMI: both failed. 
 
Intra-arterial test: both 
underestimated systolic, 
mean arterial pressures, 
QuietTrak also 
underestimated diastolic 
pressures. 
 
Neither monitor can be 
recommended for 
clinical use in women 
with proteinuric pre-
eclampsia. 
122 Tape 
1994 
QuietTrak monitor Accuracy study 
against mercury 
device 
59 Normotensive 
women at 13-26 
weeks gestation  
Assessed vs mercury 
device on all women. 7 
readings in each subject, 
means compared. Not 
using recognised 
validation protocol. 
 
 
94% systolic BP and 
99% diastolic BP within 
5 mmHg cf mercury 
readings. 
Device accurately 
determined blood 
pressures during 
pregnancy. 
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Table 1.3. (cont.) Publications relating to ambulatory blood pressure devices used in pregnancy, grouped by monitor  
Reference 
First author 
Year 
Monitor(s) Study design Sample 
size 
Subjects Description Findings Recommendation 
123 Modesti 
1996 
QuietTrak monitor Validation study 30 Pregnant women  Accuracy assessed by 
BHS protocol and 
AAMI criteria vs 
mercury device 
BHS 1993:  
Systolic: Grade A 
Diastolic: Grade A 
AAMI: passed. 
Passed all ratings, 
acceptable to patients. 
124 Penny 
1996 
Quiettrak monitor Validation study 85 Pregnant women in 
BP groups as per 
BHS protocol. 
28 in second 
trimester, 57 in 
third trimester. 
Accuracy assessed by 
BHS protocol and 
AAMI criteria vs 
mercury device 
BHS 1993:  
Systolic: Grade B 
Diastolic Grade B 
AAMI: „narrowly failed.‟ 
Recommend for use in 
pregnancy, noting 
Korotkoff V is 
measured, and accuracy 
at high BP levels may 
be reduced. 
125 Clark 
1991 
TM-2420 monitor Validation study 30 Pregnant women: 
11-38 weeks 
gestation 
-2 chronic 
hypertensive, rest 
normotensive. 
Accuracy assessed by 
AAMI criteria vs 
Hawksley random-zero 
sphygmomanometer. 
AAMI: 
Passed 
Reliable estimates of 
systolic and diastolic 
Korotkoff phase V BP 
in pregnancy 
126 Franx 
1994 
Oxford medilog 
monitor 
Validation study 32 Pregnant women in 
mid-trimester 
10 hypertensive, 
including 8 with 
proteinuria 
Accuracy assessed by 
BHS protocol and 
AAMI criteria vs 
mercury device 
BHS 1990:  
Systolic: Grade C  
Diastolic: Grade C 
AAMI: passed criteria  
Differences were found 
in performance of 
device between 
normotensive and 
hypertensive women. 
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Table 1.3. (cont.) Publications relating to ambulatory blood pressure devices used in pregnancy, grouped by monitor 
Reference 
First author 
Year 
Monitor(s) Study design Sample 
size 
Subjects Description Findings Recommendation 
127 O‟Brien 
1995 
SpaceLabs 90207 
TM-2420 
Overview of 
validation 
studies 
N/A Pregnant women: 
see individual 
entries in this 
Table. 
Review of factors 
influencing validation of 
ABPM devices (all 
patient groups).  
 
Three pregnancy studies 
are quoted. 
 
In pregnancy three 
studies are quoted:  
-O‟Brien 1993114  
-Shennan 1993
115
 
-Clark 1991
125 
First two fulfilled 
requirements, Clark 
study used random zero 
sphygmomanometer so 
results „questionable‟ 
Manufacturers of 
devices must be 
encouraged to have 
independent evaluation 
according to approved 
procedure. 
24 O‟Brien 
2001 
SpaceLabs 90207 
Profilomat 
QuietTrak 
Overview of 
validation 
studies 
N/A Pregnant women: 
see individual 
entries in this 
Table. 
Review of current status 
of device validation and 
recommendations of the 
European Society of 
Hypertension. Only 
includes studies with 
strict adherence to BHS 
and AAMI protocols.  
 
 
 
In pregnancy seven 
studies quoted: 
References 114-116, 
118, 121,123,124   
 
Only two of nine devices 
(QuietTrak 
123
 and 
SpaceLabs 90207 
115
 ) 
validated in pregnancy 
passed BHS and AAMI 
criteria. 
Only devices with 
Grade A or B under 
BHS protocol and 
fulfilling AAMI criteria 
are recommended. 
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The aims of protocols to assess BP monitoring devices are to standardise validation with 
minimum standards of accuracy and performance, and allow comparison of devices. In 1990, 
O‟Brien et al published the British Hypertension Society (BHS) protocol for the evaluation 
of automated and semi-automated BP measuring devices, with special reference to 
ambulatory systems.
128
 In the USA, the Association for the Advancement of Medical 
Instrumentation (AAMI) had produced standards for these devices in 1987, but these were 
not published in a journal, and did not cover all aspects (eg interdevice variability and patient 
acceptability).  
 
The BHS protocol has six phases: observer training, before-use interdevice variability 
assessment, in-use assessment, after-use interdevice variability assessment, device validation 
on 85 subjects with specific characteristics/range of BP, and report of evaluation. Grades 
vary from A to D, depending on the percentage of readings in the test which differ from the 
mercury standard by ≤5, 10, or 15 mmHg. For example, in the original protocol, for an A 
grade (the best), 80% of measurements have a difference of ≤5 mmHg from the standard and 
95% have a difference of ≤15 mmHg. Initially, acceptable limits were not strictly defined, 
with a Grade C „acceptable‟ according to Greer129, although later publications suggest a 
minimum B/B grading for systolic and diastolic BP (see below). For the AAMI criteria of 
accuracy, the device should not differ from mercury readings by more than 5 mmHg 
(standard deviation 8 mmHg or less).
  
 
The latest versions of the BHS and AAMI protocols were published in 2001 and 2003 
respectively.
24, 26  
The revised BHS protocol further stipulated that systems must be validated 
in „special groups‟ such as pregnant women, using a sample size of 30 people if already 
passed in the general population. Devices should achieve at least grade B for systolic and 
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diastolic blood pressures to pass. A „questionable‟ recommendation can be given if evidence 
is inadequate. The joint criteria (AAMI and BHS) are used in most validation studies. 
 
Table 1.3 (above) shows the results of validation and accuracy studies for ABPM monitors in 
pregnancy. The first published study of the TM-2420 monitor by Clark et al did not use the 
BHS/AAMI standards, but did conclude that the monitor was reliable.
125 
In 1993, two papers 
assessed the SpaceLabs 90207 ambulatory device in pregnant women.
114, 115 
The grades are 
shown in Table 1.3. The study by Shennan et al found a B/B grade and a pass for AAMI 
standards, and stated the device was accurate. In O‟Brien et al‟s study the Grade C for 
diastolic BP and the failure of diastolic BP to pass the AAMI criteria suggest suboptimal 
performance. The authors themselves state the grade but not whether this is an overall pass 
or fail, and recommend further studies before assuming devices valid in non-pregnant 
individuals are accurate in pregnancy. Interestingly this paper is extensively cited as a 
validation study in many publications on ABPM in pregnancy.  
 
In 1994, in a comparison of automated and auscultatory readings (not ABPM) in 40 
normotensive and 17 pre-eclamptic primigravid women, Quinn found that automated BP 
measurement devices underestimated blood pressure in women with pre-eclampsia by up to 
30 mmHg.
130
  The concern is that oscillometric devices (including ABPM monitors) might 
be affected by changed haemodynamics in pre-eclampsia, with a reduction in vessel wall 
compliance. A further study of the SpaceLabs 90207 device in 30 women with severe pre-
eclampsia showed a Grade C/C which the authors describe as within acceptable limits, as 
long as clinicians are aware of possible discrepancies between 
oscillometry/sphygomanometry.
116 
Adding this group to the previous validation study by the 
same group maintained the grade B overall. An assessment of the Oxford monitor was 
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published by Franx in 1994, with Grade C in systolic and diastolic readings. Accuracy of the 
device was worse in women with hypertension.
126 
 
 
In a different approach in 1995, Brown et al compared the SpaceLabs 90207 and 
Accutracker II ABPM monitors with intra-arterial recordings.
117 
Although results were poor, 
mercury devices also compared poorly. The study design and use of the BHS grading was 
strongly criticised in a letter by O‟Brien,131 but in their reply the authors justify the study as 
exploring the hypothesis that automated devices might have been superior to mercury 
sphygmomanometers. Although useful to know that both methods are equally inaccurate 
related to direct methods, the relevance of further comparisons with intra-arterial pressure is 
questionable for practical and ethical purposes.  
 
In 1995, in a review of the topic, O‟Brien et al noted that of 43 ABPM devices, only 18 were 
validated according to the BHS/AAMI criteria.
127
 Of these only 9 fulfilled the accuracy 
protocols stated in the paper of BHS grade B/B and AAMI standard met. Deviations from the 
protocol were common, and the authors refer to „pernicious practices‟ such as companies 
transferring validation between models. Three studies in pregnancy are discussed (all 
referenced in Table 1.3): two are described as fulfilling AAMI and BHS criteria. Of these 
two, Shennan 1993 does conclude that the device fulfils the criteria in hypertensive pregnant 
women.
115 
The other study in normotensive pregnancy (O‟Brien 1993) in fact failed the 
device by criteria on reference to the original paper.
114 
 
 
The SpaceLabs 90207 device was assessed again for accuracy by Brown et al in 1998, 
comparing to an OMRON portable self-initiated device and mercury measurements.
119 
They 
found overestimation of BP by the ambulatory monitor. However, the authors state that the 
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ABPM device is designed to be used over 24 hours and high numbers of readings would 
improve data stability. The authors recommend comparison with mercury readings in 
individuals. In a 1996 paper, Modesti et al studied the Welch Allyn QuietTrak ambulatory 
monitor, an auscultatory device, and it passed BHS and AAMI standards.
123 
Two years 
previously, Tape had compared the QuietTrak to mercury readings with reported good 
correlation, but without formal validation.
122 
In 1996 Penny et al added a further relevant 
study of the QuietTrak device, which passed BHS but just failed AAMI protocols.
124
 The 
authors suggest that the marginal loss in grading at higher levels, less than that in 
oscillometric measurement, might offer an advantage in women with severe pre-eclampsia as 
the auscultatory device is not affected by changes in vessel wall compliance. 
 
Examining this hypothesis, Franx et al compared an auscultatory (Profilomat) and 
oscillometric (SpaceLabs 90207) device in normotensive, hypertensive and (mild) pre-
eclamptic pregnancies.
126 
They concluded that they were as accurate as each other, but 
conclusions could not be drawn for women with severe pre-eclampsia. They used the 1990 
version of the BHS protocol to allow comparison with previous studies. Wide limits of 
agreement caused concern, with for example a Profilomat diastolic BP of 85 mmHg 
indicative of a level between 71-102 mmHg phase V diastolic BP on mercury measurement.  
Auscultatory (QuietTrak)  vs oscillometric (SpaceLabs 90207) monitors were then compared 
in women with pre-eclampsia by Natarajan et al, who found that „neither monitor can be 
recommended for clinical use in women with proteinuric pre-eclampsia.‟ 121 Both devices 
failed on all counts in this population, with underestimation of BP compared to both mercury 
and intra-arterial readings. 
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Franx et al also make the important point that all these validation studies are done on women 
who are static, although ambulatory monitors by definition are used in motion during usual 
daily activities.  Practically speaking it would not be possible to perform regular sequential 
mercury readings under controlled conditions during normal activities, as the protocols for 
validation require. However, other practical aspects of ABPM can be examined, and Livi et 
al studied the reproducibility of measurements over consecutive monitoring periods.
120 
Women (some of whom were hypertensive) were hospitalised but mobile, and they found 
high overall reproducibility between the two time periods, supporting increasing use of the 
technique. 
 
In conclusion, it is important to interpret individual blood pressure measurements with care 
and confirm readings with mercury devices, still the „gold standard.‟ It is also suggested that 
ambulatory devices should be used with caution (if at all) in women with pre-eclampsia. In 
the future, the development of continuous waveform analysis with a finger device is a 
promising area.
24 
Inflationary oscillometry, achieving Grade B/A in a study of women with 
pre-eclampsia by Golara et al, may also be applicable to future ambulatory devices, with 
improved accuracy.
23 
 
 
In an update in 2001, O‟Brien reviewed the latest data on device validation, with seven 
papers found.
24 
As stated in Table 1.3 and the discussion above, nine formal validations of 
several ABPM devices in pregnancy are quoted, with only two studies of devices passing 
(SpaceLabs 90207 in Shennan et al 1993, and QuietTrak in Modesti et al 1996).
115, 123
 One 
further study by Franx et al 1994 was not included in O‟Brien‟s review; the device failed.118 
Most of the reports in the literature of ABPM in pregnancy use the SpaceLabs device. There 
are also two reports on women‟s experience of the device, described in Section 4.5. 
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The conclusions on validation on a small number of measurements contrast with positive 
findings of the clinical use of 24-hour ABPM in pregnancy in a selection of the research in 
this area, discussed in the next section.  
 
1.4.3 Ambulatory blood pressure monitoring in pregnancy 
Given the importance of blood pressure disorders in pregnancy (section 1.3.2), there has 
been interest in the place of ABPM in the pregnant woman. In 1971 Seligman used an 
automated device taking 5-minute readings over 24 hours in normotensive, chronic 
hypertensive and pre-eclamptic pregnant women, showing a nocturnal drop in BP which was 
blunted in pre-eclampsia.
132
 Other groups confirmed the pattern of change in the diurnal 
variation in pre-eclamptic pregnancies, using automated rather than ambulatory equipment 
on hospitalised women at rest.
133,
 
134
 In 1984 Rayburn studied self-measurement of BP in 59 
pregnant women with chronic hypertension, showing significantly lower measurements at 
home and when the average of two readings was used.
135
  
 
As automated ambulatory monitoring devices became available, investigators began studies 
of this new technology in pregnancy, to further explore the possibility that BP readings 
outside the clinic might be more accurate, and to study patterns of blood pressure during 
usual activity. It was also hoped that the use of ABPM might decrease sources of error in 
conventional BP measurement, as outlined above in section 1.2.3. Tables 1.4-1.9 summarise 
the main areas of research. The sections of National Guidelines and Specialist Society 
recommendations relating to ABPM use in pregnancy (Table 1.11) and overall conclusions 
of reviews of ABPM in pregnancy (Table 1.12) are also included.  
 34 
 
The work done in this area initially focussed on establishing normal values and patterns of 
ABPM in pregnancy, with emphasis on the 24-hour variation in BP over time. For the first 
time multiple readings over day and night were available while a patient continued normal 
activity (Table 1.4). Frequently reported findings were the normal decrease in BP at night, 
known as „dipping‟, and the rise of BP between the second and third trimester.
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Table 1.4. Studies of normal values and patterns of ABPM in normal pregnancy  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
136 Margulies 1989 
 
Cross-sectional 11 Normotensive 
pregnant women in 
third trimester. 
Del Mar Avionics 
Pressurometer III in 
hospital, over 24 hours. 
Sleep values 
significantly lower than 
awake, patterns similar 
to non-pregnant women 
in previous studies. 
ABPM allows adequate 
diagnosis of hypertensive 
disease in pregnancy. 
137  
 
Clark 1991 Longitudinal 140 Primiparous 
normotensive 
women 
TM2420 monitor  used 
over 24 hours, ABPM at 
18 & 28 weeks 
Significant rise in mean 
waking Systolic BP 
(SBP) & Diastolic BP 
(DBP) between 18 and 
28 weeks gestation, 
sleeping BP always 
significantly lower than 
waking values. 
Normal BP pattern in 
pregnancy is a rise 
between 18 and 28 
weeks even if no 
evidence of pre-
eclampsia.  
112 Cugini 1992 
 
Longitudinal 30 +30 Primiparous 
normotensive 
pregnant women  
(n=30). Results 
compared to 30 
non-pregnant 
women. 
SpaceLabs 90207, 
ABPM in hospital at 8-
10, 18-20, 32-34 weeks 
gestation. Analysed 
using noninferential and 
inferential biometry. 
Values tend to increase 
during second and third 
trimesters. Compared to 
non-pregnant values, 
overall lowering in 
pregnancy of the mesor 
(midline estimating 
statistic of rhythm.) 
The standard limits in the 
study are appropriate 
references for gestational 
BP monitoring. 
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Table 1.4. (cont.) Studies of normal values and patterns of ABPM in normal pregnancy  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
138  
 
Contard 1993 Longitudinal 48 19 nulliparous and 
29 multiparous 
women, singleton 
pregnancy, body 
mass index <27, no 
hypertension or 
diabetes. 
SpaceLabs 90207 (n=22) 
Diasys 200 (n=26) 
ABPM at 3, 6 and 9 
months gestation. 
BP highest in day, lowest 
at night, lowest in first 
trimester, minimal 
increase before 9
th
 
month. 
Reference values may 
help define an alteration 
in the level and/or 
Circadian variation of BP 
during abnormal 
pregnancies. 
139  
 
Halligan 1993 Longitudinal 106 „Caucasian‟ 
primigravid 
women 
normotensive at 
booking. 
SpaceLabs 90207, 
ABPM at 9-16, 18-24, 
26-32, 33-40 weeks 
gestation, and 6 weeks 
postpartum. 
DBP was lowest at 18-24 
weeks. Day & night BP 
rose significantly at 33 to 
40 weeks. Postpartum 
DBP greater than at 9-16 
weeks. Nocturnal BP 
preserved throughout 
Study provides reference 
values for ABPM in 
healthy primigravid 
women. 
140  
 
Ferguson 1994 Cross-sectional 150 + 
30 
150 pregnant and 
30 age- and 
weight-matched 
non-pregnant 
women.  
172 White, 8 
Black. 
Accutracker II ABPM at 
18-22 (n=50), 30-32  
(n=50) and 36-38 (n=50) 
weeks gestation. 
BP always lower at 
night. All indices 
elevated at 36-38 weeks 
compared to earlier, but 
not higher than non-
pregnant. Normal mean 
BP curves established for 
each gestation. 
ABPM is a useful tool 
for the measurement and 
treatment of BP 
abnormalities during 
pregnancy. 
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Table 1.4. (cont.) Studies of normal values and patterns of ABPM in normal pregnancy  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
141  
 
Stella 1996 Longitudinal 192 „Healthy‟ pregnant 
women (20-42 
years, 85 
nulliparous and 
107 multiparous). 
 
SpaceLabs 90207 ABPM 
in hospital at 8-12, 20-
28, 32-40 weeks 
gestation.. Also studied 
132 pre-eclamptic 
women. 26 chronic 
hypertensive women (see 
next table). 
All waking indices 
higher than sleep 
measurements. 24-hour 
mean BP decreased in 
third trimester. Range of 
normal pressure values 
for each hour of day 
across 3 trimesters. 
Reference values may 
help to define alteration 
in Circadian rhythm and 
level of BP in 
pathological pregnancies. 
142 Siamopoulos 
1996 
 
Longitudinal 22 Normotensive   
pregnant women 
aged 18-29. 1
st 
trimester (n=9), 2
nd 
trimester (n=9), 3
rd
 
trimester (n=4). 
Profilomat ABPM in all 
women, 6 had ABPM at 
12, 34 and 32 weeks 
gestation. 
Levels lowest at night, 
rising in third trimester. 
ABPM is a useful tool 
for the evaluation of BP 
variability during 
pregnancy. 
143 Taylor 2001 
 
Longitudinal 102 „Healthy‟ 
normotensive 
women booking 
before 14 weeks 
gestation. 
SpaceLabs 90207 ABPM 
at <14, 19-22, 27-30, 35-
37 weeks gestation and 
5-9 weeks postpartum, & 
sleep diaries. Assessed 
„non-dippers‟ (less than 
10% decrease in mean 
arterial BP in sleep.) 
„Non-dippers‟ were 
common (occurred in 1:3 
women), status changed 
during pregnancy.  
 
As „non-dipping‟ is 
common and inconsistent 
in normal pregnancies is 
unlikely to be a useful 
predictor of pre-
eclampsia.  
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Table 1.4. (cont.) Studies of normal values and patterns of ABPM in normal pregnancy  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
144 Ayala 2001 Longitudinal 205 Normotensive 
pregnant women, 
mean age 30 years, 
112 nulliparous, 93 
multiparous, <16 
weeks gestation at 
recruitment 
SpaceLabs 90207 ABPM 
for 48 hours on 
recruitment then 4-
weekly until delivery. 
Chronobiology analysis   
to assess influence of 
parity and age. 
Reference values 
independent of parity or 
age, depend on 
rest/activity and 
gestation 
Reference thresholds can 
be developed as function 
of rest-activity cycle and 
gestation, independent of 
parity or age. 
145 Hermida 2001 
 
Longitudinal 235 Untreated white 
women with 
uncomplicated 
pregnancies, <16 
weeks gestation at 
recruitment. 
SpaceLabs 90207 ABPM 
for 48 hours on 
recruitment then 4-
weekly until delivery. 
Chronobiology analysis. 
Time-qualified tolerance 
intervals calculated, 
across gestation. 
Upper limits were 
markedly below usual 
thresholds used to 
diagnose hypertension in 
pregnancy. This method 
may help improve  
prognosis and diagnosis. 
146  Higgins 2002 Cross-sectional 933 „Healthy‟ 
normotensive 
primigravid White 
women at 18-24 
weeks gestation.  
SpaceLabs 90207 ABPM 
for 24 hours and 
compared in women in 
working group (n=245), 
not working (n=289), & 
not working on day of 
ABPM (n=399). 
Significant independent 
relation between work 
and ABPM, and work 
with subsequent pre-
eclampsia. 
 
Findings suggest further 
studies are warranted in 
third trimester. Data may 
be important to allow 
optimal management of 
hypertension in 
pregnancy. 
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 Researchers then turned to assessing ABPM patterns in hypertensive pregnancies (Table 
1.5), suggesting that changes in diurnal patterns and establishing ABPM thresholds could 
help with diagnosis, management and treatment. The effect on the nocturnal dip, with some 
studies reporting a drop in the day-night difference in pre-eclampsia, was proposed as a 
potential screening method, as well as providing possible insight into the physiological 
changes of the disorder. In Halligan et al‟s study to establish normal values in 106 
primigravid women, three of the four patients who developed pre-eclampsia had shown loss 
of nocturnal dip at 18-24 weeks gestation.
139
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Table 1.5. Studies of ABPM patterns in hypertensive pregnant women  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
147  
 
Rath 1990 Cross-sectional 
comparative 
36  Normotensive 
(n=17) and pre-
eclamptic (n=19) 
pregnant women  
SpaceLabs 90207 ABPM 
for 24 hours. Information 
from Shennan
6
 and on-
line abstract. 
Normotensive women 
had significant nocturnal 
decline in BP. Women 
with pre-eclampsia had 
attenuated nocturnal fall 
in BP, some had an 
increase.  
Hypertensive 
emergencies are more 
likely to occur at night; 
consider this when 
prescribing anti-
hypertensive drugs. 
148  Montan 1995 Prospective 
controlled  
20  Women with pre-
eclampsia admitted 
in 3
rd
 trimester 
with BP >140/90 
and proteinuria > 
0.25 g/24 hrs. 
SpaceLabs 90207 ABPM 
once for 24 hours, 
readings compared with 
conventional BP.  
ABPM well-tolerated, 
reliable. Measurements 
comparable to 
conventional BP.  
ABPM is likely to 
improve our 
understanding and 
clinical management of 
hypertension in 
pregnancy. May be 
suitable to assess anti-
hypertensive drug use. 
149  Halligan 1996 Cross-sectional 
comparative 
observational 
48 Normotensive 
(n=24) and pre-
eclamptic (ISSHP 
definition:  n=24) 
pregnant women, 
mean gestation 35 
weeks. 
SpaceLabs 90207 ABPM 
to assess diurnal 
variation and BP. 
Drop in day-night BP 
difference in pre-
eclampsia inversely 
related to mean BP. 
Blunting of day-night BP 
difference may be useful 
adjunctive measure of 
disease severity in pre-
eclampsia. 
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Table 1.5. (cont.) Studies of ABPM patterns in hypertensive pregnant women  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
141 Stella 1996 Longitudinal 
comparative 
observational 
350 -132 women with 
pre-eclampsia (BP 
>140/90,proteinuria 
>0.5 g/24 hrs),  
-26 women with  
chronic 
hypertension (BP 
>140/90 <20 wks)  
-192 „healthy‟ 
pregnant women. 
SpaceLabs 90207 ABPM 
in hospital at 8-12, 20-
28, 32-40 weeks 
gestation.  
NB: in pre-eclampsia, 
ABPM done at diagnosis 
and in the third trimester. 
BP in hypertensive 
women remained higher 
in the day than the night, 
and was at least 20 
mmHg higher than 
normal pregnancies at all 
times.  
In hypertension in 
pregnancy ABPM can 
provide useful support 
for clinical decision-
making and managing 
anti-hypertensive 
treatment. May reduce 
hospital stays and 
contain costs. 
150  Ayala 1997 Longitudinal 
comparative 
observational 
113 Recruited <16wks 
-71remained 
normotensive  
-28 women  had 
gestational 
hypertension (BP 
>140/90) 
-14 women had 
pre-eclampsia 
 (BP >140/90, 
proteinuria >0.3 
g/24 hrs. 
ABPM-630 Colin 48-hrs 
ABPM on recruitment 
then 4-weekly until 
delivery. Analysed with 
chronobiology 
techniques. 
Differences in circadian 
rhythm-adjusted mean 
between normal & 
hypertensive pregnancies 
found in all trimesters. In 
hypertensive women BP 
is stable in 1
st
 half of 
pregnancy then increases 
to delivery. 
 
Non-invasive ABPM 
with chronobiometric 
methods for analysis 
offers new end points 
that allow early 
assessment of the risk of 
gestational hypertension 
and pre-eclampsia. 
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Table 1.5. (cont.) Studies of ABPM patterns in hypertensive pregnant women 
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
151 Hermida 2000 Longitudinal 
comparative 
observational 
202 Recruited <16 wks 
-124 remained 
normotensive 
-55 women had 
gestational 
hypertension (BP 
>140/90) 
-23 women had 
pre-eclampsia (BP 
>140/90, 
proteinuria >0.3 
g/24 hrs.) 
ABPM-630 Colin 48-hrs 
ABPM on recruitment 
then 4-weekly until 
delivery. Analysed with 
chronobiology 
techniques. 
Circadian differences in 
normal/hypertensive 
pregnancies: new end 
points for management 
Differences in BP 
between healthy and 
complicates pregnancies 
can be seen in the first 
trimester. These new end 
points could lead to early 
identification of 
hypertension in 
pregnancy allowing early 
prophylactic 
intervention. 
152 Brown 2001 Prospective 
double-blind 
cohort  
186 158 women in third 
trimester successful 
monitoring: 
-63 pre-eclampsia  
-68 gestational 
hypertension 
-27 essential 
hypertension 
(Definitions as 
Brown 2000
44
) 
SpaceLabs 90207 ABPM 
on recruitment, results 
unavailable to patients or 
treating clinicians to 
reduce bias. 
Sleep hypertension 
common, especially in 
pre-eclampsia,  
ABPM can select a 
group of hypertensive 
pregnant women with 
elevation of night BP as 
a manifestation of 
overall raised BP, 
predominantly occurring 
in pre-eclampsia. 
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Table 1.5. (cont.) Studies of ABPM patterns in hypertensive pregnant women  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
110 Lambert 2001 Retrospective data 
analysis 
206 Hypertensive (BP 
>140/90) pregnant 
women over 20 
weeks gestation  
Selects data from 
Penny 1998 
153  
(Table 1.7) with at 
least 10 daytime 
and 5 night 
readings. 
SpaceLabs 90207 ABPM 
performed once.  
Heterogeneity found in 
the within-subject 
variances, allowing for 
this impacts little on the 
model estimates of mean 
profiles. 
Bayesian approach to 
analysis is a powerful 
way to analyse ABPM 
data. Within-subject 
variances can be 
modelled. 
154 Walker 2002 Cross-sectional 
comparative 
40 -20 normotensive 
pregnant women  
-20 hypertensive 
pregnant women:  
9 gestational 
8 pre-eclamptic 
3 chronic 
hypertensive 
(Definition as 
Brown 2000
44
) 
All in third 
trimester 
SpaceLabs 90207 ABPM 
on all patients once as an 
inpatient and once in 
hospital. 
For women on 
antihypertensive 
treatment, ABPM varied 
between home & hospital 
settings 
Hospitalisation does not 
significantly lower BP in 
pregnant women as a 
group, but differences for 
women on medication 
means women are at risk 
of under or over 
treatment if conventional 
BP is used. 
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However, further studies of ABPM as a „screening‟ test for hypertension (particularly pre-
eclampsia), were mostly disappointing, particularly in normal pregnancies, with low positive 
predictive values (Table 1.6). Although Kyle et al found women who developed pre-
eclampsia had some raised indices, the maximum positive predictive value quoted was 45% 
with a sensitivity of 53%.
155
  The use of the nocturnal „dip‟ has also been questioned: Taylor 
showed „nondippers‟ were common and the status changed during pregnancy (Table 1.4).143   
 
In a large study of 1102 primigravid women, Higgins et al showed the best predictor for pre-
eclampsia (24 hour mean diastolic BP of 71 mmHg)  had a sensitivity value of 22% and a 
positive predictive value of 15%.
156 This study is cited as „conclusive evidence that mid-
trimester ABPM in a healthy primigravid population is not a clinically useful predictor of 
hypertension later in the pregnancy.‟ 32 One group has performed complex chronobiological 
calculations on blood pressure series in pregnancies, and reported very high sensitivities and 
specificities for this method in predicting hypertensive outcomes.
157, 158 However, this 
method is not currently widely used. Diabetic women, who have an increased risk of 
hypertensive complications of pregnancy, have been identified as a group where ABPM 
screening may be useful.
159,
 
160
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Table 1.6. Studies of ABPM as a screening test/predictor of hypertension in pregnancy.  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
155 Kyle 1993 
 
Prospective 
interventional 
145 Normotensive 
nulliparous women 
recruited at 
booking, mean age 
28 years. 
Originally 161 
recruits: 145 had 
data for awake 
ABPM vs clinic 
reading analysis, 
127 had data for 24 
hour analysis 
TM2420 ABPM at 18 & 
28 weeks. 
Primary outcome: pre-
eclampsia.  
NB definition is not 
standard: Diastolic BP 
(DBP) increase of 25 
mmHg to 90 or more, 
not all had proteinuria. 
Rate of pre-eclampsia 
17/145=11.7%. 
Awake systolic and mean 
arterial pressure (MAP) 
significantly raised in 
women with pre-eclampsia 
at 18 & 28 weeks; with 
diastolic BP at 28 weeks. 
With MAP ≥85 at 28 wks, 
sensitivity 65%, positive 
predictive value (PPV) 
31%. Adding heart rate 
≥90 bpm: PPV 45%. 
2
nd
 trimester ABPM was 
raised when pre-
eclampsia arises, but 
predictive values are 
low, limited use. Adding 
heart rate increases 
efficiency; may be of 
clinical value if effective 
prevention at 28 wks is 
found. 
156 Higgins 1997 
 
Prospective 
interventional 
1048 Healthy 
primigravid 
women recruited 
from antenatal 
clinic, all White. 
Originally 1102 
recruits, 1048 had 
data for analysis. 
SpaceLabs 90207 
ABPM at 18-24 weeks.  
Primary outcome: pre-
eclampsia (rate 
23/1048= 2.2%) 
Secondary outcome: 
gestational hypertension 
(rate 64/1048=6.1%) 
Definitions standard: 
Davey & McGillivray
53
 
Significantly higher 
ABPM in hypertensive 
groups compared to 
normotensive. Best 
predictor of pre-eclampsia: 
mean DBP ≥71 mmHg: 
sens 22%, PPV 15% 
ABPM in a healthy 
primigravid population, 
at 18-24 weeks is not a 
useful predictor of 
hypertension  
 46 
 
Table 1.6. (cont.) Studies of ABPM as a screening test/predictor of hypertension in pregnancy  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
161  
 
Hermida 1997 Prospective 
interventional 
113 „Caucasian‟ 
women <16 weeks 
at recruitment, 
-71 „healthy‟ 
pregnant women 
-28 developed 
gestational 
hypertension 
-14 developed pre-
eclampsia 
ABPM-630 Colin 48-hrs 
ABPM at recruitment & 
4-weekly to delivery. 
Primary outcome: pre-
eclampsia (definition: 
gestational hypertension 
+ proteinuria >0.3g/24 
hrs.) 
Secondary outcome: 
gestational hypertension 
(new BP>140/90) 
Considerable overlap in 24 
hour mean distribution in 
normotensive/hypertensive 
women. PPV <55% for 
any variable in any 
trimester. 
24-hr mean is not useful 
to predict pre-eclampsia 
or gestational 
hypertension. 
157 Hermida 1998 
 
Prospective 
interventional 
152 „Caucasian‟ 
women <20 weeks 
at recruitment, 
-92 „healthy‟ 
pregnant women 
-42 developed 
gestational 
hypertension 
-18 developed pre-
eclampsia 
ABPM-630 Colin 48-hrs 
ABPM at recruitment & 
4-weekly to delivery. 
Primary outcome: pre-
eclampsia (definition: 
gestational hypertension 
+ proteinuria >0.3g/24 
hrs.) 
Secondary outcome: 
gestational hypertension 
(new BP>140/90) 
„Hyperbaric index‟ (total 
area of patient‟s BP above 
upper limit of tolerance 
interval for Circadian 
variability) calculated. 
Identified subsequent pre-
eclampsia/gestational 
hypertension, PPV above 
96% for all trimesters, 
100% in third trimester. 
Using the „tolerance-
hyperbaric test‟, ABPM, 
preferably at booking, 
provides sensitive end 
points for early risk 
assessment and a guide 
for preventative 
intervention in high risk 
pregnancy. 
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Table 1.6. (cont.) Studies of ABPM as a screening test/predictor of hypertension in pregnancy  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
162  Benedetto 1998 Prospective 
interventional 
180 Women at high 
risk of pre-
eclampsia or fetal  
growth restriction. 
-90 who had 
abnormal uterine 
artery Doppler 
scan (resistance 
index ≥0.58 at 20-
22 wks.)  
-the next 90 with 
normal Doppler 
SpaceLabs 90207 
ABPM at 20-24 wks. 
Primary outcome:  
pre-eclampsia and 
pregnancy induced 
hypertension (PIH) 
(Definition standard: 
Davey & McGillivray
53
) 
Secondary outcome: 
fetal growth restriction 
(birth weight <10
th
 
centile) 
Using midline estimating 
statistics of rhythm 
(MESOR) above cut-off 
value 111/68 mmHg,  
abnormal uterine artery 
Doppler + raised ABPM 
gave sensitivity of 58%  & 
PPV 63% for PIH and pre-
eclampsia (not assessed 
separately) 
Fetal growth restriction:   
sensitivity 30%, PPV 20% 
This two-stage test of 
ABPM on women with 
abnormal uterine artery 
Doppler in high-risk 
women „might indicate‟ 
women at risk of PIH or 
pre-eclampsia. 
159 Flores 1999 Prospective 
interventional 
32 -22 normotensive 
type 1 diabetic 
women 
-10 pregnant 
nondiabetic 
women 
All <10 weeks 
gestation. 
SpaceLabs 90207 
ABPM at 7-12, 20-24, 
30-34 weeks gestation.. 
Primary outcome: 
pregnancy induced 
hypertension (PIH)=pre-
eclampsia & gestational 
hypertension together. 
(Definitions standard: 
Davey & McGillivray
53
) 
„PIH‟ occurred in 8 (36%) 
of diabetic women and 1 
(8%) control. 
In diabetics, receiver 
operator curves showed 
nocturnal SBP >105 
mmHg in 2
nd
 trimester 
best predictor for „PIH‟: 
sensitivity 85%, PPV 
87%. 
ABPM may be useful in 
screening for PIH in 
pregnant diabetic 
women. 
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Table 1.6. (cont.) Studies of ABPM as a screening test/predictor of hypertension in pregnancy  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
160 Lauszus 2001 
 
Prospective 
interventional 
151 Type 1 diabetic 
women. Originally 
185 recruits, data 
available on 151. 
Sensitivity and 
specificity 
calculated for  the 
87 primiparous 
women 
SpaceLabs 90207 
ABPM at 13, 25, 33 
weeks gestation and 3 
months post partum. 
Primary outcome: 
Pre-eclampsia  
(definition: new DBP 
≥90 mmHg, proteinuria 
>0.3g/24 hrs).  
ABPM was higher from 1
st 
trimester onwards in 
women with pre-
eclampsia. 25 (29%) of  
primiparous subjects had 
pre-eclampsia.  
Best predictor was 
daytime BP >122/74: 
sensitivity 68%, PPV 
47%. 
ABPM is a „reliable‟ 
measurement for 
prediction of pre-
eclampsia in 
primiparous women with 
insulin dependent 
diabetes. 
158 Hermida 2001 
 
Prospective 
interventional 
328 All<16 weeks 
gestation  
-205 remained 
normotensive  
-92 women 
developed 
gestational 
hypertension 
-31 women 
developed pre-
eclampsia  
SpaceLabs 90207 48-hrs 
ABPM at recruitment & 
4-weekly to delivery. 
Primary outcome: pre-
eclampsia (definition: 
gestational hypertension 
+ proteinuria >0.3g/24 
hrs) and gestational 
hypertension (new 
BP>140/90 after 20 wks) 
For pre-eclampsia and 
gestational hypertension 
combined, threshold 
Systolic BP (SBP)/MAP/ 
DBP of >130/100/80 (day) 
and >110/85/70 (night) 
gave best results: 
sensitivity 78% and PPV 
64%. 
„Blood pressure load‟ 
(percentage of values 
above a given reference 
limit) is a good predictor 
of „hypertension in 
pregnancy‟.  
NB: lower limits than 
conventional BP. 
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Table 1.6. (cont.) Studies of ABPM as a screening test/predictor of hypertension in pregnancy 
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
163  
 
Brown 2001 Prospective single-
blind comparative 
cohort 
286 -122 pregnant 
women at risk of 
pre-eclampsia 
-164 pregnant 
women at „usual 
risk‟ for pre-
eclampsia 
Mean gestation 25 
weeks. 
SpaceLabs 90207 
ABPM at 18-30 weeks 
while normotensive 
(BP<140/90, no pre-
eclampsia). Results 
unavailable to clinicians 
to reduce bias. Primary 
outcome: combined pre-
eclampsia/ gestational 
hypertension 
(Definitions as Brown 
2000
44
) 
Primary outcome in  
high risk group: 55 (45%)  
usual risk group: 13 (8%) 
Both groups: ABPM 
higher in women 
developing hypertension 
Best predictors: usual risk 
group 24-hr SBP ≥115 
mmHg (sensitivity 77%) 
High risk group sleep DBP 
≥62 (sensitivity 70%) 
In high and normal risk 
women raised ABPM is 
related to pre-eclampsia, 
but with low sensitivities 
 
164  Tranquilli 2004 Prospective 
interventional  
334 Normotensive non-
proteinuric 
nulliparous 
pregnant women 
SpaceLabs 90207 at 20 
wks gestation.  
Primary outcome: 
pregnancy induced 
hypertension „PIH‟ (pre-
eclampsia/gestational
45
) 
Secondary outcome: 
fetal growth restriction 
(weight <5
th
 centile) 
Analysed with 
chronobiology. PIH in 33 
(10%) For both outcomes 
ABPM 24 hour DBP mean 
was significantly higher.  
Most effective threshold is 
68 mmHg for 
hypertension (PPV 89%), 
67 mmHg for growth 
restriction (PPV 61%). 
ABPM at 20 weeks in 
primigravida „reliably 
predicts‟ idiopathic 
IUGR and PIH, using 24 
hour diastolic mean. 
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Other women who are high-risk for pre-eclampsia, especially those with chronic or 
gestational hypertension, have also been investigated as a group for the predictive value of 
ABPM for maternal and fetal outcome (Table 1.7). Here the results have been more 
encouraging when ABPM is compared to conventional BP recording. Prospective 
observational studies have suggested ABPM is superior to conventional methods in 
predicting proteinuria in women with new hypertension after 20 weeks gestation.
165
 Peek et 
al showed ABPM in 109 nulliparous hypertensive women improved identification of patients 
at high risk of poor obstetric outcome (caesarean and preterm delivery, admission to neonatal 
unit, and proteinuria).
166 
However, a larger study of 348 women showed the only outcome 
where ABPM was superior to day unit BP was severe hypertension within two weeks.
153
 
 
In a prospective cohort study
 
Bellomo et al classified a subset of women with raised 
conventional BP and normal ABPM as having white coat hypertension, (WCH). In 144 
women with hypertension in the third trimester, 42 (28%) had WCH.
167
 The remaining 
women with „true‟ hypertension had significantly higher rates of pre-eclampsia (61.7% „true‟ 
vs 7.1% WCH), longer hospital stay, lighter babies and shorter pregnancies compared to 
normotensive controls and women with WCH. Interestingly the caesarean rate was similar in 
WCH and „true‟ hypertensive groups (45.2% vs 41.1%), but significantly lower in 
normotensives (12.4%). The authors suggest this may reflect influence of conventional BP 
on clinical decision-making. One limitation to this study is that ABPM was only performed 
once and patients were admitted to hospital the day before performing the test. However the 
method used seemed to identify a group of women with WCH and significantly lower 
associated risk. 
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Bar also reported a high rate of WCH (62%) in women presenting with raised conventional 
BP in the second trimester, with associated decreased risk of pre-eclampsia, preterm delivery 
and growth restriction. 
168 
The issue of white coat hypertension is discussed below. 
 
Four further papers have looked specifically at fetal growth and birth weight (Table 1.7), 
with Waugh et al showing ABPM to be the best predictor of fetal growth in women with 
non-proteinuric hypertension. In a prospective observational study of 237 women (mean 
gestation at referral 35.6.weeks) there was an associated fall in birth weight of 68.5g for 
every increase of 5 mmHg in daytime mean DBP, but day-unit measurements showed no 
association.
169 
Churchill et al reported similar correlation in a study of 209 healthy 
nulliparous women, with a 5 mmHg increase in mean 24-hour DBP at 28 weeks gestation 
associated with a 68g decrease in birth weight, and a 76 g decrease at 36 weeks gestation, 
using multivariate analysis.
170  
 
Maggioni et al used chronobiology techniques to show a larger Circadian amplitude of DBP 
on ABPM was associated with growth restriction (< 10
th
 centile) in normotensive women.
171 
However, an inverse relation between the Circadian amplitude of SBP and fetal growth 
restriction was seen in hypertensive women, possibly related to compensatory mechanisms in 
hypertensive women. Only 19 women had IUGR overall in the study, with five having 
„pregnancy-induced hypertension‟ so limited conclusions can be drawn from this paper. 
Finally, Tranquilli et al showed that 139 women with growth restricted babies who were 
normotensive by conventional BP, had significant higher ABPM measurements compared to 
a control group with normal fetal growth.
172
 The authors state that these higher levels in the 
normal range may still influence (or be the consequence of) altered uterine and placental 
perfusion, and ABPM can be used to aid investigation for women with small babies. 
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Table 1.7. Studies of ABPM as a predictor of perinatal outcome in hypertensive pregnancies 
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
166 Peek 1996 
 
Prospective 
observational 
109 Nulliparous white 
women with BP at 
least 140/90 after 
20 weeks 
gestation.  
(mean gestation 35 
weeks). 
SpaceLabs 90207 
ABPM vs mean of 6 
conventional readings 30 
minutes apart on day 
unit. 
Outcomes: proteinuria, 
delivery <37 weeks, 
birth weight <10
th
 
centile, neonatal unit 
admission, Caesarean  
With Diastolic BP (DBP) 
>90 mmHg, relative risk 
with ABPM  greater  than 
conventional:  
Proteinuria p=0.034 
Preterm delivery p<0.001 
Low birth weight p=0.001 
Neonatal Unit (NNU) 
admission p=0.001 
Caesarean delivery 
p=0.007 
ABPM appears to 
improve the 
identification of patients 
who are at high risk of 
poor obstetric outcome, 
and is worthy of further 
evaluation. 
173 Engfeldt 1996 Prospective 
observational 
20 -12 women with 
untreated chronic 
hypertension 
(BP>140/90 in 1
st
 
trimester or known 
chronic 
hypertension) 
-8 normotensive 
women 
SpaceLabs 90207 
ABPM at 8-14, 19-23, 
34-36 weeks and 3 
months postpartum 
Primary outcome: 
superimposed pre-
eclampsia (definition 
proteinuria ≥2+ dipstick, 
or >0.3 g/24hours) 
3 women (25%) developed 
pre-eclampsia. No 
consistent pattern in 
ABPM. In both groups 
nocturnal „dip‟ was absent 
in 6 women on at least one 
reading.  
In women with chronic 
hypertension, absent 
nocturnal dip was of no 
value in predicting pre-
eclampsia. 
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Table 1.7. (cont.) Studies of ABPM as a predictor of perinatal outcome in hypertensive pregnancies  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
165 Halligan 1997 
 
Observational 
study 
48 Primiparous 
women presenting 
with hypertension 
(mean of ≥140/90 
on 5 readings 30 
minutes apart) at  
>20 wks gestation. 
Mean gestation 
35.5 wks 
SpaceLabs 90207 
ABPM vs conventional 
BP (CBP) on the day 
unit: mean of 5 readings 
30 minutes apart 
(Korotkoff 4) 
 
Outcome: 24-hour urine 
proteinuria levels 
On regression analysis 
day-time (p=0.026) and 
night-time (p=0.004) 
ABPM had significant 
positive relation with log 
proteinuria. No 
conventional parameters 
reached statistical 
significance. 
ABPM gives better 
information on disease 
status in pre-eclampsia 
(assessed by proteinuria) 
than conventional BP 
measurement 
170 
 
Churchill 1997 Prospective 
observational 
209 Nulliparous 
women (86% of 
244 consecutively 
referred women 
meeting criteria of 
study: excluding 
medical disorders, 
twin pregnancy.) 
Eight infants 
delivering <32 wks 
were excluded. 
SpaceLabs 90207 
ABPM at 18 (n=209), 28 
(n=202) and 36 weeks 
(n=179) gestation. 
Outcomes: birth weight, 
ponderal index, head 
circumference. 
In multivariate analysis, 
diastolic ABPM at 28 and 
36 weeks were inversely 
associated with birth 
weight. Diastolic ABPM 
at 28 weeks was a 
significant predictor of 
head circumference at 
birth. 
There is a continuous 
inverse relationship 
between maternal BP 
and birthweight in 
nulliparous women. 
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Table 1.7. (cont.) Studies of ABPM as a predictor of perinatal outcome in hypertensive pregnancies  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
153 Penny 1998 
 
Prospective 
observational 
study. 
Clinicians blinded 
to ABPM results. 
348 Women >20 wks 
gestation with BP 
≥140/90 not on 
anti-hypertensive 
treatment. 
270 were fully 
compliant with 
ABPM, analysis 
done on all 348 
women. 
SpaceLabs 90207 
ABPM vs mean of up to 
5 BP measurements 30 
minutes apart. Outcomes 
birth weight <3
rd
 centile, 
preterm delivery, NNU 
admission. BP >160/110, 
proteinuria (>500 mg on 
24 hour urine or 2+) in 2 
weeks & overall. 
With threshold of 135/85, 
ABPM had increased 
sensitivity & decreased 
specificity for all 
outcomes except systolic 
BP & proteinuria. ABPM 
predicted severe 
hypertension within 2 
weeks significantly  better 
than CBP 
ABPM may reduce 
inpatient antenatal 
admissions, and may 
allow better risk 
assessment. A 
randomised controlled 
trial was proposed. 
167 Bellomo 1999 
 
Prospective cohort 
study. 
 
247 -144 women with 
BP>140/90 (mean 
of 3 readings 5 
minutes apart). 
Subdivided: 102  
„true‟ and 42 white 
coat hypertension 
(WCH) 
-103 normotensive 
women.  
All at gestation 26-
38 wks. 
TM 2420 ABPM on all. 
WCH defined: office BP 
≥ 140/90 with ABPM 
below departmental 
reference ranges. 
Outcomes of pregnancy 
duration, pre-eclampsia 
(proteinuria >0.3 g/24h) 
caesarean, placental & 
neonatal weight, Apgars 
& hospital stay 
compared in 3 groups.  
 Shorter pregnancy 
duration, more pre-
eclampsia, lower birth 
weight & longer neonatal 
stay were seen in the true 
hypertension group vs the 
other two (all p <0.001). 
Caesarean rates were 
similar in WCH & true 
hypertension; in both 
groups rates were higher 
than controls. 
In women with elevated 
BP in the third trimester, 
ABPM is better than 
office BP (distinguishing 
true hypertension from 
WCH) in predicting 
outcomes (pre-
eclampsia, early 
delivery, birth weight).  
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Table 1.7. (cont.) Studies of ABPM as a predictor of perinatal outcome in hypertensive pregnancies 
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
168 Bar 1999 
 
Prospective cohort 
study. 
Clinicians blinded 
to ABPM results. 
60 60 women at 14-28 
wks gestation with 
at least two BP 
readings ≥140/90 
30 minutes apart . 
Subdivided: 23 
women with „true‟ 
and 37 with white 
coat hypertension 
(WCH). 
SpaceLabs 90202 
ABPM. WCH defined as 
office BP ≥140/90 with 
ABPM daytime mean 
below 135/85.    
Outcomes: pre-
eclampsia, growth 
restriction, preterm 
delivery  
Pre-eclampsia (p=0.005), 
growth restriction 
(p=0.014), & preterm 
delivery (p=0.01) were 
significantly more likely 
in the „true‟ hypertension 
group. 
2
nd
 trimester ABPM 
differentiates WCH (rate 
of 62% in this study) 
with associated better 
pregnancy outcomes 
compared with „true‟ 
hypertension. 
 
169 Waugh 2000 
 
Prospective 
observational study 
348 Pregnant women 
>20 wks gestation, 
office BP ≥140/90. 
111 excluded 
(proteinuria), 3 
excluded (missing 
data).  
ABPM  data in 184 
(daytime) & 151 
(nighttime). 
SpaceLabs 90207 on all 
women. Women with 
proteinuria (>0.3 g/24 
hrs or 2 consecutive 
urine dipstick readings 
≥1+) were excluded. 
Primary outcome: birth 
weight. 
A significant inverse 
association found between 
daytime ABPM and birth 
weight: an increase in 5 
mmHg associated with 
birth weight fall of 68.5 g. 
Remained after adjusting 
for confounders. No 
association between day 
unit BP and birth weight. 
Evidence that maternal 
BP may be important 
variable in the 
association between 
birth weight and 
subsequent adult 
hypertension. 
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Table 1.7. (cont.) Studies of ABPM as a predictor of perinatal outcome in hypertensive pregnancies  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
174 Hermida 2002 
 
Prospective cohort 
study. 
Clinicians blinded 
to ABPM. 
444 Women <16 wks 
gestation  in a 
tertiary unit. 41 
withdrew.5 groups: 
-high office & high 
ABPM n=65 
-normal office, 
high ABPM n=63 
-both normal 
n=222 
-high office,normal 
ABPM n= 13 
-pre-eclampsia: 
both high, 
proteinuria n=40 
SpaceLabs 90207 
ABPM over 48 hours at 
recruitment & monthly. 
Hyperbaric index used. 
Proteinuria defined as 
>0.3 g/24h.  
Unlike average office BP, 
the hyperbaric index was 
significantly higher in pre-
eclampsia. Normotensive 
women as defined by 
ABPM had better 
outcomes (birth weight, 
preterm delivery, 
Caesarean section) 
„Hyperbaric index‟ 
derived from ABPM is 
markedly superior to 
office measurements for 
diagnose „true 
gestational hypertension‟ 
& predict pregnancy 
outcomes. 
 
171 Maggioni 2005 Prospective 
observational 
study. 
52 Women in third 
trimester.  
-33 uncomplicated 
pregnancies 
-19 with growth 
restriction 
confirmed at birth 
SpaceLabs PA 2500 
ABPM. Growth 
restriction defined as 
birth weight <10
th
 
centile. Five women in 
each group had raised 
BP (>140/90 mmHg). 
The circadian amplitude of 
diastolic BP was larger in 
fetal growth  restriction 
(chronobiology used). The 
finding persisted in 
separate analysis of 
normotensive women. 
The circadian amplitude 
of diastolic BP, already 
known to be associated 
with risk of stroke and 
shortened lifespan, is 
related to fetal growth 
restriction. 
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Table 1.7. (cont.) Studies of ABPM as a predictor of perinatal outcome in hypertensive pregnancies  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
172 Tranquilli 2005 Prospective cohort 
study. 
Clinicians blinded 
to ABPM results. 
279 -139 women with  
fetal growth 
restriction 
-140 normotensive 
women matched 
for age & gestation  
(32-34 weeks) 
without fetal 
growth restriction. 
All primigravid. 
SpaceLabs 90207 
ABPM in all women.  
Growth restriction 
defined as birth weight 
<10
th
 centile, corrected 
for gender. 
Normotensive pregnant 
women with fetal  
growth restriction had 
significantly raised ABPM 
compared to control group 
(p<0.0001). 
Even in the absence of  
overt hypertension, 
pregnant women with 
growth restricted babies 
have blood pressure 
higher than normal. 
ABPM can aid accurate 
evaluation of idiopathic 
non-genetic intrauterine 
fetal growth restriction.  
87 Giannubilo 
2006 
Prospective cohort 
study. 
423 -223 pregnant 
women with „mild 
chronic 
hypertension‟ (BP 
≥140/90 twice 4 
hours apart)  
-200 controls 
matched for age & 
parity 
SpaceLabs 90207 
ABPM (1
st
, 2
nd
, 3
rd
 
trimester, post-partum, 6 
wks post partum). 
Doppler of uterine 
arteries at 24 weeks 
gestation. Outcome: 
superimposed pre-
eclampsia (new 
proteinuria >0.3 g/24 
hrs/uncontrolled BP/ 
abnormal liver function). 
Mean ABPM was 
significantly higher in 
cases vs controls. Mean 
ABPM at 24 weeks 
(threshold of 121/78) is of 
most prognostic value for 
predicting  superimposed 
pre-eclampsia. 
In women with chronic 
hypertension in the 
second trimester, ABPM 
and uterine artery 
Doppler velocimetry are 
able to detect those at 
risk of superimposed 
pre-eclampsia. 
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Although reviews (see below) often quote the study of anti-hypertensive medication as an 
area where there is a possible role for ABPM, only one study was found in the literature 
review (Table 1.8). Neri suggested ABPM was an effective and reliable method, in a study 
comparing glyceryl-trinitrate and oral nifedipine.
175 
ABPM has also been used as a research 
tool in assessing effects of combined spinal epidural anaesthesia and antenatal thyrotrophin 
releasing hormone on blood pressure.
176, 177 
The use of repeated measurements with the 
technique allowed for smaller sample sizes in these studies. 
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Table 1.8. Studies of ABPM to evaluate anti-hypertensive medication or as a research tool 
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
176  Shennan 1995 Prospective 
observational 
62 Women in labour 
using combined 
spinal epidural 
(CSE) analgesia. 
SpaceLabs 90207 
ABPM done before and 
following procedure 
with readings every 10 
minutes, increased to 5 
minutes at spinal 
injection. One reading 
was taken post partum. 
ABPM showed a 
significant fall (>20%) in 
systolic BP in 8 women on 
administering the spinal 
injection. 52 women 
received an epidural dose 
and none had significant 
hypotension. 
Combined spinal 
epidural analgesia does 
not cause significant 
maternal hypotension on 
mobilising once the 
spinal injection is given.  
177 Peek 1995 Therapeutic trial 21 -16 normotensive 
women 
-5 women with 
pre-eclampsia 
(diastolic BP >100, 
proteinuria), on 
medication & for   
preterm delivery 
SpaceLabs 90207 used 
to monitor BP before, 
during and after 
administration of 
thyrotropin releasing 
hormone (TRH) to 
promote fetal lung 
maturation. 
Rises in systolic BP and 
mean arterial pressure 
were significantly greater 
in pre-eclamptic women 
after TRH vs 
normotensive women. BP 
levels of up to 190/135 
were recorded. 
In women with pre-
eclampsia, TRH for fetal 
lung maturation should 
be used with great 
caution. 
 
 
 
175 Neri 1999 Therapeutic trial 36 All women had 
BP>140/90 twice 4 
hrs apart. 4 had 
proteinuria >0.3 
g/24h.All >24 wks 
gestation 
SpaceLabs 90207 
ABPM at start & 2 wks 
after oral nifedipine 
(n=12), glyceryltrinitrate 
continuous (n=12) or 
intermittently (n=12). 
30 women completed the 
study. No significant 
effects were seen on blood 
pressure in any groups 
using chronobiology 
methods. 
ABPM effective and 
reliable method to 
evaluate effect of 
different treatment 
options 
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As discussed above, identification of women with white coat hypertension (WCH) using 
ABPM could potentially identify high risk groups more reliably and target intervention more 
appropriately. This is an area where ABPM is frequently used in the non-pregnant 
population. This phenomenon of persistently elevated clinic pressure with normal blood 
pressure at other times was first noted by Ayman and Goldshine over 60 years ago.
178,
 
30 
 
 
White coat hypertension is defined as the transient rise of a patient‟s BP in response to the 
clinic surroundings or the presence of the observer. In an early report Mancia measured 
intra-arterial blood pressure continuously while a doctor took regular blood pressure 
measurements using a cuff.
179
 The extent of the rise in BP was surprisingly marked: in 
„almost all‟ of the 48 normotensive and hypertensive subjects tested „the doctor's arrival at 
the bedside induced immediate rises in systolic and diastolic blood pressures peaking within 
1 to 4 minutes (mean 26.7 +/- 2.3 mm Hg and 14.9 +/- 1.6 mm Hg above pre-visit values).‟ 
By the end of the visit, levels had decreased to only slightly higher than the pre-visit 
readings.  
 
Over the years the definition of WCH has been refined, and is now described as BP ≥140/90 
mmHg in the office, with a normal daytime ABPM of <135/85, although the exact cut-off for 
ABPM varies slightly in the literature.
103, 180 
WCH is found in 15-30% of the general 
population and should be considered in newly diagnosed hypertensives, although the lack of 
clinical characteristics makes this difficult. There is debate about whether this is a truly 
benign condition, and there is probably a small increase in risk compared to the 
normotensive population. It may precede development of „true‟ hypertension. White coat 
hypertension is more common in female, young populations and therefore might be expected 
to arise in pregnancy. 
37,  181  
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Relevant studies of white coat hypertension in pregnancy are outlined in Table 1.9.  Rayburn 
et al found that on ABPM, daytime systolic and diastolic BP were at least 5 mmHg lower 
than elevated clinic readings in 80% and 83% of women respectively.
182
 They warned 
against unnecessary treatment of hypertension, suggesting a period of „close observation‟ 
before making any therapeutic decisions in pregnant patients with WCH.  In 1997 Biswas et 
al also found high rates of WCH at 28-37 weeks gestation, with only 38% of women 
diagnosed with „non-proteinuric hypertension‟ in the clinic being truly hypertensive on 
ABPM using mean DBP of 85 mmHg as the threshold.
183 A mean „white coat effect‟ on the 
systolic BP of 20 mmHg in normotensive women and 11 mmHg in hypertensive patients was 
noted. The authors suggest that in asymptomatic women with no proteinuria and clinic 
diastolic readings of 90-110 mmHg, the incidence of true hypertension is only 33% and 
justifies ABPM. 
 
A series of papers from one group provide insight into the growing body of evidence on 
white coat hypertension in pregnancy. In 1999 Brown et al‟s paper „The white coat effect in 
hypertensive pregnancy: much ado about nothing?‟ examined the presence of white coat 
hypertension (raised conventional BP and normal ABPM) and white coat effect (magnitude 
of difference between conventional BP and ABPM).
184 
They found that systolic and diastolic 
WCH were present in only 3.2% and 4.2% of a group of 120 women in the second half of 
pregnancy with conventional BP of  ≥ 140 mmHg systolic and/or ≥ 90 mmHg diastolic BP. 
They did however report a diastolic white coat effect of ≥ 10 mmHg in 20% of women in the 
study. Outcomes in this group (severe hypertension, anti-hypertensive drugs, abnormal 
laboratory values, birth weight and fetal growth restriction) were the same as women not 
exhibiting the effect. Possible explanations for the lower rate of WCH in this study include 
the inclusion of women with mild hypertension, screening before inclusion with averaging of 
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several conventional readings, and including women on anti-hypertensive drugs. However, 
the authors concluded that: „we can see little point in recommending ABPM or other 
automated blood pressure devices for the purpose of identifying a white coat effect in women 
with hypertension in the second half of pregnancy.‟ 
 
In a review of the subject in 2000, „White coat hypertension in pregnancy: fact or fantasy?‟ 
Brown and Davis suggest two potential implications of white coat effect/hypertension in 
pregnancy.
185
 The first is the administration of anti-hypertensive medication to pregnant 
women who may not have true hypertension. The second is the implication for prognosis of 
the pregnancy: is this finding benign or a marker for future complications? They suggest 
separate approaches to women in early and late pregnancy. The criteria for diagnosing raised 
BP on initial consultation are very important: studies suggest that repeated readings by a 
midwife rather than a doctor may lower rate of white coat hypertension (reflecting findings 
in non-pregnant patients). Supporting evidence includes a study by Turnbull et al which 
found increased rates of hypertension (10%) in women randomized to shared care as 
opposed to those with midwifery led care (4.8%), despite both groups of over 600 women 
being at equal risk.
186
 In a study of day assessment unit care, 60% of women referred with 
raised BP in antenatal clinic had normal BP after a more prolonged period of readings by 
midwives.
187
  
 
Olofsson and Persson also found, in women with mean gestation of 35 weeks, that the rate of 
WCH was nearly 30% following an initial raised BP
188
, and Biswas diagnosed it in 62% of 
women.
183
 However, in their own study in later pregnancy, Brown et al found a much lower 
rate of white coat hypertension (quoted above) after repeated readings by a midwife.
184
 In 
summary, in later pregnancy midwifery recording of BP and repeating of elevated readings 
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on a day unit might decrease white coat effect and allow identification of a high-risk group, 
as in some studies outlined in Table 1.9 and discussed above. In at least one third of cases in 
women with no other worrying features the women will be normotensive and can be 
followed up on the day assessment unit. 
 
However, in early pregnancy the situation is different. When BP is taken in young women, 
sometimes for the first time in their lives, a certain percentage will have white coat 
hypertension. Some women already carrying the label of „essential hypertension‟ will also 
come into this group. Before long-term medication is started ABPM can help confirm true 
hypertension, and ongoing studies were suggested to confirm the risks in this group. In a 
later paper, Brown et al went on to recommend that the gold standard for diagnosis of WCH 
is ABPM, and that an automated self-initiated device showed wide limits of agreement and 
could not replace ABPM.
189
  
 
 
Finally, in 2005 Brown‟s group reported on „The natural history of white coat hypertension 
during pregnancy.
‟ 190
 In a cohort of 241 women with an early pregnancy diagnosis of 
essential hypertension, 32% had white coat hypertension on ABPM. Cut-off points for 
normal ABPM were ≤ 130/80 mm Hg at under 26 weeks and ≤ 135/85 mmHg after 26 weeks 
gestation.
191 
In 50% the diagnosis of WCH was unchanged through pregnancy and no anti-
hypertensives were given; for 40% of the women the diagnosis changed to gestational 
hypertension. Pregnancy outcomes were good for both these groups. Only 8% of these 
women developed pre-eclampsia, compared to 22% of the women with true essential 
hypertension (p=0.008). However, as in the study by Bellomo,
167 
the caesarean section rate 
was high (40%) in the WCH group, possibly as a reaction to raised conventional BP 
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measurements near term. This emphasises uncertainties amongst clinicians in decision-
making in these women. 
 
Based on these findings, the paper recommended ABPM (or a validated home BP device) to 
establish if an initial diagnosis of essential hypertension in early pregnancy is correct. If 
white coat hypertension is found, outcomes should be much better but frequent monitoring is 
still necessary. This study repeated ABPM about every four weeks. By avoiding anti-
hypertensive medication in women who have WCH thoughout pregnancy, about one in three 
women with apparent essential hypertension can avoid these drugs.   
 
A large study in 2006 by Giannubilo et al described in Table 1.7, confirmed the role of 
ABPM in 223 pregnant women with mild chronic hypertension.
87 
Superimposed pre-
eclampsia developed in 34.9% and was predicted with a specificity of 89% using mean 
diastolic BP of 78 mmHg at 24 weeks gestation. 
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Table 1.9. Studies of ABPM values compared to conventional BP values, including white coat hypertension 
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
182 Rayburn 1993 Prospective 
comparative 
30 Previously 
normotensive 
women (mean 
gestation 31 wks) 
attending a routine 
clinic, latest office 
BP elevated to 
>140/90 or rise of 
30/15 over 
booking BP. 
SpaceLabs 90207 
ABPM at home. Mean 
day and night values 
compared to office 
values taken with 
mercury, random zero 
sphygmomanometer. 
In 27 women (90%), 
ABPM was below office 
values. In 3 women the 
levels were the same. In 
no case were ABPM 
values greater than office 
measurements. 
This form of „mild 
hypertension‟ in 
pregnancy is often 
specific to a clinic visit 
and may lead to 
unnecessary treatment. 
192  
 
Brown 1993 Prospective 
comparative 
42 Pregnant women in 
third trimester: 
normotensive and 
hypertensive 
(numbers not given 
for each group) 
Accutracker II ABPM 
Hawkesley random zero  
sphygmomanometer 
readings compared over 
90 minutes seated 
(n=42) & 30 minutes 
standing/ walking 
(subgroup, n=20) 
Seated and ambulatory 
ABPM overestimated 
systolic BP by 5 and 7 
mmHg, & underestimated 
phase V diastolic BP by 3 
& 4 mmHg respectively. 
ABPM readings with the 
Accutracker II are 
reasonably comparable 
to mercury readings in 
pregnant women, 
particularly for group 
data. 
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Table 1.9. (cont.) Studies of ABPM values compared to conventional BP values, including white coat hypertension  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
188 
 
Olofsson 1995 Prospective 
comparative 
99 Pregnant women, 
mean gestation 35 
wks, hospitalised 
for new 
hypertension (BP 
≥140/90 at 2 
consecutive visits 
& repeatedly 
raised thereafter).  
SpaceLabs 90202 
ABPM twice (n=14), 3 
times (n=3) & 4 times 
(n=2), and routine 
conventional BP (CBP) 
in parallel at least 5 
times daily. Note women 
hospitalised and on bed 
rest during monitoring. 
ABPM SBP was 
significantly higher and 
DBP was significantly 
lower than CBP.  
ABPM and CBP gave 
significantly correlated 
but different values of 
BP. New definitions of 
hypertension are needed 
if ABPM used in 
pregnancy. 
193  
 
Churchill 1996 Prospective 
comparative 
239 -209 nulliparous 
pregnant women 
with no history of 
hypertension 
-30 nulliparous 
non pregnant 
women as controls 
SpaceLabs 90207 
ABPM at 18, 28, &36 
wks gestation compared 
to random zero device. 
62 cases had ABPM 12 
wks postpartum .  
24-hr median ABPM was 
higher than office BP in 
pregnancy (p<0.001). 
After delivery the 
difference was non-
significant and was similar 
to other surveys and the 
non pregnant controls. 
ABPM and CBP are 
different in pregnancy, 
and are different entities. 
Care should be taken in 
predicting obstetric 
outcome from the results 
of ambulatory BP 
recordings.  
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Table 1.9. (cont.) Studies of ABPM values compared to conventional BP values, including white coat hypertension 
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
183 
 
Biswas 1997 Prospective 
observational 
128 Pregnant women 
28-37 wks 
gestation with 
diastolic BP  
≥90 mmHg twice 
30 mins apart, and 
no proteinuria 
SpaceLabs 90207ABPM 
at home.  
Valid recordings in 120 
women. 46 (38.3%) had 
true hypertension defined 
by ABPM (threshold 24-hr 
mean diastolic BP 85 
mmHg.) White coat effect 
was seen in both groups, 
as mean BP was almost 
always lower than initial 
clinic readings. 
White coat hypertension 
(WCH) is „common‟ in 
pregnancy. ABPM can 
help identify true 
hypertension without 
requiring hospitalisation. 
33.3% of asymptomatic 
patients with diastolic 
BP 90-110 mmHg have 
true hypertension. 
194  
 
Yohay 1997 Prospective 
observational 
47 Pregnant women in 
the third trimester 
-17 pre-eclampsia: 
(BP ≥140/90 or  
>30/15 increase 
twice 6 hours 
apart.) 
-15 with chronic 
hypertension (BP 
as above <20 wks.) 
-15 normotensive  
Accutracker ABPM. 
Note definition of pre-
eclampsia does not 
include proteinuria.  
ABPM readings were 
lower than CBP in 
hypertensive women. The 
difference was more 
pronounced in pre-
eclamptic women than 
chronic hypertensives. 
ABPM appears to be a 
promising method for 
the evaluation of 
hypertensive disorders 
of pregnancy. 
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Table 1.9. (cont.) Studies of ABPM values compared to conventional BP (CBP) values, including white coat hypertension (WCH)  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
191 
 
Brown 1998 Prospective 
comparative 
259 Attendees at 
routine antenatal or 
high risk for pre-
eclampsia due to 
history. Women 
with chronic or 
white coat 
hypertension were 
excluded. 
SpaceLabs 90207 
ABPM up to four times 
in pregnancy. 276 
successful studies made. 
Seven readings taken of 
alternating ABPM x3 & 
mercury readings x4. 
Smallest difference used 
to compare devices 
Awake ABPM 
measurements are 
significantly higher than 
mercury device 
measurements. Only 2% 
of women discontinued 
monitoring. Normal 
ranges are described 
across gestation. 
Women tolerate ABPM 
well and use is feasible 
in pregnancy. In a 
research setting with 
repeated readings in a 
relaxed setting,  
conventional values are 
lower than ABPM for 
„awake‟ measurements. 
195  
 
Koenen 1998 Prospective cross-
sectional  
comparative 
10 Hospitalised 
pregnant women. 
Four had 
pregnancy-induced 
hypertension 
(diastolic BP >90).  
SpaceLabs 90207 
ABPM with repeated 
mercury measurements 
using Y-tube connector 
at 9 predetermined 
timepoints. 
None of the contrasts 
between any pair of time 
points reached statistical 
significance. However, 
substantial within-subject 
variability of the pressure 
difference was seen. 
Difficulty in estimating 
precisely the pressure 
difference between 
methods is an 
impediment for 
interpretation of ABPM 
data. 
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Table 1.9. (cont.) Studies of ABPM values compared to conventional BP values, including white coat hypertension  
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
184 
 
Brown 1999 Prospective 
blinded 
121 Hypertensive 
women in second 
half of pregnancy 
admitted to 
hospital or 
antenatal day unit. 
Mercury readings 
done 4-6 times and 
averaged. 
SpaceLabs 90207 
ABPM WCH defined: 
mean mercury BP≥140 
/90 & awake ABPM 
normal for gestation. 
White coat effect (WCE) 
is difference between 
them. Perinatal 
outcomes compared in 
women with and without 
WCE ≥20 (systolic) and 
10 mmHg (diastolic). 
Systolic and diastolic 
white coat hypertension in 
3.2% and 4.2% of group. 
White coat effect found in 
4.2% (systolic) & 20.2% 
(diastolic). Outcomes 
assessed in latter group 
(n=24) showed no 
difference compared to 
those without diastolic 
white coat effect. 
White coat hypertension 
(WCH) is an „infrequent 
occurrence‟ in mild late 
hypertension, no 
difference in outcome if 
present. Using ABPM to 
detect white coat effect 
in women with 
hypertension in the 
second half of pregnancy 
does not appear to be 
clinically useful. 
196  
 
Hermida 2004  403 -235 normotensive 
-128 gestational 
hypertension (>20 
wks, BP>140/90 & 
raised hyperbaric 
index) 
-40 pre-eclampsia 
(BP as above & 
proteinuria >0.3g/ 
24 h.) 
SpaceLabs 90207 for 48 
hrs from recruitment at 
<16 wks and 4-weekly. 
The tolerance-hyperbaric 
test (where diagnosis of 
hypertension is based on 
the hyperbaric index 
calculated by reference 
to a time-specified 
tolerance limit), is used. 
When measured in the 
third trimester, hyperbaric 
index gave a sensitivity of 
99.2% & specificity of 
100% in predicting any 
pregnancy hypertension. 
This compares to 14.4% 
and 99.5% for systolic of 
140 and 4% and 100% for 
diastolic BP. 
Sensitivity of ABPM is 
superior to conventional 
BP in predicting 
hypertension when the 
hyperbaric index is used. 
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Table 1.9. (cont.) Studies of ABPM values compared to conventional BP values, including white coat hypertension   
Reference 
 
First author 
Year 
Study design Sample 
size 
Subjects Description Findings Conclusion 
189 Brown 2004 Prospective 
observational 
66 Pregnant women 
being assessed for 
possible „white 
coat 
hypertension.‟, 
mean gestation 23 
weeks. 
SpaceLabs 90207 awake 
ABPM vs 6 self-initiated 
automated BP readings 
(Omron HEM 705CP). 
Primary outcome 
measure: Limits of 
agreement between BP 
on each device. 
Average BP was identical 
(125/77) in both devices, 
but with wide limits of 
agreement (systolic -20 to 
+23 mmHg, diastolic -9 to 
+15 mmHg). 
ABPM is the gold 
standard for clinical 
management of women 
with white coat 
hypertension. This 
Omron self-initiated 
device cannot reliably 
replace it as individual 
BP differences are 
probably too great.  
190 Brown 2005 Prospective 
interventional 
241 Pregnant women: 
early pregnancy 
diagnosis of 
essential 
hypertension (EH). 
86 had the 
diagnosis 
confirmed pre-
pregnancy as home 
monitor/ABPM≥ 
135/85. 
The remaining 155 
women had SpaceLabs 
90207 ABPM in early 
pregnancy.  Those with 
white coat hypertension 
(WCH) were untreated 
& had ABPM monthly. 
Primary outcome: pre-
eclampsia (spot 
urine:creatinine ≥ 30). 7 
women excluded with 
miscarriage <20 weeks. 
78/241 (32%) women had 
white coat hypertension. 
38 (50%) retained this 
diagnosis and had good 
pregnancy outcomes as 
did the 32 (40%) with 
gestational hypertension. 6 
(8%) developed pre-
eclampsia vs 35 (22%) of 
women with essential 
hypertension (p=0.008).  
About one third of 
women with apparent 
essential hypertension 
early in pregnancy have 
WCH. ABPM is 
recommended for 
diagnosis & ongoing 
surveillance, & should 
reduce use of 
antihypertensives by 1/3. 
Pregnancy outcomes are 
good in WCH. 
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The literature search revealed publications stating guidelines and recommendations on 
ABPM in pregnancy from specialist conferences, and position statements of various 
organisations. None of these give details of the literature search used and they are generally 
presented as consensus statements and expert opinion. Two papers mention the hierarchy of 
evidence assessed. In their statement on behalf of the British Hypertension Society, O‟Brien 
et al
180 
 grade the strength of evidence according to Shekelle et al (Table 1.10)
197
, allocating 
Grade C-D to recommendations on use of ABPM in pregnancy. McGrath
102 
,on behalf of the 
National BP Advisory Committee of the National Heart Foundation of Australia, provided 
overall recommendations graded according to the National Health and Medical Research 
Council quality-of-evidence ratings.
198
 However, the recommendations related to ABPM use 
in pregnancy are not graded in this publication. Table 1.11 summarises these guidelines and 
statements. 
 
Table 1.10 Classification schemes for interpreting evidence for guidelines
197 
 
 
Category of evidence Description 
Ia Evidence for meta-analysis of randomised controlled trials 
Ib Evidence from at least one randomised controlled trial 
IIa Evidence from at least one controlled study without randomisation 
IIb Evidence from at least one other type of quasi-experimental study 
III Evidence from non-experimental descriptive studies, such as 
comparative studies, correlation studies, and case-control studies 
IV Evidence from expert committee reports or opinions or clinical 
experience of respected authorities, or both 
Strength of 
recommendation 
Description 
A Directly based on category I evidence 
B Directly based on category II evidence or extrapolated 
recommendation from category I evidence 
C Directly based on category III evidence or extrapolated 
recommendation from category I or II evidence 
D Directly based on category IV evidence or extrapolated 
recommendation from category I, II or III evidence 
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Table 1.11. Guidelines and Society recommendations for ABPM in pregnancy  
Reference 
Author 
Year 
Group represented Objective  Conclusions related to pregnant women Recommendations  
199 
Staessen 
1995 
4
th
 International Consensus 
Conference on ABPM 
(Leuven, Belgium, 1994) 
Focus on technical aspects of 
ABPM in all patient groups 
 
If monitor is used in special populations, a 
specific demonstration of its accuracy in 
these defined subgroups is warranted. 
Validation of devices in pregnant women 
is essential.  
200 
Staessen 
1999 
7
th
 International Consensus 
Conference on ABPM 
(Leuven, Belgium, 1999) 
To reach a consensus on the 
clinical use of ABPM 
-As with non-pregnant women, main 
indication for ABPM in pregnancy is to 
measure white coat effect, avoiding 
unnecessary /excess antihypertensive drugs. 
-Normal values have been defined 
-Evidence for prediction of pre-eclampsia 
inconclusive, but has predicted birth weight. 
ABPM is „especially indicated‟ for 
pregnant women. 
180 
O‟Brien 
2000 
British Hypertension 
Society 
To advise on the use and 
interpretation of ABPM in adults 
 
-Main use in pregnancy is identifying white 
coat hypertension 
-Normal values are now defined through 
pregnancy 
-Correlates better with proteinuria and 
predicts complications of hypertension, 
including low birth weight, better than 
conventional BP 
-Women identified as white coat 
hypertensives have more Caesareans than 
normotensive women. 
-ABPM may be used to avoid 
unnecessary hospital admission or drug 
administration.  
-Some caesarean deliveries might be 
avoided by identifying women with white 
coat hypertension. 
 
Overall conclusion: ABPM is of benefit 
in diagnosing and treating hypertension in 
pregnancy (evidence strength C–D, see 
text for details). 
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Table 1.11. (cont.) Guidelines and Society recommendations for ABPM in pregnancy  
Reference 
Author 
Year 
Group represented Objective  Conclusions related to pregnant women Recommendations  
201 
Staessen 
2001 
8
th
 International Consensus 
Conference on ABPM 
(Sendai, Japan, 2001) 
To reach a consensus on the 
prognostic significance of new 
techniques of automated blood 
pressure measurement. 
Several studies of „gestational hypertension‟ 
have shown that, compared to office 
measurement, ABPM is a better predictor of 
maternal and fetal complications. 
-Pregnancy is a special indication for 
ABPM to measure the white coat effect 
and reduce unnecessary antihypertensive 
drug use. 
-Further studies are needed to address 
application of ABPM in high-risk 
pregnant women with chronic 
hypertension, Type 1 diabetes or 
hypertensive nephropathy. 
102 
McGrath 
2002 
National BP Advisory 
Committee of the National 
Heart Foundation of 
Australia: position 
statement. 
To provide guidance on how and 
when ABPM should be applied 
in practice, and how to interpret 
results. 
NB hierarchy of evidence 
described but not applied to 
pregnancy recommendations. 
ABPM should be considered in hypertension 
in pregnancy. 
-ABPM has a role in assessing 
hypertension in pregnancy.  
-Definitive outcome studies are needed in 
the form of randomised controlled trials 
comparing management of hypertension 
based on office BP measurement vs 
ABPM (general recommendation for all 
patient groups.) 
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Further papers providing reviews, clinical overviews and commentaries on the use of ABPM 
in pregnancy are listed in Table 1.12. The QUORUM statement on assessment of quality of 
reporting of systematic reviews was used as a basis to assess the publications.
202
 However, 
only one publication qualifying as a systematic review using formal meta-analysis was 
identified: a Cochrane review by Bergel and Carroli.
203
 The title, structured abstract, and 
methodology for searching, selection, and validity assessment complied with the QUORUM 
checklist. There was a discussion with a future research agenda as suggested. As no 
randomized trials were identified for the meta-analysis, further QUORUM assessment on 
areas such as data abstraction and quantitative data synthesis was not relevant.  
 
The other references described in Table 1.12 have been described as clinical overviews or 
commentaries to emphasise that they are not systematic reviews. Their main conclusions and 
recommendations are summarised in the table. Validation of the monitors used in pregnancy 
is frequently recommended in these publications. The need for objective validation of 
ambulatory monitors has been referred to in the discussion on ABPM in the general 
population (Section 1.4.1). Validation in pregnant women has been reviewed in Section 1.4.2 
above.  
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Table 1.12. Reviews, overviews and commentaries on ABPM in pregnancy  
Reference 
Author 
Year 
Type of publication Details (using QUORUM) Findings / Conclusions Recommendations  
204  
Halligan  
1991 
Clinical overview Systematic review: No 
Structured abstract: No 
Literature search described: No 
Types of studies specified: No 
-Five studies are underway in the use 
of ABPM in pregnancy.  
-Results so far indicate ABPM is an 
acceptable method of measuring BP 
in pregnancy. 
Possible roles for ABPM in antenatal 
management of hypertension include 
modification of classification systems, clinical 
confirmation, and predicting pre-eclampsia 
129  
Greer  
1993 
Commentary Systematic review: No 
Structured abstract: No 
Literature search described: No 
Types of studies specified: No 
-Summarises three studies in that 
issue of the journal. 
-Concludes that ABPM can provide 
accurate assessment of blood 
pressure in pregnancy  
-Consider Korotkoff V for measuring with 
ABPM. 
-If ABPM is used, it is important to relate these 
measurements to clinical outcome 
30  
Halligan  
1995 
Clinical overview Systematic review: No 
Structured abstract: No 
Literature search described: No 
Types of studies specified: No 
-Discusses device validation 
evidence, values in normal 
pregnancy, patient acceptability, use 
in preeclampsia, applications in 
antenatal care.  
Overall, ABPM may lead to reappraisal of 
clinical management of hypertension in 
pregnancy. 
Potential uses include: 
-overcoming sampling, measurement and white 
coat hypertension errors of conventional BP  
-diurnal changes may aid diagnosis of pre 
eclampsia 
-cost and patient satisfaction benefits of 
outpatient monitoring 
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Table 1.12. (cont.) Reviews, overviews and commentaries on ABPM in pregnancy 
Reference 
Author 
Year 
Type of publication Details (using QUORUM) Findings / Conclusions Recommendations  
31  
Halligan  
1996 
Clinical overview Systematic review: No 
Structured abstract: No 
Literature search described: No 
Types of studies specified: No 
-Discusses technical aspects 
including problems with 
conventional BP, validation of 
devices, reference values, and white 
coat hypertension in pregnancy. 
-ABPM has been introduced into 
clinical obstetric practice without 
evidence of significant benefit. 
-May reduce number of antenatal admissions and 
direct clinical action to high-risk patients. 
-A randomised controlled trial is needed 
comparing ABPM to conventional BP 
measurement. 
32  
Walker  
1998 
CME review article Systematic review: No 
Structured abstract: No 
Literature search described: No 
Types of studies specified: No 
-Summarises limitations of 
conventional BP measurement, 
history and device validation in 
ABPM, patterns in normal 
pregnancy, ABPM and perinatal 
outcome. 
-In pregnancy ABPM may be considered the 
optimal research instrument  
-The ultimate place of ABPM „awaits 
clarification.‟ 
6  
Shennan  
1998
 
Clinical overview Systematic review: No 
Structured abstract: No 
Literature search described: No 
Types of studies specified: No 
-Reviews significance of 
hypertension in pregnancy, 
limitations of conventional BP, 
equipment validation, use in 
pregnancy 
-ABPM clearly has advantages over 
conventional measurement, with potential in 
assessing at risk hypertensive pregnancies.  
-Not always accurate especially in pre-eclampsia 
-Validate devices.  
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Table 1.12. (cont.) Reviews, overviews and commentaries on ABPM in pregnancy 
Reference 
Author 
Year 
Type of publication Details (using QUORUM) Findings / Conclusions Recommendations  
103  
Pickering  
2000 
Clinical overview Systematic review: No 
Structured abstract: No 
Literature search described: No 
Types of studies specified: No 
One section of paper is on ABPM in 
pregnancy. It describes a study 
finding 29% of women with clinic 
hypertension have white coat 
hypertension; these women may 
have unnecessary caesarean sections. 
Reference not given for this paper. 
No specific recommendations for ABPM in 
pregnancy. 
205  
Waugh  
2000 
Clinical overview Systematic review: No 
Structured abstract: No 
Literature search described: No 
Types of studies specified: No 
Discusses technical aspects 
including haemodynamic changes in 
normal and hypertensive pregnancy, 
and validation issues. 
-Validation procedure is essential and should 
include formal validation in pre-eclampsia 
-Additional care must be taken in interpreting 
readings form devices not validated in pre-
eclampsia. 
33  
Feldman  
2001 
Clinical overview Systematic review: No 
Structured abstract: No 
Literature search described: No 
Types of studies specified: No 
Summarises studies on patterns of 
ABPM in normal pregnancy and as a 
predictor of outcome in two tables. 
These describe study characteristics 
(how many subjects, trimester of 
monitoring, primary outcome) but do 
not formally assess quality or how 
studies selected. 
-ABPM is promising in predicting pre-eclampsia 
in chronic hypertensive women. 
-Further research is needed to better define the 
role of ABPM in routine and high-risk obstetric 
practice. 
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Table 1.12. (cont.) Reviews, overviews and commentaries on ABPM in pregnancy 
Reference 
Author 
Year 
Type of publication Details (using QUORUM) Findings / Conclusions Recommendations  
206  
Redon  
2001 
Clinical overview Systematic review: No 
Structured abstract: No 
Literature search described: No 
Types of studies specified: No 
Discusses reference values, 
prediction of pre-eclampsia and 
white coat hypertension. 
-ABPM may be useful in „gestational 
hypertension‟ 
-The role of ABPM in high-risk pregnancies 
needs to be explored. 
 
37  
Higgins  
2001 
Clinical overview Systematic review: No 
Structured abstract: No 
Literature search described: No 
Types of studies specified: No 
Discusses conventional and ABPM 
measurement in pregnancy, 
including white coat hypertension 
and prognostic value in late 
pregnancy. 
-Careful blood pressure measurement with a 
mercury device remains the gold standard 
-All ABPM devices should be validated for use 
in pregnancy, preferably in patients with pre-
eclampsia 
-Randomized trials of ABPM compared with 
conventional BP measurement in hypertensive 
women are now urgently needed 
203 
Bergel  
2002 
Systematic review for 
the Cochrane Library 
Systematic review: Yes 
Structured abstract: Yes 
Literature search described: Yes  
Types of studies specified: Yes 
Two reviewers evaluated all 
potentially relevant articles, 
examined each study for inclusion 
and assessed methodological quality 
using Cochrane guidelines. 
No trials were included. 
-There is no randomized controlled trial 
evidence to support the use of ABPM during 
pregnancy. 
-Randomized trials are needed. 
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Table 1.12. (cont.) Reviews, overviews and commentaries on ABPM in pregnancy  
Reference 
Author 
Year 
Type of publication Details (using QUORUM) Findings / Conclusions Recommendations  
207  
O‟Brien  
2003 
Clinical overview Systematic review: No 
Structured abstract: No 
Literature search described: No 
Types of studies specified: No 
-Main use in pregnancy is 
identifying white coat hypertension 
-Normal values are now defined 
through pregnancy 
-Correlates better with proteinuria 
and predicts complications of 
hypertension, including low birth 
weight, better than conventional BP 
-Women identified as white coat 
hypertensives have more Caesareans 
than normotensive women. 
-White coat hypertension may occur in  ≤30% of 
pregnancies, main use of ABPM is to detect this.  
-Caesarean sections may be avoided if ABPM 
was used to measure BP rather than conventional 
technique. 
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Outpatient monitoring has potential benefits in cost and convenience to patients and 
institutions. The increasing use of ABPM in pregnancy coincided with the establishment of 
the obstetric day-care unit,
208,
 
209
 with a trend away from prolonged antenatal admission for 
pregnancy complications such as hypertension. In the non-pregnant population there is now 
evidence that the additional costs of ABPM are offset in the first year by savings in patients 
with white coat hypertension (26% of the total) who would have otherwise received 
treatment.
210
 These savings applied with the factoring in of a 10% conversion rate to 
established hypertension in those patients in whom WCH is a pre-hypertensive state. A 
related editorial suggested that the recognition of white coat hypertension in pregnancy „has 
the potential to reduce anxiety, hospital admissions and drug use, with significant cost 
savings.‟ 211 
 
All relevant studies found in the literature search are listed in the tables above. The search 
was performed with the help of a clinical librarian, and a wide range of terms was used 
including truncated terms and alternative spellings. When full references were obtained their 
reference list was checked against the database for further publications. Every publication 
found relating in any way to the use of ABPM in pregnant women was included in the 
Tables. The reasons for not including studies, such as being automated rather than 
ambulatory monitoring, have been described in section 1.1.2. We did not actively seek 
unpublished studies and that could lead to missing studies and publication bias. The search 
excluded publications in languages other than English due to costs of obtaining full text 
papers and translating them. This is a potential disadvantage, which might lead to missing 
relevant papers.
212
 However, our finding that there were no randomized trials of ABPM in 
pregnancy was the same as that of the published Cochrane review, conducted with the full 
support of the Cochrane Collaboration with no language restrictions. 
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There were limitations in many of the publications described in the tables above, with small 
numbers of patients (few had power calculations), giving a higher chance of a Type II error 
(false negative). They often did not include information on potential confounding variables 
for outcomes such as age, parity, or ethnicity. It could not be defined whether they were 
prospective or retrospective studies in some cases and there was a lack of reporting of 
patients excluded from analysis; this could lead to selection bias. As discussed in section 
1.3.1, the problem of the varied definitions of hypertension in pregnancy was evident in 
reviewing the publications; when definitions were given they are included in the tables 
above. 
 
Within those limitations, the research described above suggests that there are valid reasons 
for believing that ABPM assessment of hypertensive pregnant women may be superior to 
conventional antenatal clinic blood pressure readings in two main ways. Firstly, it will 
identify women suffering from white coat hypertension and thereby prevent unnecessary 
treatment and monitoring. Secondly, by assessing the blood pressure more accurately 
obstetricians will be able to identify women at risk of adverse perinatal outcomes. These two 
aspects are not mutually exclusive: it is likely that the correct identification of women with 
white coat hypertension allows better allocation of risk. 
 
However, all the studies performed so far are cohort or case controlled studies and thus 
subject to bias. They may not have identified adverse consequences of ABPM, such as more 
and possibly unnecessary obstetric intervention. Alternatively, the beneficial effects of 
ambulatory blood pressure monitoring may have been considerably over-estimated. The 
clinical effectiveness of ABPM needs to be tested in a prospective randomized study, 
comparing the technique with conventional methods of monitoring blood pressure in 
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pregnant women. A paper published in the Lancet in 2001 stated that such randomized trials 
are now urgently needed.
37 
 
 
The Cochrane review (latest view date December 2007) entitled „Ambulatory versus 
conventional methods for monitoring blood pressure during pregnancy‟, stated that: „given 
the observational data suggesting that ABPM can enhance assessment of blood pressure in 
pregnancy, and experimental data in non-pregnant subjects showing that hypertensive 
patients monitored with ABPM might have better outcomes, there is a clear need for 
randomized trials of ABPM compared with conventional blood-pressure measurement in 
pregnancy, and in particular in hypertensive pregnant women. There is no randomized 
controlled trial evidence to support the use of ABPM during pregnancy.‟ 203  
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1.5 AIMS AND OBJECTIVES OF THIS THESIS  
This thesis aims to test the hypothesis that in pregnancies complicated by hypertension, 
ambulatory blood pressure monitoring improves clinical assessment and outcome for both 
mother and fetus. There are three objectives: 
-To quantify the risks of hypertension in pregnancy to mother and baby in a local multi-
ethnic population. 
-To ascertain the extent to which the technique of ambulatory blood pressure monitoring 
(ABPM) is useful in the assessment of hypertensive pregnancies, and assess its predictive 
value for significant maternal and fetal outcomes.  
-To evaluate the potential benefits of employing ABPM in hypertensive pregnancies in the 
clinical setting. 
 
These objectives will be met by conducting the following experiments/investigations: 
-Analysis of a local database of 625 pregnancies in women with hypertension, specifically 
assessing maternal and fetal outcomes in different diagnostic and ethnic groups. 
-A retrospective analysis of ABPM in a cohort of 100 hypertensive pregnant women, to 
determine the specific maternal and fetal predictive qualities of the technique. 
-A randomized controlled trial of ABPM in hypertensive pregnancies in the clinical setting. 
Hypertensive pregnant women not requiring delivery within 24 hours were eligible. All had 
24-hour ABPM as well as conventional BP measurement.  Half of the participants had the 
monitoring results revealed to the clinician, and the other half had their results concealed. 
Primary outcome measures were admission to hospital for hypertension, antihypertensive 
medication, induction of labour for hypertension, and caesarean section. 
 
 
 84 
 
CHAPTER 2: 
PERINATAL OUTCOMES IN A MULTI-ETHNIC 
HYPERTENSIVE, PREGNANT POPULATION 
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2.1 ABSTRACT  
Objective: To investigate obstetric, perinatal and neonatal outcomes in hypertensive women 
attending a specialist antenatal clinic. 
Design: Retrospective cohort study  
Setting: An inner city hospital antenatal hypertension clinic.  
Participants: 627 pregnancies in 509 women with prospective data from 1980-2002.  
Main outcome measures: Obstetric, perinatal and neonatal outcomes 
Results: From a database of 627 pregnancies, 317 (50.6%) had chronic hypertension (CH), 
123 (19.6%) gestational hypertension (GH), 61 (9.7%) secondary hypertension (SH) and 45 
(7.2%) pre-eclampsia (PE). Compared to the obstetric population, pregnancies in 
hypertensive women had an increased risk of Caesarean section, and (with the exception of 
GH) a baby weighing <2.5 kg or delivered preterm. Overall in the study population, there 
were increased rates of stillbirth in pregnancies in Black (40:1000) and Asian (64.8:1000) 
compared to White women (14:1000), though statistical significance was only reached 
comparing pregnancies in White and Asian women (percentage difference -5.1%; 95% 
confidence intervals (CI) -6.9, -1.5; p=0.007). Perinatal mortality rates (PMR) per 1000 live 
and stillbirths were lower in pregnancies in White vs Asian women: (28.0 vs 83.3, 
percentage difference -5.5%; 95% CI -8.4, -1.2; p=0.013). Outcomes in chronic hypertension 
were analysed further. Pregnancies with chronic hypertension alone had lower perinatal 
mortality rates than with superimposed pre-eclampsia (49.8 vs 115.9, percentage difference           
-6.6%; 95% CI -14.2, -0; p=0.049). Pregnancies in White women with chronic hypertension 
had lower stillbirth rates compared to Asian women: 11:1000 vs 102:1000 (percentage 
difference -9.1%; 95% CI -10.8, -2.6; p=0.008). The majority (88.2%) of stillborn babies 
from pregnancies in chronic hypertensive women weighed less than the 10
th
 centile. 
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Compared to White women, more pregnancies in Asian women with CH were booked after 
20 weeks gestation (White vs Asian 3.2 % vs 18%, percentage difference -14.8%; 95% CI    
-18.8, -6.4; p=0.001). The mean birth weight was greater in pregnancies in White women 
compared to those in Asian women (2.73 vs 2.37 kg, difference 0.36 kg; 95% CI 0.12, 0.6; 
p=0.003). 51% of pregnancies in Asian women and 43.9% of those in Black women 
delivered a baby under 2.5 kg vs 31.2 % of White women (p=0.016 overall). 
Conclusion: This cohort seen in one centre with complete follow-up is comparable with 
other series in the world literature. Our results confirm the high perinatal mortality rates in 
pregnancies in women with chronic hypertension. Black and Asian chronic hypertensive 
pregnancies are particularly at risk due to increased rates of stillbirths of low birth weight 
babies.   
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2.2 INTRODUCTION 
The hypertensive disorders of pregnancy and their important implications for feto-maternal 
outcome have been described in Section 1.3. A detailed and prospectively gathered 
computerised database is held for women attending a specialist antenatal hypertension clinic 
at City Hospital, Birmingham. Women want accurate information about the likely outcome 
of their pregnancy, particularly if they have a pre-existing medical condition such as chronic 
hypertension. Clinicians also need to be able to accurately allocate risk factors for adverse 
outcomes, and indeed the whole principle of antenatal care is underpinned by risk 
assessment. This study was conducted to address these issues for a local population and also 
for pregnant women in general. 
 
Previous analysis of 436 pregnancies from the database reported increased risks of perinatal 
mortality, preterm delivery and lower birth weight in Indo-Asian women with chronic 
essential hypertension.
213
 A further database study of pre-eclampsia and other obstetric 
outcomes in pregnancies of 159 normotensive and 213 chronic hypertensive women was 
published in 2001.
84
 Further analysis of obstetric and neonatal outcomes in 627 pregnancies 
in women attending this antenatal hypertension clinic, including 317 chronic hypertensive 
pregnancies, is reported below. Outcomes in pregnancies in the different diagnostic groups 
and amongst different ethnic groups were of particular interest. 
2.3 METHODS 
All women attended the antenatal hypertension clinic at a District General Hospital in 
Birmingham. The hospital serves a population of about 300,000 people, of whom 64% are 
White, 25% are Indo-Asian and 11% are Afro-Caribbean. Ethnicity was self-reported, using 
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the hospital definitions in use at the time of the data collection. Information on demographic 
data, clinic blood pressure (BP) measurements, blood tests, drugs, complications and 
obstetric and neonatal outcomes are recorded prospectively onto a proforma. Seemingly 
spurious or extreme values are checked with the hospital notes. The data are then entered 
into a computerised database and validated. Two further researchers checked the data by 
cross-checking the proforma against the database manually for each entry. Outlying data or 
obvious errors were re-checked with the original hospital notes. For the current study, active 
follow-up of babies was conducted to ascertain their status at one week of age, to obtain 
accurate data for early neonatal deaths, and thus the true perinatal mortality rate.  
 
Pregnant women are referred to the clinic by their midwife, general practitioner or 
obstetrician early in the pregnancy because of a history of pre-eclampsia or hypertension in a 
previous pregnancy, known chronic hypertension, or the discovery of hypertension in the 
first trimester. A team comprising of an obstetrician and physician with an interest in 
hypertension then conducts all pregnancy care. The BP is measured according to a strict 
protocol. The woman is seated in a quiet room with her right arm supported and the correct-
sized cuff sited at the level of the heart. The first and fifth Korotkoff sounds are taken for 
systolic and diastolic BP respectively and a total of three readings taken over a minimum of 
three minutes.
214
 The recorded blood pressure is the average of the last two readings. Initially 
the Hawksley Random Zero sphygmomanometer was used, to reduce observer error. Over 
the last five years, the Omron HEM 705 CP automatic blood pressure measuring device was 
used. All devices are regularly calibrated and their accuracy checked. Proteinuria is 
measured using dipstick urine testing (Multistix, Bayer, USA) and where applicable, by 24-
hour urine collection for total protein.  
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A cohort of pregnancies in women from the database were analysed retrospectively. 
Obstetric and neonatal outcomes in 627 pregnancies in 509 women attending the clinic 
between 1980 and 2002 were studied. Hypertensive disorders were classified by criteria 
described by Davey and McGillivray
53 
and endorsed by the International Society for the 
Study of Hypertension in Pregnancy (ISSHP) (Table 2.1). Renal hypertension was defined as 
hypertension in the presence of renal disease diagnosed pre-pregnancy, or when history and 
investigations confirmed renal disease.  The final diagnosis was made in retrospect when two 
researchers independently classified the cases. If there was any disparity the cases were 
discussed and agreement reached. Data used in the analysis included maternal age, ethnicity, 
smoking status, parity, medication at booking, blood pressure, gestation at delivery, mode of 
delivery and birth weight. Birthweight centiles were classified as per the Child Growth 
Foundation Charts.
215
 Stillbirth was diagnosed in babies born at or after 24 weeks gestation 
with no signs of life. Perinatal mortality rate was defined as the total number of stillbirths 
and early neonatal deaths (those occurring in the first week of life) per 1000 live and 
stillbirths.  
 
Continuous variables are expressed as mean (range), mean (standard deviation) or medians 
(interquartile range), and categorical variables as percentages. The Anderson-Darling 
normality test was used to test for normal distribution of continuous variables. Statistical 
tests performed were the χ2 test, Fisher‟s exact test and analysis of variance (ANOVA). A p 
value of 0.05 was considered significant. The Bonferroni correction was used for multiple 
comparisons, dividing 0.05 by the number of comparisons to obtain a p value. Data were 
analysed using Excel, statpages.org online calculators and Minitab version 13.1 
216
. 
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Table 2.1. Definitions of hypertensive disorders in pregnancy 
Hypertension in pregnancy 
A. Diastolic blood pressure of ≥110 mmHg 
B. Diastolic blood pressure of ≥90 mmHg on two or more occasions >4 h apart 
Proteinuria in pregnancy  
A. One 24-hr urine collection with total protein excretion ≥300 mg 
B. Two clean midstream urine samples collected >4 h apart with 1+ on reagent strip with 
specific gravity <1030 and pH <8 
Pre-eclampsia 
Hypertension plus proteinuria in a previously normotensive woman 
Gestational hypertension 
Hypertension after the 20th week of pregnancy in a woman not known to have previous 
chronic hypertension, resolving after 6 weeks post delivery. 
Chronic hypertension 
Hypertension at the first booking visit before the 20th week of pregnancy in the absence of 
trophoblastic disease, or at any stage of pregnancy in a woman known to have chronic 
hypertension, or at more than 6 weeks after delivery. 
Chronic hypertension with superimposed pre-eclampsia 
Chronic hypertension with proteinuria developing towards the end of pregnancy
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2.4 RESULTS 
Diagnostic categories for the pregnancies in the study are shown in Table 2.2 below. Using 
the definitions in Table 2.1, pregnancies were assigned to diagnostic groups as shown. On 
assessment in the clinic, in 45 pregnancies hypertension was not confirmed by strict criteria. 
22 were diabetic pregnancies and 5 multiple pregnancies. These were not included in the 
hypertensive diagnostic groups due to these confounding factors. Six pregnancies ending 
with first trimester miscarriage and three with no outcome data were found, and these were 
also not placed in the hypertensive groups, as outcomes could not be analysed. 
Table 2.2 Diagnosis in 627 pregnancies in 509 women 
Diagnosis No of pregnancies: n (%) 
Chronic hypertension  317 (50.6) 
              -No pre-eclampsia 248/317 (78.2) 
              -Superimposed pre-eclampsia 69/317 (21.8) 
Gestational hypertension 123 (19.6) 
Secondary hypertension 61 (9.7) 
              -Renal 53/61 (86.9) 
              -Other  8/61 (13.1) 
Pre-eclampsia  45 (7.2) 
Other: not assigned to hypertensive diagnostic groups 81 (12.9) 
              -Normotensive  45 
              -Diabetes 22 
              -Multiple pregnancy 5 
              -Miscarriage <12 weeks 6 
              -No outcome data 3 
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Maternal characteristics, mode of delivery, gestation at delivery and birth weight are shown 
in Tables 2.3 and 2.4. Information is included for the entire clinic study population of 627 
pregnancies in the first column of these tables, followed by pregnancies in the different 
diagnostic groups, and the hospital obstetric population as a whole in 1994 (where data were 
available from the Hospital Annual Report). In Table 2.3, as expected, mothers in 
pregnancies with chronic hypertension tended to be older, with a median age of 32 years. 
There was also a trend for a higher proportion of chronic hypertensive pregnancies to be in 
women of Black ethnic origin (38.8% vs 28.5% of the clinic population). Overall, 27% of the 
clinic study population were pregnancies in primiparous women: this was higher in the 
pregnancies with pre-eclampsia where 37.8% were in primiparous women.  
 
In Table 2.4, pregnancies in all diagnostic groups had a significantly higher risk of caesarean 
delivery compared to the general obstetric population rate of 16.6% (p<0.013). All 
pregnancies in hypertensive diagnostic groups (except gestational hypertensives) were more 
likely to deliver before 37 weeks, compared to the general obstetric population. With the 
exception of gestational hypertensive pregnancies, there was also an increased risk of 
delivering a low birth-weight baby (<2.5 kg).  
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Table 2.3. Maternal characteristics in pregnancies in total study population & different 
diagnostic groups. 
 Total 
study 
population 
n=627 
Chronic 
hypertension 
n=317 
Gestational 
hypertension 
n=123 
Secondary 
hypertension 
n=61 
Pre-
eclampsia 
 
n=45 
Age (years): 
-median (IQR) 
-NK 
 
31 (26-35) 
1 
 
32 (28-36) 
0 
 
29 (24-33) 
0 
 
27 (24-32) 
0 
 
30 (26-33) 
0 
Ethnicity: n (%) 
-Asian 
-Caucasian 
-Black 
-Other 
-NK 
 
225 (35.9) 
220 (35.1) 
179 (28.5) 
1 (0.2) 
2 (0.3) 
 
100 (31.5) 
93 (29.3) 
123 (38.8) 
1 (0.3) 
0 
 
49 (39.8) 
55 (44.7) 
18 (14.6) 
0 
1 (0.8) 
 
227 (44.3) 
26 (42.6) 
8 (13.1) 
0 
0 
 
21 (46.7) 
15 (33.3) 
9 (20) 
0 
0 
Primiparous: 
-n (%) 
-NK 
 
169 (27) 
1 (0.2) 
 
68 (21.5) 
0 
 
44 (35.8) 
0 
 
19 (31.1) 
0 
 
17 (37.8) 
0 
 
See Table 2.2 for details of exclusion criteria for allocation to diagnostic group. 
IQR = interquartile range 
NK = not known
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Table 2.4. Obstetric and neonatal data 
 Total study 
population 
n=627 
Chronic 
hypertension 
n=317 
Gestational 
hypertension 
n=123 
Secondary 
hypertension 
n=61 
Pre-eclampsia 
 
n=45 
Hospital 
1994* 
n=3664 
Statistically significant results† 
Hypertensive diagnostic groups vs 
hospital obstetric population.* 
% difference (95% confidence intervals) 
Mode of delivery: n (%) 
-Normal 
-Instrumental 
-Elective caesarean 
-Emergency caesarean 
-Total caesarean 
 
 
 
-Other/NK 
 
300 (47.8) 
43 (6.9) 
120 (19.1) 
141 (22.5) 
261 (41.6) 
 
 
 
23 (3.7) 
 
152 (47.9) 
23 (7.3) 
57 (18.0) 
77 (24.3) 
134 (42.3)
a 
 
 
 
8 (2.5) ‡ 
 
65 (52.8) 
12 (9.8) 
25 (20.3) 
21 (17.1) 
46 (37.4)
b 
 
 
 
0 
 
23 (37.7) 
2 (3.3) 
20 (32.8) 
15 (24.6) 
35 (57.4)
c 
 
 
 
1 (1.6) 
 
15 (33.3) 
2 (4.4) 
7 (15.6) 
20 (44.4) 
27 (60)
d 
 
 
 
1 (2.2) 
 
 
 
241 (6.6) 
267 (10.0) 
608 (16.6) 
 
 
 
 
 
a 25.7% (20.3, 31.2) 
b 20.8% (12.7, 29.6) 
c 40.8% (28.3, 52.4) 
d 43.4% (28.8, 56.4) 
 
 Table 2.2 has exclusion criteria for allocation to diagnostic group. 
* Hospital data from Annual Report    † χ2 test, p<0.013, Bonferroni correction for multiple comparisons     ‡ 7 mid-trimester losses, 1 not recorded 
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 Table 2.4. (cont.) Obstetric and neonatal data  
 
 Total study 
population 
n=627 
Chronic 
hypertension 
n=317 
Gestational 
hypertension 
n=123 
Secondary 
hypertension 
n=61 
Pre-eclampsia 
 
n=45 
Hospital 
1994* 
n=3664 
Statistically significant results† 
Hypertensive diagnostic groups vs 
hospital obstetric population.*  
% difference (95% confidence intervals) 
Gestation (wks):  
-median (IQR) 
-NK: n (%) 
 
38 (35-39) 
6 (1) 
 
38 (34-39) 
1 (0.3) 
 
38 (37-39) 
0 
 
37 (34-39) 
0 
 
35 (32-37) 
0 
  
Gestation <37 wks: 
-n (%) 
 
205 (32.7) 
 
116 (36.6)
a 
 
16 (13) 
 
29 (47.5)
b 
 
26 (57.8)
c 
 
442 (12.2)
 
 
a 24.5% (19.4, 29.9) 
b 35.5% (23.5, 47.8) 
c 45.7% (31.3, 59.0) 
Birth weight (kg): 
-median (IQR) 
-NK: n (%) 
 
2.8 (2.1-3.3) 
30 (4.8) 
 
2.6 (1.9-3.2) 
7 (2.2) 
 
3.0 (2.6-3.5) 
2 (1.6) 
 
2.8 (1.8-3.2) 
4 (6.6) 
 
2.3 (2.6-2.8) 
1 (2.2) 
 
 
 
 
Birth weight <2.5 kg:  
-n (%) 
 
217 (34.6) 
 
134 (42.3)
a 
 
27 (22) 
 
24 (39.3)
b 
 
26 (57.8)
c 
 
507 (13.6)
 
 
a 28.4% (23.1, 33.9) 
b 25.5% (14.2, 38.0) 
c 43.9% (29.5, 57.2) 
 
IQR=interquartile range.  5 twin pregnancies excluded in birth weight data in 1st column „Total‟.  Table 2.2 has exclusion criteria for allocation to diagnostic group. 
* Hospital data from Annual Report    † χ2 test, p<0.013, Bonferroni correction for multiple comparisons   
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Perinatal outcomes are shown in Table 2.5.  The first row shows initial analysis of outcomes in all 
605 singleton pregnancies of 24 weeks or over in the entire clinic population where ethnic origin 
and outcomes were available. There were increased rates of stillbirth in pregnancies in Black and 
Asian women, which were statistically significant (p=0.007) when comparing pregnancies in White 
and Asian women (percentage difference -5.1%; 95% confidence intervals -6.9, -1.5). Perinatal 
mortality was also significantly worse (p=0.013) in pregnancies in Asian compared to White 
women (White vs Asian percentage difference -5.5%; 95% confidence intervals -8.4, -1.2).  
 
The data were then analysed separately for pregnancies in women in the different hypertensive 
diagnostic groups to compare perinatal outcomes. In pregnancies in women with chronic 
hypertension, superimposed pre-eclampsia conferred a significantly increased risk of perinatal 
death, giving a perinatal mortality rate of 115.9:1000 in this group (Table 2.5). 
 97 
 
Table 2.5. Perinatal outcomes 
 All births  
≥24 weeks 
Stillbirths 
n (%) 
Statistical analysis Early 
neonatal 
deaths 
Perinatal 
mortality 
n (%) 
Statistical analysis Stillbirth 
rate** 
Perinatal 
mortality 
rate** 
All pregnancies in clinic:* 
Ethnic group: 
-White women 
-Black women 
-Asian women 
605 
 
214 
175 
216 
24 (4.0) 
 
3 (1.4)
a 
 
7 (4.0) 
14 (6.5)
b 
 
 
 
a vs b: p=0.007† 
% difference (95% CI):  
-5.1% (-6.9, -1.5) 
8 
 
3 
1 
4 
32 (5.3) 
 
6 (2.8)
c 
8 (4.6) 
18 (8.3)
d 
 
 
c vs d: p=0.013† 
% difference (95% CI):  
-5.5% (-8.4, -1.2) 
39.7 
 
14.0 
40.0 
64.8 
52.9 
 
28.0 
45.7 
83.3 
Diagnostic groups: 
-Gestational hypertension 
-Secondary hypertension 
-Pre-eclampsia (PE) 
-Chronic hypertension: 
    -Uncomplicated 
    -Superimposed PE 
    
    -Total 
 
123 
60 
45 
 
241 
69 
 
310 
 
3 (2.4) 
1 (1.7) 
2 (4.4) 
 
11 (4.6) 
7 (10.1) 
 
18 (5.8) 
  
2 
4 
0 
 
1 
1 
 
2 
 
5 (4.1) 
5 (8.3) 
2 (4.4) 
 
12 (5.0)
e 
8 (11.6)
f 
 
20 (6.5) 
 
 
 
 
 
e vs f: p=0.049‡ 
% difference (95% CI):  
-6.6% (-14.2, -0) 
 
24.4 
16.7 
44.4 
 
45.6 
101.4 
 
58.1 
 
40.7 
83.3 
44.4 
 
49.8 
115.9 
 
64.5 
West Midlands 1994       6.1 10.6 
 
* Excludes pregnancies in women with unknown outcomes/ethnic origin, ethnic origin „other‟ & multiple pregnancies.   CI = confidence interval 
Significant p values shown: χ2 and Fisher‟s exact tests.   † χ2 test: p<0.017 Bonferroni correction for multiple comparisons ‡ χ2 test: p <0.05.      
** Stillbirth & perinatal mortality rates per 1000 total births ≥24 weeks gestation.  
West Midlands data: Confidential Enquiry on Stillbirths and Deaths in Infancy (CESDI) 4
th
 Annual Report
217
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As shown in Table 2.5, most stillbirths in the pregnancies in the hypertensive diagnostic 
groups (18 out of 24) occurred in the mothers with chronic hypertension. These 18 cases 
were examined further. Two women had two stillbirths each, and two women underwent 
obstetric hysterectomy for postpartum haemorrhage. No babies had congenital anomalies, 
and all presented as antepartum intrauterine deaths. Further characteristics of the pregnancies 
and babies where stillbirth occurred are shown in Table 2.6. The majority of babies were 
small, with 88.2% having birth weights below the 10
th
 and 58.8% below the 3
rd
 centile. 
Pregnancies in Black and Asian women with chronic hypertension had higher rates of 
stillbirth compared to White women, statistically significant for pregnancies in White vs 
Asian women (percentage difference -9.1%; 95% confidence intervals -10.8, -2.6; p=0.008). 
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Table 2.6. Details of stillbirths in 18 of 317 chronic hypertensive pregnancies 
 Births  
≥24 weeks* 
Number of stillbirths 
n (%) 
Stillbirth rate per 
1000 births ≥ 24 
weeks 
Ethnic origin 
-White 
-Black 
-Asian 
 
 
90 
121 
98 
 
1(1.1)
a 
7 (5.8) 
10 (10.2)
b 
a vs b: p=0.008† 
% difference (95% CI): 
-9.1% (-10.8, -2.6) 
 
11 
58 
102 
 Findings 
Superimposed pre-eclampsia: 
-White 
-Black 
-Asian 
 
1 / 1 
4 / 7 
2 / 10 
Gestation (weeks): 
-mean (range) 
-median (IQR) 
 
28.3 (24-38) 
27 (25-31) 
Birth weight (kg) ‡ 
-mean (range) 
-median (IQR) 
 
0.92 (0.36-3.1) 
0.60 (0.52-1.09) 
Birth weight <2.5 kg‡ 16/17 (94.1%) 
Birth weight <10
th
 centile 15/17 (88.2%) 
Birth weight <3
rd
 centile 10/17 (58.8%) 
 
* One pregnancy in woman ethnic origin „other‟; seven pregnancies mid-trimester loss <24 weeks 
† χ2 test. Only p values significant at p<0.017 shown (Bonferroni correction)  
CI=confidence intervals 
‡ Birth weight not recorded in one case. Birth weight centiles adjusted for sex and gestation. 
 
 
To examine potential confounding factors that might explain the variation in stillbirth rates 
in different ethnic groups, all 317 pregnancies in the Black, White and Asian women with 
chronic hypertension were compared in Table 2.7 (one pregnancy in a woman with ethnic 
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group „other‟ was excluded). There were no differences in age. Pregnancies in White women 
were more likely to be defined as primiparous compared with Asian and Black women. 
Rates of smoking were assessed and pregnancies in White women had the highest rates of 
smoking (23.7%). However, up to 13% of pregnancies had missing data and numbers were 
relatively small (only 1% of pregnancies in Asian women were in smokers) so statistical 
analysis to compare groups could not be done. Data on body mass index were also not 
collected.  
 
More pregnancies in Black women were conceived on anti-hypertensive drugs compared to 
pregnancies in White women, although this did not reach statistical significance: 46.3% vs 
33.3%, p=0.054.  Levels of blood pressure at three stages of pregnancy were also compared 
to see if severity of hypertension varied between the three ethnic groups. The mean diastolic 
BP at over 30 weeks gestation was the only statistically significant different measurement 
and was higher in pregnancies in White women.  
 
Of note is that data are unavailable on BP readings under 20 weeks gestation due to late 
booking in 3 (3.2%) pregnancies in White women, 11 (8.9%) in Black women and 18 (18%) 
in Asian women. Pregnancies in Asian women were found to be significantly more likely to 
be booked for antenatal care after 20 weeks compared to those in White women (White vs 
Asian percentage difference -14.8%, 95% confidence intervals -18.8, -6.4). Rates of 
superimposed pre-eclampsia and preterm delivery were similar in the three groups. The 
mean birth weight was greater in pregnancies in White women compared to those in Asian 
women (2.73 vs 2.37 kg, difference 0.36 kg; 95% confidence intervals 0.12, 0.6; p=0.003). 
Over half the pregnancies in Asian women and 43.9% of those in Black women with chronic 
hypertension resulted in babies with birth weights under 2.5 kg, significantly more than the 
rate in pregnancies in White women (statistics in Table 2.7, p=0.016 overall).  
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Table 2.7. Characteristics of 316 pregnancies with chronic hypertension by ethnicity  
 White  
(n=93) 
Black  
(n=123) 
Asian  
(n=100) 
Test P value % difference  
(95% confidence intervals) 
For significant results 
Age (years): mean (SD) 31.4 (5.4) 32 (5.9) 31.9 (5.7) ANOVA 0.793  
Primiparous: n (%) 30 (32.2)
a 
26 (21.1)
b 
11 (11)
c χ2 test 0.001 overall a vs b 11.1% (-0.7, 22.5)  
a vs c 21.3% (9.9, 30.2) 
b vs c 10.1% (0.3, 18) 
Smoker: n (%) 
NK 
22 (23.7) 
8 (8.6) 
11 (8.9) 
16 (13.0) 
1 (1.0) 
1 (1.0) 
- -  
Anti-hypertensive drug at conception: n (%) 31 (33.3)
a 
57 (46.3)
b 
34 (34) χ2 test 0.078 overall  
0.054 a vs b 
 
Mean systolic BP (mmHg): 
-<20 wks gestation: mean (SD) 
NK: n (%) 
-20-30 wks gestation: mean (SD) 
NK: n (%) 
>30 wks gestation: mean (SD) 
NK: n (%) 
 
136.7 (15.0) 
3 (3.2)
a 
134.0 (10.6) 
6 (6.5) 
139.0 (11.6) 
11 (11.8) 
 
136.3 (15.6) 
11 (8.9) 
135.3 (15.2) 
5 (4.1) 
137.7 (17.3) 
14 (11.4) 
 
134.9 (13.5) 
18 (18)
c 
135 (14.5) 
4 (4) 
138.1 (15.6) 
13 (13) 
 
ANOVA 
χ2test 
ANOVA 
 
ANOVA 
 
0.716 
0.001 a vs c 
0.774 
 
0.836 
 
 
a vs c -14.8% (-18.8, -6.4) 
 
NK=not known.   ANOVA=Analysis of variance        BP levels may be unknown as patient not yet booked in clinic or delivered preterm 
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Table 2.7. (cont.) Characteristics of 316 pregnancies with chronic hypertension by ethnicity  
 White 
(n=93) 
Black 
(n=123) 
Asian 
(n=100) 
Test P value % difference or difference 
between means  
(95% confidence intervals) 
For significant results 
Mean diastolic BP (mmHg): mean (SD)* 
<20 wks gestation 
20-30 wks gestation 
>30 wks gestation 
 
86.9 (9.9) 
84.3 (7.7) 
90.2 (7.3)
a 
 
84.7 (9.6) 
83.1 (11.2) 
86.2 (11.0)
b 
 
86.8 (10.0) 
85.7 (9.3) 
89.2 (9.5)
c 
 
ANOVA 
ANOVA 
ANOVA 
 
0.203 
0.143 
0.009 overall  
 
 
 
a vs b 4.0 mmHg (1.25, 6.75) 
a vs c 1.0 mmHg (-1.57, 3.57) 
b vs c -3.0 mmHg (-5.92, -0.08) 
Superimposed pre-eclampsia: n (%) 20 (21.5) 30 (24.4) 19 (19) χ2test 0.623  
Gestation at delivery (wks): mean (SD) 36.5 (4.9) 36.2 (4.5) 35.4 (4.7) ANOVA 0.235  
Gestation at delivery <37 wks: n (%) 30 (32.3) 42 (34.1) 44 (44) 
[NK:1] 
χ2test 0.159  
Birth weight (kg): mean (SD) 2.73 (0.82)
a 
[NK: 3] 
2.49 (0.93)
b 
2.37 (0.84)
c 
[NK:4] 
ANOVA 0.017 overall, 
a vs c 0.003 
a vs b 0.24 kg (0, 0.48) 
a vs c 0.36 kg (0.12, 0.6) 
b vs c 0.12 kg (-0.12, 0.36) 
Birth weight <2.5 kg: n(%) 29 (32.2)
a
 
[NK: 3] 
54 (43.9)
b 
51 (53.1)
c
 
[NK:4] 
χ2test 0.016 overall a vs b -11.7% (-24.1, 1.6) 
a vs c -20.9% (-34.1, -6.7) 
b vs c -9.2% (-22.2, 4.1) 
NK=not known.  * Data for values NK as systolic BP in first section of table above. ANOVA=Analysis of variance        
BP levels may be unknown as patient not yet booked in clinic or delivered preterm 
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Another possible confounder when assessing perinatal outcomes relates to the fact that the 
database spans a long time period (1980-2002.) Obstetric practice has changed over this 
time. The high overall stillbirth rates in pregnancies complicated by chronic hypertension 
might be related to different practices in the early years of data collection. Table 2.8 shows 
the distribution over time of chronic hypertensive pregnancies, divided into periods of five 
years (last time period three years.) These are divided by ethnic group and show trends of 
stillbirth over time. Four cases with missing data on year of birth (including one mid-
trimester loss), one case of ethnicity „other‟ and 6 further cases of mid-trimester loss are 
excluded from stillbirth data. Statistical analysis is not done as the absolute numbers are low, 
but the trends can be seen. The Caesarean section rate over these time periods for the same 
cases is also shown.  
 
The highest stillbirth rate of 100 (per 1000 births ≥24 weeks) is seen in the earliest time 
period (1980-84).  However, following this the rate fluctuates, with the lowest rates of 
33:1000 and 28:1000 followed by two periods with higher rates. On analysing the Caesarean 
section rate, the lowest rate in 1980-84 (38%), is followed by an overall increase in rates 
with some variation. 
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Table 2.8. Stillbirths and caesarean section rates in pregnancies with chronic 
hypertension by time period.*  
Years  
(total no of 
pregnancies)* 
Chronic hypertensive 
pregnancies ≥ 24 
weeks (n) 
No. of stillbirths (n) Stillbirth 
rate:1000 
births  ≥ 
24 weeks  
Caesarean 
section  
n (%) 
 White Black Asian White Black Asian 
1980-84 
(n=40) 
12 11 17 0 1 3 100 15 (38) 
1985-89 
(n=61) 
6 24 31 0 0 2 33 28 (46) 
1990-94 
(n=71) 
24 29 18 0 1 1 28 28 (39) 
1995-99 
(n=76) 
23 36 17 1 3 2 79 35 (46) 
2000-02 
(n=58) 
23 21 14 0 2 2 69 28 (48) 
1980-2002 
(n=306) 
88 121 97 1 7 10 59 134 (44) 
 
*Excludes 11 pregnancies in total: 4 pregnancies with missing data on year of birth (includes 
1 mid-trimester loss), 6 further mid-trimester losses and one pregnancy in woman ethnic 
origin „other‟. 
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2.5 DISCUSSION 
This study represents one of the largest British series in the literature of pregnancies in 
hypertensive women undergoing antenatal care in a single centre. Data were collected 
prospectively and neonates followed up to seven days of age. The pregnancies in women 
with chronic and secondary hypertension represent the proportion of pregnant women in our 
population with these disorders, as strenuous efforts are made to identify them and refer 
them to the specialist antenatal hypertension clinic. The statistics for perinatal outcome in 
these women are based on accurate denominator data, as all pregnancies in women with 
these diagnoses in our population will be included.  
 
However, for pregnancies complicated by pre-eclampsia and gestational hypertension, the 
entire populations of pregnancies in women with those diagnoses are not represented, and 
denominator data are incomplete. Pregnancies in women seen in the clinic with these 
disorders may represent a subgroup with atypical or serious disease, and this may explain the 
high perinatal mortality rates in these groups when compared to other papers, particularly in 
pregnancies in women with gestational hypertension.
44, 63, 66 
There may be a bias towards an 
increased proportion of pregnancies in women with early-onset pre-eclampsia, and caution 
should be exercised when interpreting results from a small group of pregnancies with 
isolated pre-eclampsia who attended the clinic. 
 
We analysed data by pregnancy rather than individual woman attending the clinic. Some 
women had more than one pregnancy. Overall, 627 pregnancies were assessed in 509 
women. The outcomes we were reviewing, particularly perinatal outcomes, use the 
individual pregnancy as the denominator. It would not be possible for example to assess 
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gestation, Caesarean section rates or stillbirth by woman rather than by pregnancy. Each 
pregnancy is assessed on it‟s own characteristics and outcomes as would happen in clinical 
practice. The group of 18 stillbirths analysed in pregnancies in women with chronic 
hypertension occurred in 16 women (two women had two stillbirths), so were not skewed by 
a small number of patients with poor obstetric history. 
 
The incidence of chronic hypertension in pregnancy is set to rise with the trend for delayed 
child-bearing.
218
 There has been some discussion in the literature about whether risks of poor 
outcome in pregnant women with chronic hypertension are confined to those with severe 
disease and those developing superimposed pre-eclampsia.
76, 81,
 
82 
A systematic review by 
Ferrer et al examined 46 studies reporting risks of prematurity, small for gestational age, low 
birth weight and fetal growth restriction, and concluded that in all but two papers, chronic 
hypertension was associated with an increased risk of these outcomes.
219
 Women with 
chronic hypertension in our study had significantly more low birth weight babies (42.3% vs 
13.6%) compared to the hospital obstetric population (Table 2.4).    
 
Most of the studies in Ferrer‟s review did not separate outcomes in mild and severe chronic 
hypertensives, precluding comparisons between the two groups. Women with high-risk 
chronic hypertension are also reported to be at risk of serious maternal complications 
including pulmonary oedema, hypertensive encephalopathy, stroke and renal failure, as well 
as preeclampsia and placental abruption.
220
 Expert advice and consensus in a recent review 
suggests high-risk women (for example, with target organ damage, BP >180/110, and age 
over 40 years) should have aggressive antihypertensive therapy and monitoring.
218 
The 
benefit of medication in uncertain in those of lower risk, who have better expected outcomes.  
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This review stated an urgent need to conduct randomized trials, especially needed as a meta-
regression analysis has shown a link between anti-hypertensive treatment and restricted fetal 
growth.
221
 With a view to conducting such a trial, a 2003 paper studying 305 patients found 
16.4% of pregnancies achieved the primary outcome of one or more serious perinatal 
complications/birth weight < 3
rd
 centile in women with non-proteinuric hypertension at <34 
weeks.
86
 Interestingly, outcomes were the same for gestational and pre-existing 
hypertension. Subsequently, a pilot study of the ongoing CHIPS (control in hypertension in 
pregnancy study) trial with 132 women (same criteria) showed a definitive trial of outcomes 
in tight vs less tight BP control is feasible.
222
 Non-proteinuric gestational hypertension (GH) 
has traditionally been associated with better outcomes, but recent work states that when 
severe, GH can result in more adverse perinatal outcomes than mild pre-eclampsia.
85, 223 
Diagnostic allocation is not rigid: up to 50% of women with GH will progress to 
preeclampsia and some may have undiagnosed chronic hypertension. This is of interest in 
relation to the poor outcomes for women with gestational hypertension attending our clinic, 
alluded to above. 
 
Preterm delivery was studied by Sibai et al in women with chronic hypertension (n=761) and 
normal pregnancies (n=2738).
83 
Compared to women with uncomplicated pregnancies, those 
with chronic hypertension had more „indicated‟ preterm deliveries (21.9% vs 3.4%), but the 
same rate of spontaneous preterm delivery. This suggests that rather than hypertension 
leading to preterm labour, it is intervention by the medical team that leads to early delivery 
of the baby. In our study, 36.6% of women with chronic hypertension delivered preterm 
compared to the overall hospital rate of 16.5% Chronic hypertensives also had more 
caesarean sections: 42.3% vs 16.6% (Table 2.4, p<0.013), suggesting babies born preterm 
were due to early elective delivery. 
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In their systematic review Ferrer et al concluded that chronic hypertension consistently 
tripled the risk for perinatal mortality with an odds ratio of 3.4 (95% CI 3.0-3.7), compared 
to normotensive mothers or general obstetric populations.
219
 The perinatal mortality rate of 
49.8:1000 in our study was much higher than the general population, even in cases 
uncomplicated by pre-eclampsia. The extremely high perinatal mortality rates of 115.9:1000 
in our series in women with chronic hypertension and superimposed pre-eclampsia have 
been reported previously in the literature. Sibai et al described perinatal death rates of 24% in 
21 of 211 mild chronic hypertensives with superimposed pre-eclampsia,
69
 and 32% in 91 
women with chronic hypertension in 303 cases of severe pre-eclampsia.
70
 In a further paper 
studying pregnancies in 44 women with severe chronic hypertension, 23 women developed 
superimposed pre-eclampsia with a perinatal mortality of 48%: all deaths in the series 
occurred in this group.
71 
Mabie et al described the course of 169 pregnancies with chronic 
hypertension where women with superimposed pre-eclampsia necessitating delivery at 27-34 
weeks gestation had a perinatal mortality of 238:1000.
72
 In 1990 Ferrazzani et al reviewed 
444 hypertensive women and found a perinatal mortality rate of 129:1000 in a group 
combining superimposed pre-eclampsia and pre-eclampsia.
74 
  
 
In a detailed analysis of 337 chronic hypertensive pregnancies Rey et al described an 
incidence of perinatal death of 10.8% with superimposed pre-eclampsia.
76
 A New Zealand 
study found a perinatal mortality rate of 80:1000 in 26 women with superimposed pre-
eclampsia.
81
 Sibai et al‟s 1998 paper using strict diagnostic criteria in 193 women with 
superimposed pre-eclampsia reported a perinatal death rate of 8%.
82
 In view of the poor 
associated perinatal outcomes with superimposed pre-eclampsia, it is important to establish 
the risk of developing this complication: in our study this was 21.8%. This is comparable 
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with rates in the literature of 10% 
69
, 17% 
81
, 21.4% 
76
, 25% 
82
,
 
28.4% 
87
, 34% 
72 
and 52% 
71
. 
The large variety in rates may partly be due to variation in definitions used and populations 
studied, and are a good example of difficulty in comparing published data in this field. Using 
current definitions in 154 women with severe hypertension a 2004 study quoted rates of 
superimposed pre-eclampsia of 78%.
224
 
 
The incidence of superimposed pre-eclampsia did not vary significantly between the three 
ethnic groups of women in our study (Table 2.7), although 38.8% of women with chronic 
hypertension were Black compared to 28.5% of the clinic population (Table 2.3). Some 
previous authors have described an increased risk of superimposed pre-eclampsia and other 
adverse outcomes in Black compared to White women with chronic hypertension. The 
established increased incidence of chronic hypertension in Black women was confirmed by 
Ananth et al with a relative risk of 1.9 when compared to White women in a paper analysing 
nearly 300,000 pregnancies in total.
78 
In 1996 in the USA the incidence of chronic 
hypertension was 25.0:1000 deliveries among Black (African-American) women, an excess 
of 14.5 cases per 1000 deliveries compared with rates for other women.
225
 Rey and Couturier 
describe a relative risk of 2.2 (95% CI 1.4-3.4) for superimposed pre-eclampsia in Black vs 
White chronic hypertensive women, confirmed by logistic regression analysis.
76
 Samadi et al 
quote similar rates, with a doubling of the risk of superimposed pre-eclampsia in African-
American vs White women with chronic hypertension.
226
 In contrast, Sibai et al reported that 
black race was not a risk factor for superimposed pre-eclampsia in an analysis of 763 women 
with chronic hypertension.
82
 In 2005, Bryant et al reported that Black women without 
chronic hypertension were also more likely to have pre-eclampsia than White women, and 
increased pre-eclampsia rates in this population could not be solely attributed to higher rates 
of chronic hypertension.
227
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Ananth et al describe an increased absolute risk of stillbirth in Black vs White chronic 
hypertensive women, although after adjustment for potential confounders such as age, 
education and smoking, adjusted risk ratios tended to be greater among Whites compared to 
Blacks (stillbirth was defined as occurring after 20 weeks gestation in this study).
79
 A study 
specifically addressing comparisons between White and Black women found superimposed 
pre-eclampsia, perinatal mortality and prematurity to be significantly more frequent in Black 
than in White women with chronic hypertension.
88
 Rates of perinatal mortality and 
prematurity were raised in Black chronic hypertensives without pre-eclampsia compared to 
Black normotensive pregnant women, but no such difference was found between White 
chronic hypertensive women without pre-eclampsia and their White normotensive control 
group. The authors suggest ethnic differences in perinatal outcomes in these women are not 
purely explained by superimposed pre-eclampsia.  
 
The effect of ethnicity on maternal outcome in hypertension in pregnancy was assessed by 
Mackay et al in 2001, reviewing 4024 maternal mortalities.
60
 Black women were 3.1 times 
more likely to die from pre-eclampsia or eclampsia as those of White ethnicity. Further work 
is needed to identify what differences contribute to this excess perinatal and maternal 
mortality and address it with specific interventions. The possibility that poor access to 
medical care and higher prevalence of chronic disease with generally poorer physical fitness 
may explain previously reported elevated risks of hypertension in pregnancy in Black 
women was explored in a 1994 paper studying 8259 pregnant women in the military.
228
 The 
authors suggest that health, education and socio-economic differences between black and 
white populations are significantly reduced in this group: in particular there was equal access 
to health care. Their hypothesis was supported in that Black and White women in this 
selected population appeared to be at equal risk for the development of all pregnancy-
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induced hypertension, but this paper excluded those with pre-existing chronic hypertension. 
Unfortunately no data on socio-economic status of women were collected in our study; 
therefore it was not possible to investigate the possible confounding effects of this variable. 
 
Although a body of literature exists assessing differences in White and Black women in this 
field, there is little data about perinatal outcomes in hypertensive Asian women compared to 
those of other ethnic groups. In a 2007 study of 197,061 nulliparous women in London, 
perinatal mortality was highest among South Asian women at all gestational ages.
229
 Among 
South Asian and Black women the most important factor linked with antepartum stillbirth 
was birth weight below 2000g; hypertension was not included in this logistic regression 
analysis.  In our study, marked differences in perinatal mortality rates were found between 
pregnancies in women in the three ethnic groups. When pregnancy outcomes in all women 
attending the clinic were assessed, stillbirth was more common in pregnancies in Black and 
Asian women, and statistically more frequent in pregnancies in Asian compared to White 
women. Perinatal mortality was also significantly raised in pregnancies in Asian women 
when compared to those in White patients. This is consistent with previous database 
publications, with perinatal mortality quoted as 1.6% for White & 10% for Asian women.
213
 
 
Previous work on this database also reports stillbirths in 4.47% of 179 pregnancies with 
uncomplicated chronic hypertension, and 5.9% of 34 pregnancies with superimposed pre-
eclampsia.
84
 With further data, our results for 317 chronic hypertensive pregnancies showed 
stillbirth rates of 45.6:1000 and 101.4:1000 respectively. Most stillbirths occurred in 
pregnancies in women with chronic hypertension. We examined pregnancy characteristics in 
this diagnostic group to assess possible factors contributing to the increased risk. We also 
examined the possibility of confounding factors, particularly in pregnancies in Black and 
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Asian women in this group when compared to White women, which might contribute to the 
increased risks in these ethnic groups. Documented characteristics of pregnancies at raised 
risk of stillbirth include extremes of maternal age, smoking, inequalities and social 
deprivation, obesity, prior stillbirth, and medical problems such as diabetes, hypertension 
and antiphospholipid antibodies. Congenital anomalies, fetal growth restriction & congenital 
infections are among recognised causes. However, many stillbirths are still classified as 
„unexplained.‟ 230, 231  
 
When assessing the characteristics of pregnancies with chronic hypertension in our study 
group, more pregnancies in White women were primiparous.  However, the mean age of the 
mothers in the three ethnic groups was not significantly different. There were no significant 
differences (with one exception) between the blood pressure measurements in the three 
groups. It is noted that there was a non-significant trend for more pregnancies in Black than 
White women to be booked with the mother on anti-hypertensive drugs, which might 
indicate more severe disease and mask potentially higher levels of BP in this group. 
Unfortunately rates of smoking and effect of body mass index could not be assessed due to 
small numbers and missing data. We did assess trends over time to see if figures were 
skewed by adverse outcomes from early years of the database, and found that although the 
highest rate of stillbirth was in the first five years, subsequent time periods showed a 
fluctuating rate with no definite pattern of declining rates. 
 
Babies born to Black and Asian chronic hypertensive women were lighter than White babies. 
No significant link was found between ethnicity and anti-hypertensive treatment (Table 2.7) 
to explain these differences.
221
 There are known racial differences in birth weight 
particularly in Asian babies, which may contribute to this effect.
232
 When assessing the 
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stillborn babies, growth restriction was common in these pregnancies in women with chronic 
hypertension, with 88.2% of the babies having a birth weight less than the 10
th
 centile 
corrected for sex and gestation. In summary, the raised perinatal mortality figures in 
pregnancies in Black and Asian women with chronic hypertension therefore generally 
represent mothers presenting with intrauterine deaths of growth-restricted babies with a 
mean gestational age of 28.3 weeks. Prematurity and low birth weight in surviving babies 
will contribute to morbidity but were of limited importance in perinatal mortality. None of 
the stillborn babies in this group had congenital anomalies.  
 
The role of growth restriction in stillborn babies in the West Midlands has been highlighted 
in reports from the West Midlands Perinatal Institute (WMPI).
233
 In 1997 to 2005, fetal 
growth restriction was the commonest feature of stillborn babies, present in over 40% of 
cases. Efforts need to be directed to encouraging women to attend early for antenatal care, 
and detecting the growth-restricted fetus.  Customised growth charts allowing for effects of 
ethnicity, parity and body mass index are recommended by WMPI, aiding more accurate 
diagnosis and classification of small babies. The possible link between anti-hypertensive 
medication and growth restricted babies also needs further investigation.
221
 
 
A West Midlands Perinatal Institute (WMPI) report on trends, factors and inequalities on 
stillbirths and infant mortality in the West Midlands from 1997-2005 was published in 
2007.
233
  The report used the Index of Multiple Deprivation (IMD) to assess five quintiles of 
increasing deprivation.
 
This area based score, revised in 2007, contains seven domains which 
relate to income deprivation, employment deprivation, health deprivation and disability, 
education skills and training deprivation, barriers to housing and services, living 
environment deprivation, and crime.
234
 For stillbirth and perinatal mortality rates, the report 
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showed the gap between most deprived and the rest of the population was shown to be 
increasing in recent years, with the highest rates in the populations living in the most 
deprived quintile. 
 
The data on address which is needed to calculate deprivation scores such as the IMD were 
not in our database. It is possible that this is an important confounding factor, if Asian and 
Black women with pregnancies in the study were more likely to live in deprived areas than 
White women. The WMPI report above did show that overall, when compared to mothers of 
European-British origin, babies of African Caribbean, Pakistani and Indian mothers were at 
significantly increased risk of stillbirth, perinatal death and infant death. Whether 
confounded by social deprivation or not, this is a high risk group for adverse perinatal 
outcomes. These findings support the generalisability of our results. 
 
We found that pregnancies in Asian women with chronic hypertension were more likely to 
be booked in clinic after 20 weeks gestation than White women, and this lack of early 
antenatal care may be relevant in this group. The WMPI report also showed rates of booking 
with the midwife within the first 12 weeks were lowest in Asian and Afro-Caribbean 
mothers. Late booking is a known marker for poor pregnancy outcome for mother and 
baby.
58 
 
In summary, our study supports current targeted measures in women to encourage earlier 
attendance in pregnancy, detect growth restricted babies and intervene appropriately, 
especially in pregnancies in women with chronic hypertension from Asian and Black ethnic 
groups, who have been found to be at increased risk of antepartum stillbirth in this study. 
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In its eighth annual report, the Confidential Enquiry into Stillbirths and Deaths in Infancy 
(CESDI), now the Confidential Enquiry into Maternal and Child Health (CEMACH) 
introduced an enquiry into the care of diabetic pregnancies, which was reported in 2007.
       
231, 235
 CESDI stated that diabetes is the most common pre-existing medical disorder 
complicating pregnancy in the UK (4:1000 pregnancies) and quoted perinatal mortality rates 
of 36.1:1000 - 42.8:1000. The perinatal mortality rates we have quoted in this study for 
women with chronic hypertension exceed those for diabetic women, and when pre-eclampsia 
is superimposed on chronic hypertension, rates are nearly three times higher than for 
diabetes. Chronic hypertension occurs in 1-5% of pregnant women, a similar incidence to 
diabetes, and will be increasingly more common as the average age of childbearing continues 
to rise. Asian and Black women are particularly at risk. Hypertension in pregnancy, 
particularly chronic hypertension, would be a suitable area for a future CEMACH enquiry. 
 
Review of our database has shown the burden of perinatal morbidity and mortality in women 
with hypertension in pregnancy. Improvements are needed in the process of allocating risk in 
pregnancy, with better prediction of adverse outcome and targeting of appropriate care. 
Section 1.4.3 of this thesis has reviewed the use of ambulatory blood pressure monitoring 
(ABPM) in pregnancy. In the next chapter an analysis of the predictive value of ABPM is 
presented. 
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CHAPTER 3: 
A RETROSPECTIVE ANALYSIS OF THE USE AND 
PREDICTIVE VALUE OF AMBULATORY BLOOD 
PRESSURE MONITORING IN 100 PREGNANT 
HYPERTENSIVE WOMEN 
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3.1 ABSTRACT 
Objective: To determine the accuracy with which ambulatory blood pressure monitoring 
(ABPM) can predict obstetric and neonatal outcomes. 
Design: Retrospective records-based cohort study 
Setting: Obstetric department of a district general hospital 
Participants: 100 hypertensive pregnant women undergoing ABPM. 
Main outcome measures: Regression analysis to assess correlation of conventional BP 
monitoring (CBPM) and ABPM with obstetric and perinatal outcomes 
Results: Of 100 women, 18 had chronic hypertension, 50 needed antihypertensive drugs and 
84 were admitted for hypertension; 36 had labour induced for hypertension and 57 had 
caesarean sections. Twenty-seven babies were preterm; 22 went to the neonatal unit. There 
was one 23-week fetal loss, one stillbirth and one neonatal death. Development of 
proteinuria, and gestation and weight at birth were significantly associated with mean ABPM 
systolic and diastolic pressures. These were more accurately predicted compared to CBPM. 
Conclusion: ABPM predicted certain obstetric and neonatal outcomes more accurately than 
CBPM.  
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3.2 INTRODUCTION 
Measurement of blood pressure is the most commonly used screening test in pregnancy. 
Hypertensive disease of pregnancy is consistently a leading cause of direct maternal 
mortality in the United Kingdom, with the mortality rate from pre-eclampsia and eclampsia 
unchanged over two of the last three Confidential Enquiries into Maternal Deaths, and a 
slight increase in the 2007 Report.
57, 58
 Morbidity to both mother and fetus is significant, 
particularly when premature delivery is needed.
236
 
 
Ambulatory blood pressure monitoring (ABPM) is established in management in the non-
pregnant hypertensive individual and has been reviewed above in Section 1.4.  
3.3 OBJECTIVES 
ABPM in pregnancy had been used at our unit for eight years. We performed a detailed 
analysis of its use and assessed its predictive ability for important obstetric and neonatal 
outcomes in our clinical setting. The study was a pilot study preceding the randomized study 
reported in chapter four of this thesis. 
3.4 METHODS 
Subjects 
One hundred pregnant hypertensive women underwent ABPM from 1996–2002, using the 
SpaceLabs ambulatory blood pressure monitor 90207.
115
 The technique was performed as 
described in section 4.3 „Monitors and ambulatory monitoring process.‟ All women had 
hypertension in pregnancy and had ABPM as requested by a consultant obstetrician.   
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Data collection  
The medical notes were examined and data placed on a proforma (Appendix 2). These data 
were entered onto an Excel database and analysed using Excel and MiniTab version 13.1.
216
 
Birthweight centiles were classified as per the Child Growth Foundation Charts.
215 
Conventional blood pressure readings were an average of the two most recent measurements 
taken at least 4 hours apart. Hypertensive disorders were classified as in Chapter 2, using the 
criteria described by Davey and McGillivray, endorsed by the International Society for the 
Study of Hypertension in Pregnancy (ISSHP) and shown in Table 2.1.
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Statistical analysis 
Initial analysis of outcomes was performed using descriptive statistics. Results are given 
using median (interquartile range) or percentages. Single and multiple linear regression 
analyses were done for continuous outcomes. Logistic regression analysis was done for 
binary outcomes, with categorical variables entered as factors in the model. Significance was 
set at p <0.05. Odds ratios and 95% confidence intervals are given for binary outcomes. 
3.5 RESULTS 
The women had a median age of 31 (interquartile range 26-35) years with a body mass index 
(BMI) of 27.4 (23-33) kg/m
2
; 58% were nulliparous. Ninety-five % were White, with 4% 
Asian and 1% Black. Only 6% were current smokers. One or more medical problems were 
present at booking in 38%, with 18% of the total noted to have chronic hypertension. 
Overall, 6% were on anti-hypertensive drugs at booking. Of those with previous pregnancies, 
36% had pre-eclampsia and 38% had been delivered by caesarean section. 
 
The women had a median of 6 (3-12) days in hospital antenatally and 11 (7-17) inpatient 
days in total. Overall, 84% were admitted for hypertension a median of 2 (1-2) times.  
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Clinical pregnancy data are shown in Table 3.1.  There were three perinatal losses: a 
miscarriage at 23+3 weeks gestation, an intrauterine death at 40+2 weeks, and early neonatal 
death at 24+3 weeks. The diagnosis at discharge was pre-eclampsia in 34%, chronic 
hypertension in 23%, and pre-eclampsia superimposed on chronic hypertension in 10%. At 
discharge, 43% of the women were taking anti-hypertensive drugs.  
 
All women had ABPM: 80% had one episode, 12% two, 7% three and 1% four episodes. 
Results are in Table 3.2. Regression analysis was done to assess the correlation between 
conventional and ambulatory blood pressure readings and significant pregnancy outcomes. 
This is shown in Table 3.3. Predictors included in all models were age, BMI and consultant. 
Numbers of smokers and non-white race were too small for inclusion. For growth restriction 
and birth weight, the model also includes primiparous status and previous baby weighing 
<2.5 kg. For gestation at delivery and preterm delivery, the model also includes previous 
baby <37 weeks gestation.  For proteinuria of 2+ or more on dipstick testing, the model also 
includes primiparous status. For day unit attendance, the outcome is corrected for gestation 
at delivery. For caesarean delivery, the model also includes previous Caesarean section 
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Table 3.1. Pregnancy data and obstetric/neonatal outcomes (n=100)  
  
 Yes No Not done 
24-hour urinary protein >0.3g  24%  22%  54%  
Proteinuria ≥2+ on dipstick  32% 
Antenatal steroids 17% 
Antenatal anti-hypertensive drugs 49% 
Acute anti-hypertensive drugs 16% 
Induction of labour 53% 
 Hypertension Post-term Other 
Indication for induction 36 (68%) 8 (15%) 9 (17%) 
 Normal Elective 
CS 
Emerg CS Ventouse 
Mode of delivery 39% 15% 42% 4% 
HDU admission 13% 
Magnesium sulphate given 4% 
Gestation at delivery (weeks)* 38.6 (36.9-40) 
Delivery <37 weeks gestation 27% 
Birth weight (g)* 3082 (2611-3461) 
Birth weight <10
th
 centile 19% 
Male infant 53% 
Female infant 47% 
Neonatal unit (NNU) admission 22% 
Length of stay on NNU (days)* 17 (5-38) 
Length of stay all babies* 5 (3-6) 
 
*Median (interquartile range) 
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Table 3.2. ABPM results  
 
 ABPM 1  
(n=100) 
ABPM 2  
(n=20) 
ABPM 3  
(n=8) 
ABPM 4 
(n=1) 
Gestation 
(weeks) 
29.7 
(20.3-34.2) 
28.7  
(23.6-32.1) 
32.2  
(29.7-33.2) 
31.1 
Duration 
(hrs:min) 
23:27 
(22:44-23:55) 
22:57  
(11:17-23:33) 
23:10  
(10:49-23:53) 
23:51 
No. of 
readings  
46 (40-48) 44 (26-46) 43 (31.8-47.5) 49 
% successful 94 (90.8-97) 94 (92-97) 94 (90-96.3) 100 
24-hour mean 
SBP 
128 
(122-136) 
138  
(126.5-145.3) 
137  
(126.8-146.8) 
129 
24-hour mean 
DBP  
79 (74.8-86) 86 (79.8-92.3) 89.5 (79-94.3) 76 
CSBP*  140 (130-148) 145 (137-150) 140 (138.5-142) 142 
CDBP*  90 (84.8-98) 98 (90-101) 93.5 (85-103) 84 
 
Results as median (interquartile range), mmHg unless stated otherwise. 
*CS/DBP=conventional  systolic/diastolic BP at time of  ABPM 
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Table 3.3. Regression analysis of conventional vs. ambulatory blood pressure monitoring for perinatal outcomes    
 
Outcome  Conventional Systolic BP 
 
Conventional Diastolic BP 24-hr mean Systolic BP 24-hr mean Diastolic BP 
Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate 
IUGR <10
th
centile p value 
Odds ratio  
(95% CI) 
0.25 
1.02  
(0.98,1.06) 
0.31 
1.02 
(0.98,1.06) 
0.89 
1.00 
(0.95,1.06) 
0.76 
1.01 
(0.95,1.07) 
<0.01 
1.08 
(1.03,1.14) 
<0.001 
1.11 
(1.05,1.18) 
0.01 
1.08 
(1.02,1.15) 
<0.01 
1.11 
(1.03,1.20) 
Birth weight 
 
p value 0.03 
 
0.03 <0.01 0.05 <0.001 <0.001 <0.001 <0.001 
Birth weight  <2.5 kg 
 
p value 
Odds ratio  
(95% CI) 
0.04 
1.04 
(1.00,1.09) 
0.06 
1.04 
(1.00,1.08) 
0.05 
1.05 
(1.00,1.11) 
0.14 
1.04 
(0.99,1.10) 
<0.001 
1.11 
(1.05,1.17) 
<0.001 
1.12 
(1.06,1.19) 
<0.001 
1.15 
(1.07,1.24) 
<0.001 
1.16 
(1.07,1.25) 
Gestation at delivery  p value 
 
0.07 0.11 0.08 0.02 <0.001 <0.001 <0.001 <0.001 
Delivery <37 weeks 
 
p value 
Odds ratio  
(95% CI) 
<0.01 
1.06 
(1.02,1.11) 
0.01 
1.06 
(1.01,1.10) 
0.02 
1.06 
(1.01,1.12) 
0.02 
1.07 
(1.01,1.13) 
<0.001 
1.09 
(1.04,1.15) 
<0.001 
1.11 
(1.05,1.17) 
0.001 
1.10 
(1.04,1.17) 
<0.001 
1.14 
(1.06,1.23) 
Proteinuria  p value  
Odds ratio  
(95% CI) 
0.11 
1.03 
(0.99,1.06) 
0.13 
1.03 
(0.99,1.06) 
0.09 
1.04 
(0.99,1.09) 
0.13 
1.03 
(0.99,1.06) 
<0.01 
1.07 
(1.03,1.12) 
<0.01 
1.07 
(1.03,1.12) 
0.01 
1.07 
(1.02,1.13) 
<0.01 
1.08 
(1.02,1.15) 
Day unit attendance 
 
p value 
 
0.97 0.94 0.37 0.27 0.05 0.02 0.15 0.08 
Caesarean section 
 
p value 
Odds ratio 
 (95% CI) 
0.03 
1.04  
(1.00,1.08) 
0.06 
1.04 
(1.00,1.08) 
0.04 
1.05 
(1.00,1.09) 
0.02 
1.06 
(1.01,1.12) 
0.01 
1.05 
(1.01,1.09) 
0.02 
1.06 
(1.01,1.11) 
0.06 
1.05 
(1.00,1.10) 
0.02 
1.08 
(1.01,1.15) 
Admission to HDU p value 
Odds ratio 
95% CI
 
0.02 
1.07 
(1.01,1.21) 
0.02 
1.06 
(1.01,1.12) 
0.05 
1.06 
(1.00,1.13) 
0.06 
1.06 
(1.00,1.14) 
<0.01 
1.10 
(1.04,1.17) 
<0.01 
1.11 
(1.04,1.18) 
<0.01 
1.14 
(1.05,1.23) 
<0.01 
1.16 
(1.06,1.27) 
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3.6 DISCUSSION. 
The technique of ABPM has been used in our unit for several years, as it has in obstetric 
units throughout the country. However, there have been no formal randomized prospective 
trials of its use to date in the literature. This study confirmed that ABPM can be performed 
reliably in a district hospital using midwives on the antenatal day unit, who are familiar with 
the technique. Good compliance was achieved, with median duration of recording over 22 
hours long (Table 3.2).  
 
This is a selected population from a specific geographical area, with 95% of White ethnicity, 
and only 6% were current smokers. Results should be applied to other populations with 
caution. Patients were referred by consultants for ABPM as part of routine practice in our 
unit. It is possible that individual variation in management affected outcomes such as 
gestation at delivery. Individual patient characteristics might also bias the results, for 
example women with a previous caesarean, small baby or preterm delivery would be more 
likely to have a repeat of this outcome. Individual risk factors such as body mass index or 
age might also affect results. For this reason these factors were built into the relevant models 
for regression analysis to allow for their confounding effect and to examine the relative 
predictive value of ambulatory versus conventional blood pressure monitoring.  
 
ABPM results had better correlation with certain obstetric and neonatal outcomes compared 
with conventional blood pressure monitoring in this retrospective study. In particular, 
outcomes of birth weight less than the 10
th
 centile (corrected for sex and gestation), preterm 
delivery and significant proteinuria correlated better with 24-hour mean values. This 
suggests that a raised ABPM result could predict these adverse outcomes more accurately 
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than conventional methods, and thus identify women at higher risk. Previous studies 
described in Chapter 1, Table 1.7 have reported similar findings.  
 
The benefit of ABPM may be from obtaining more reliable readings and identifying women 
with white coat hypertension, thus correctly identifying those with true hypertension in 
pregnancy. Using this method, a decrease in unnecessary interventions should result, without 
adverse effects on perinatal outcomes. ABPM may also be a more accurate predictor of 
outcome compared to conventional BP on its own merits, with the 24-hour period of 
readings during normal activity innately better linked to outcomes. These mechanisms may 
be inter-related, or act independently. 
 
The results above are useful in confirming previous research findings. However, the true test 
of the technique is whether it is being used to maximum benefit in a clinical setting. In 
particular, the question arises of whether ABPM is a useful adjunct to clinical care of women 
with hypertension in pregnancy, or simply confirms the suspicion of disease without 
changing management strategies. Given the lack of assessment of ABPM in pregnancy in 
any prospective randomized controlled trials,
203 
a Lancet review stated these are „urgently 
needed.‟ 37 Following the above results, we conducted a prospective randomized trial of the 
use of ABPM in pregnancy.  
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CHAPTER 4: 
A RANDOMIZED COMPARISON OF AMBULATORY BLOOD 
PRESSURE MONITORING VERSUS CONVENTIONAL  
OFFICE BLOOD PRESSURE MEASUREMENT IN THE 
MANAGEMENT OF PREGNANT HYPERTENSIVE WOMEN 
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4.1 ABSTRACT 
Objective: To test the hypothesis that ABPM, by identifying pregnant women with white 
coat hypertension in pregnancy, would lead to a reduction in obstetric and neonatal 
interventions compared to conventional blood pressure measurement in a pragmatic clinical 
setting. 
Design: Prospective randomized controlled trial. 
Setting: Obstetric department of a district general hospital 
Participants: 100 pregnant women undergoing ABPM with randomization to revealed or 
concealed results. 
Main outcome measures: Obstetric and perinatal outcomes including admission to hospital, 
induction of labour, caesarean section, preterm delivery, use of anti-hypertensive drugs. All 
participants were sent a questionnaire after delivery about their experience of ABPM. 
Results: The rate of induction for hypertension was 23% lower in the „revealed‟ ABPM 
group when compared to the „concealed‟ group (p=0.015). The overall rate of induction of 
labour was also lower in the „revealed‟ compared to the „concealed‟ group (37.3% vs 49%) 
but did not reach statistical significance (p=0.236). Other variables examined showed no 
statistically significant differences between groups. Of the women returning the 
questionnaire, 56/63 (89%) stated they would undergo ABPM in a future pregnancy. 
Conclusion: This study showed a reduction in the rate of induction for hypertension when 
ABPM results were available. It does not show any other clinical benefit of ABPM in 
hypertensive pregnant women. The heterogeneous nature of the study population in this 
pragmatic trial may have affected these results. Better understanding is needed of which 
group of hypertensive pregnant women will benefit from ABPM. ABPM requires further 
robust evaluation in clinical practice. Patient acceptance of the procedure is high. 
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4.2 INTRODUCTION 
Background 
This thesis aims to test the hypothesis that in pregnancies complicated by hypertension, 
ambulatory blood pressure monitoring (ABPM) improves clinical assessment and outcome 
for both mother and fetus. The objective of this section is to evaluate the potential benefits of 
employing ABPM in hypertensive pregnancies in the clinical setting, by reporting the results 
of a randomized controlled trial. This is the first prospective randomized clinical trial of 
ABPM, as confirmed in a Cochrane Review which found no studies to report.
203
 The use of 
ABPM in pregnant and non-pregnant subjects has been discussed in detail in section 1.4. 
4.3 METHODS 
Participants 
Inclusion criteria 
Any pregnant woman with a diagnosis of hypertension during pregnancy qualified for trial 
entry. Subjects were classified using the system devised by Davey and MacGillivray and 
endorsed by the International Society for the Study of Hypertension in Pregnancy (ISSHP), 
Table 2.1.
53 
For the purposes of the study, hypertension was defined as two diastolic readings 
at least 4 hours apart of ≥ 90 mmHg, using the fifth Korotkoff sound.  
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Exclusion criteria 
1. Any woman whose conventional blood pressure measurement was so severely raised that 
it warranted immediate treatment with intravenous anti-hypertensives and delivery within 
the 24-hour assessment period. 
2. Women with a concurrent medical condition such as diabetes or renal disease. 
3. Women under the age of 16 or unable to give informed consent. 
4. In the concealed results group, any women with an ABPM result defined as severe 
hypertension (170/110 or more) by recognized guidelines.
45
 Clinicians would be notified 
of the results. 
  
Participating centre 
Good Hope Hospital NHS Trust, Sutton Coldfield participated in the trial, with all six 
consultants agreeing to enrol their patients. This district hospital in the West Midlands had a 
birth rate of 3200 deliveries per annum during the study period (2003). Originally a further 
centre was to participate, but this hospital withdrew from the study for logistical reasons. 
 
Randomization and intervention 
Before commencing the trial, several presentations were given to staff to publicise it. One-to-
one sessions took place between the research fellow (CR) and team members to explain the 
procedure. Files containing all relevant paperwork were left in clinical areas and posters put 
up to publicise the study (Appendix 3). Detailed instructions were available for day unit staff 
who organised the ABPM (Appendix 4).  
 
When a woman attended the department and was found to meet the trial entry criteria, she 
was given a patient information sheet (Appendix 5). If she declined to participate, a record 
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was kept of the reason for this and her care continued as normal. If she wished to participate 
in the trial, she was asked to sign three copies of a consent form: one to keep, one for 
hospital notes and one for the research record (Appendix 6). She then underwent ABPM. The 
research fellow was informed by telephone that the patient had been recruited to the trial and 
an addressograph label placed in a notebook kept by the ABPM computer, and the patient 
was given a patient identification number (PIN). 
 
Sequential opaque sealed envelopes were pre-prepared by the research fellow, labelled 
externally with the PIN. Participants were randomized using a random number table.
237
 In 
the envelope was placed a piece of paper on which was written Group A (even numbers in 
the random number table including 0), or Group B (odd numbers in the table).  The patient 
and midwife performing ABPM were blinded as to the randomization status until after 
completing the monitoring. After completion of monitoring, the envelope was opened by the 
research fellow in a separate location to the patient before processing the results. Those in 
Group A had their ABPM recording revealed to the clinical team. The obstetrician was able 
to request further recordings if needed. Women in Group B had the results of the recording 
concealed from the clinical team.   
 
The results of the ABPM were then downloaded onto the computer. If allocated to Group A 
(revealed), a hard copy of the results was sent immediately to the referring clinician, with a 
covering letter (Appendix 7). A further copy of the results was filed in the case notes so all 
members of the team had access to it, and a third copy kept by the research fellow for 
reference. If allocated to Group B (concealed), the clinician was informed of this by letter 
(Appendix 7).  All women had ongoing care and management by their own consultant.  
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The research fellow checked if the 24-hour mean in a patient in the concealed group was 
greater than 170/110; if this occurred the patient was to be excluded from the trial and the 
clinician informed of the results. All downloaded ABPM results in Group B (concealed) 
were kept in a locked filing cabinet in a non-clinical area. The computerised results were not 
accessible to the clinicians caring for the patient.  
 
A sticker was placed on the outside of all case notes and the hand-held maternity record, 
with the patient‟s permission, stating that they were taking part in the ABPM trial and which 
group they were in. Validation of the randomization procedure was carried out by examining 
notes to ensure ABPM results in the concealed group were not available to the clinical team.  
A Trust Research Investigators File was kept by the research fellow with all documentation 
related to the trial, including consent form copies, a master randomization list, screening log 
for those declining to take part, and a recruitment/randomization log.  
 
Monitors and Ambulatory Monitoring Process 
The SpaceLabs ambulatory blood pressure monitor 90207 was used.  These oscillometric 
devices have been validated for use in pregnancy.
115 
All monitors were serviced regularly 
and checked for accuracy at the beginning, halfway through and at the end of the trial. The 
correct size of BP cuff was applied to the patient‟s non-dominant arm by a trained midwife 
(Figure 4.1). The monitor display was disabled so that the patient could not see her own 
readings. Monitors were programmed with the proprietary software on a personal computer. 
A full 24 hours of blood pressure monitoring was carried out if the patient was able to 
tolerate this.  Blood pressure readings were taken every 30 minutes.  
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After confirming that the device was working correctly, the patient either returned home or 
returned to the ward environment, to continue her normal routine. Once the period of 
recording was complete, the monitor data were downloaded onto the same computer. The 
result was processed as above (randomization and intervention). 
 
Figure 4.1: ABPM monitor in situ (photograph included with written consent of patient 
and member of staff) 
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Data collection, outcome measures and definitions 
The primary objective of the trial was to discover if ABPM allowed the treating clinicians to 
target interventions in women at higher risk, by identifying women at lower risk (with white 
coat hypertension or mild hypertension). Four primary outcome measures were chosen and 
are shown in Table 4.1, along with the secondary outcome measures: 
Table 4.1 Outcome measures 
Primary outcome measures Secondary outcome measures 
Admitted for hypertension Preterm delivery 
Antihypertensive medication Birth weight <2.5 kg 
Induction of labour (IOL) for hypertension Admission to NNU 
Caesarean section Outpatient attendances (clinic and day unit) 
 Community attendances 
 No. of inpatient admissions 
 No. of admissions for BP 
 Length of inpatient stay: antenatal, postnatal  
 Patient satisfaction with ABPM (overall) 
 
Initial patient details available at the time of recruitment were recorded prospectively from 
the patient case notes by the research fellow onto a proforma (Appendix 8). This information 
was then entered onto an Excel computer database, designed with the supervisor, with details 
of clinical recordings of blood pressure and ABPM measurements. Further antenatal and 
outcome data were recorded onto the proforma directly from patient case records, and then 
entered onto the computerised database during the pregnancy and after delivery.  
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Once the details for each patient were entered onto the computerised database, they were 
cross-checked manually with the proforma for each patient. Any queries were discussed with 
the thesis supervisor. He also checked the Excel spreadsheet data. Any seemingly spurious or 
extreme values were double-checked with the proforma and hospital case-notes. The range 
of values for each piece of data used was checked with Excel to aid identification of 
incorrect entries. The items of data collected are shown in Appendix 8.  
 
The patients were identified throughout by their allocated PIN/case number. Age was that at 
the date of last menstrual period. The body mass index was calculated by dividing booking 
weight in kilograms by height in metres
2
. Ethnicity was allocated as self-reported on the 
maternity hand-held records (West Midlands patient held record version 1.1, based on an 
original design by Rupert Fawdry, modified by the West Midlands Regional Perinatal 
Audit.) Primiparous patients were defined as those who had not delivered a baby over 24 
weeks gestation. Estimated date of delivery was calculated from ultrasound data. Gestation 
was entered in days. The diagnosis of hypertensive disorder was made in retrospect using 
criteria as defined by Davey and MacGillivray (Table 2.1).
53   
 
Admission to hospital was defined by an overnight stay, otherwise these were classified as 
ward attendances. To quantify length of stay, any part of a 24-hour period spent in hospital 
during an admission was included as a day. Preterm delivery was defined as birth before 37 
completed weeks (258 days or less). Growth restricted babies were defined as a birth weight 
less than the 10
th
 centile, adjusted for gender and gestation.
215 
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Patient Questionnaire 
In order to assess the woman‟s experience of the monitoring, a patient questionnaire was sent 
to all participants (Appendix 9). A stamped addressed envelope was included for return. 
Participants were identified by their PIN on the questionnaire. The responses on the 
questionnaires were divided into discrete variables and analysed using percentages in each 
response group. A section for free text comments was also included. 
 
Statistical Considerations 
Shown below in Table 4.2 are the power calculations for the various outcome measures 
chosen as indicators of success for the group with revealed ABPM records. The baseline 
rates for the outcome measures were based on data for the hospital. The overall incidence of 
white coat hypertension in the pregnant population in published studies is around 10-20% 
(see section 1.4.3). By detecting white coat hypertension, we proposed that rates of 
intervention might decrease by 10-15% as shown in the Table.  
 
Generalisability (external validity) is the extent to which results of a study can be generalised 
to different circumstances.
238
  We aimed to conduct a pragmatic study of well-defined 
outcomes relating to a standard intervention (ABPM). Applicability of the results of the 
study would be a matter of judgement for example in very different populations (eg different 
ethnic composition, high-risk tertiary level patients). However, a large portion of maternity 
care is conducted in district hospitals such as the setting for this study, and results would be 
generalisable to the majority of the obstetric population. 
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Table 4.2. Power calculations 
Change in Outcome Measure Confidence 
 Interval 
Power No of participants  
in each arm 
Admission rate 70%-55% (15%) 95% 80% 175 
Induction rate 60%-45%  (15%) 95% 80% 186 
Caesarean rate 40%-30% (10%) 95% 80% 351 
 
The primary analysis was intention-to-treat and involved all patients who were randomly 
assigned. Means and standard deviation (SD), and medians were calculated for baseline 
characteristics and continuous variables. Risk difference was calculated with 95% 
confidence intervals for categorical outcome variables, with χ2 test for significance. Analysis 
of variance (ANOVA) or the Mann-Whitney test were used for continuous variables. The 
Minitab statistical package was used for data analysis.
216  
  
 
Ethical approval 
Ethical approval was obtained from the North Birmingham Research Ethics Committee in 
February 2002 (Appendix 10). 
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4.4 RESULTS 
Results are presented as recommended by the Revised CONSORT (Consolidated Standards 
of Reporting Trials) Statement for Reporting Randomized Trials.
238
 Figure 4.2 shows the 
flowchart describing the flow of participants through each stage of the trial.  118 women 
were asked to take part in the trial. Eighteen were excluded. Of these, 14 women declined to 
take part for reasons such as limited time or not wanting to be monitored. Four women did 
not meet inclusion criteria: two did not speak English and no interpreter was available to take 
consent, one was diabetic and one had ABPM already performed in the pregnancy.  
 
A total of 100 women were randomized over the study period from March 2002 to December 
2003 (22 months). Fifty-one women were allocated to Group A and 49 to Group B. All 
underwent the intervention of ABPM. The median time of ABPM recording was 23 hours 
and 28 minutes. All women received the allocated randomized intervention of revealing or 
concealing the results, with no violation of the protocols detected. No women were lost to 
follow-up and all data needed to analyse primary outcomes were retrieved. There were no 
adverse events or side effects in either group. 
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Figure 4.2. Flow diagram of participants in trial 
  
       
 
 
 
 
 
 
 
118 people evaluated for 
potential enrollment 
 
18 excluded: 
 
14 declined to participate 
 
4 did not meet inclusion criteria 
 
51 in analysis 
0 lost to follow-up 
51 allocated to revealed  
ABPM result 
Group A 
 
51 received allocated intervention 
 
49 in analysis 
0 lost to follow-up 
49 allocated to usual care:   
concealed ABPM result 
Group B 
 
49 received allocated intervention 
100 randomly allocated 
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Baseline demographic and clinical characteristics of each group are shown in Table 4.3. 
 
Table 4.3. Baseline characteristics of trial groups 
Characteristic Group A 
(n = 51) 
Group B 
(n = 49) 
Mean age ± SD, years 30.2 ± 6.0 29 ± 5.0 
Mean body mass index ± SD, kg/m
2 
26.2 ± 4.3 27.3 ± 6.0 
Mean booking blood pressure ± SD, mmHg 
   Systolic 
   Diastolic 
 
119 ± 13 
75 ± 11 
 
120 ± 12 
73 ± 10 
Parity, n (%) 
   0 
   1 
   2 
   >2 
 
32 (62) 
11 (22) 
4 (8) 
4 (8) 
 
32 (65) 
12 (25) 
4 (8) 
1 (2) 
White, n (%) 46 (90) 47 (96) 
Mean gestation at trial entry ± SD, days 231 ± 39 240 ± 48 
Past history, n (%) 
   Previous pre-eclampsia 
   Pre-pregnancy hypertension  
   Previous caesarean section 
 
7 (13.7) 
8 (15.7) 
9 (17.6) 
 
5 (10.2) 
6 (12.2) 
5 (10.2) 
 
SD =standard deviation 
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Table 4.4 shows a summary of results for each primary outcome within each group, with the 
estimated effect size and its precision (95% confidence interval). There was a statistically 
significant decrease of 23% in the rate of induction of labour for hypertension in Group A 
(revealed result) compared to Group B (concealed result). In view of this, further analysis 
was done on induction of labour. Fewer women underwent induction of labour overall in 
Group A compared to Group B (37.3% vs 49%), but the overall rates of induction of labour 
were not significantly different between the two groups (Table 4.4.) All 24 inductions in 
Group B were for hypertension. Thirteen women in Group A underwent induction of labour 
for hypertension. Of the six patients induced for other indications in Group A, four were 
post-term, one had pre-labour rupture of the membranes with meconium staining of the 
amniotic fluid, and one was for maternal choice. Details of gestation at delivery of all 
women undergoing induction of labour were analysed. More induced women delivered at 
≥40 weeks gestation in Group A (8 of 19 women) compared to Group B (4 of 24 women): 
42.1% vs 16.7%. 
Table 4.4. Summary results: Primary outcomes and induction of labour (overall) 
Outcome 
n (%) 
Group A 
(revealed) 
n = 51 
Group B  
(concealed) 
n = 49 
Risk Difference 
(95% CI) 
P value  
(χ-square) 
Admitted for hypertension 35 (69) 35 (71.4) -0.03 
(-0.21, 0.15) 
0.760 
Antihypertensive medication 26 (51) 24 (49) 0.02 
(-0.18, 0.22) 
0.841 
Induction of labour for hypertension 13 (25.5) 24 (49) -0.23  
(-0.42, -0.05) 
0.015 
Induction of labour overall 19 (37.3) 24 (49) -0.12 
(-0.31, 0.08) 
0.236 
Caesarean section 20 (39.2) 19 (38.8) 0.00 
(-0.19, 0.20) 
0.964 
 
 141 
 
Table 4.5 shows results for neonatal outcomes. There were no perinatal losses. Table 4.6 
shows attendance and length of stay data. No differences were seen between the two groups 
for any of these outcomes. 
Table 4.5. Summary results. Secondary outcome measures: neonatal data 
Outcome 
n (%) 
Group A 
(revealed) 
n = 51 
Group B  
(concealed) 
n = 49 
Risk Difference 
(95% CI) 
P value  
(χ-square) 
Preterm delivery 11 (21.6) 5 (10.2) 0.11 
(-0.03, 0.25) 
0.121 
Birth weight<2.5 kg 10 (19.6) 9 (18.4) 0.01 
(-0.14, 0.17) 
0.874 
Admission to NNU 13 (25.5) 8 (16.3) 0.09  
(-0.07, 0.25) 
0.261 
 
Table 4.6 Summary results. Secondary outcomes: attendance/length of stay data 
Outcome: 
Median  
 
Group A 
(revealed) 
n = 51 
Group B  
(concealed) 
n = 49 
Point Estimate* 
(95% confidence intervals) 
P value* 
Outpatient attendances: 
antenatal clinic (n) 
5 4 1.0  
(-1.0, 2.0) 
0.380 
Outpatient attendances: 
antenatal day unit (n) 
3 3 -1 
(-2.0, 1.0) 
0.319 
Community attendances (n) 11 9 1  
(-0.001, 3.0) 
0.150 
Inpatient admissions (n) 2 2 0 
(-0.0002, -0.0002) 
0.293 
Admissions for BP (n) 1 1 0 
(-0.0000, 0.0001 
0.934 
Antenatal stay (days) 4 4 -0 
(-1.000, 1.999) 
0.682 
Postnatal stay (days)  3 3 0 
(-1.0, 1.0) 
0.696 
*Mann-Whitney test  
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As part of the trial protocol, a six week follow-up appointment was included. Only 28 
women came to their appointment (14 from Group A and 14 from Group B), giving 
inadequate data for analysis. This is not unusual in studies of this kind; for example Brown et 
al reported that only 33% of patients in a study of white coat hypertension attended their 
postpartum follow-up appointment.
190 
For the women who attended their appointment, it was 
generally used as an opportunity to answer any queries, provide information about 
hypertension in pregnancy and to remind the patient to complete the participant 
questionnaire (see below).   
 
All 100 participants were sent a questionnaire in the first 6 weeks after delivery asking about 
their experience of ABPM. A stamped envelope addressed to the research fellow was 
enclosed with the questionnaire. Sixty-three women returned completed questionnaires. 
Fifty-nine were returned within six weeks, and the remaining four questionnaires were 
returned by eight weeks after posting. Of the returned questionnaires, 32 (51%) were in 
Group A and 31 (49%) in Group B. The questionnaire is shown in Appendix 9, and results 
are summarised in Table 4.7. When asked „If 24-hour blood pressure monitoring became part 
of routine pregnancy care would you be willing to have it again in a future pregnancy?‟ 56 
women (89%) answered yes, 2 (3%) were unsure and 5 (8%) said no. 
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Table 4.7 Summary of responses to participant questionnaire  
Question Group Answer: n (%) 
No Slight Moderate Severe NR Total 
Use of arm 
limited 
A 5 (16) 21 (66) 6 (19) 0 0 32 
B 4 (13) 18 (58) 8 (26) 0 1 (3) 31 
All 9 (14) 39 (62) 14 (22) 0 1 (2) 63 
Discomfort 
from cuff 
A 6 (19) 17 (53) 7 (22) 2 (6) 0 32 
B 4 (13) 19 (61) 7  (23) 0 1 (3) 31 
All 10 (16) 36 (57) 14 (22) 2 (3) 1 (2) 63 
Daily 
activities 
limited 
A 8 (25) 19 (59) 4 (13) 1 (3) 0 32 
B 10 (32) 14 (45) 5 (16) 1 (3) 1 (3) 31 
All 18 (29) 33 (52) 9 (14) 2 (3) 1 (2) 63 
Monitor noise 
disturbing 
A 11 (34) 12 (38) 9 (28) 0 0 32 
B 12 (39) 9 (29) 7 (23) 2 (3) 1 (3) 31 
All 23 (37) 21 (33) 16 (25) 2 (3) 1 (2) 63 
Sleep pattern 
disturbed 
A 5 (16) 14 (44) 10 (32) 3 (9) 0 32 
B 10 (32) 6 (19) 7 (23) 6 (19) 2 (6) 31 
All 15 (24) 20 (32) 17 (27) 9 (14) 2 (3) 63 
Would have 
ABPM again 
 Yes No Not sure Total 
A 30 (94) 2 (6) 0 32 
B 26 (84) 3 (10) 2 (6) 31 
All 56 (89) 5 (8) 2 (3) 63 
Comments  Positive Negative Neutral Total 
A 6 (67) 2 (22) 1 (11) 9 
B 7 (44) 8 (50) 1 (6) 16 
All 13 (52) 10 (40) 2 (8) 25 
NR = no response 
 
Women were asked to enter further comments as free text. Comments were made on 25 out 
of 63 (40%) forms and are summarised in Table 4.7 above. Thirteen comments (52%) were 
positive, 10 (40%) were negative and 2 (8%) were neutral. A more selection of themes and 
comments are summarised in Table 4.8. 
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 Table 4.8 Sample of free-text responses to participant questionnaire 
Theme Example Group 
Usefulness of 
technique 
„…gave a clearer overview of my blood pressure than 
the usual one-off reading…‟ 
A 
„…worth it to know that a true picture of your blood 
pressure can be built up without having to stay in 
hospital.‟ 
A 
„…the doctors found out my true blood pressure. If a 
midwife was to come and take my b/p it was 
sometimes higher because I became anxious.‟ 
A 
Taking part in 
research 
‘I would do it again if it can help similar women 
when pregnant.‟ 
B 
„I was pleased to participate‟    A 
„Just happy to help.‟ A 
Disadvantages „…tightness of the cuff made holding, carrying things 
very difficult.‟ 
B 
„…another check a couple of minutes later 
unexpectedly – this was frustrating.‟ 
B 
„…it was cumbersome.‟ A 
„…wouldn‟t want to go shopping with 
it..noisy…embarrassing‟ 
B 
„…very uncomfortable…the metal part dug into my 
arm.‟ 
B 
Suggestions „…driving was impaired I feel this should be stressed 
before issuing…‟ 
B 
„…would choose if possible to use the monitoring 
when I wasn‟t at work…pupils found it distracting…‟ 
B 
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4.5 DISCUSSION  
This is the first randomized controlled trial of ABPM in pregnancy. The aim of this study 
was to perform a pragmatic trial of the use of ABPM as it is currently used in hypertensive 
pregnancies in the setting of a District General Hospital. Patients remained under the care of 
their booked consultant, and this team controlled patient management. The only difference 
between the two groups was the availability of the results of ABPM. The groups were 
comparable in their baseline demographic and patient characteristics (Table 4.3). The flow of 
patients was demonstrated as per the CONSORT guidelines for reporting of randomized 
trials. All patients conformed to the trial protocol and no women were lost to follow-up 
(Figure 4.2). A full CONSORT checklist is attached in Appendix 11. We have successfully 
demonstrated that such a trial is practical. 
 
The protocol specified four primary outcomes for the trial. The CONSORT statement for 
reporting randomized trials defines the primary outcome as the prespecified outcome of 
greatest importance.
238
 It states that having more that one or two primary outcomes  can lead 
to problems of interpretation due to multiplicity of analyses, and is not recommended. 
Multiple analysis of the same data increases the risk of a Type I error, attributing a difference 
to an intervention when this is by chance, leading to a false-positive finding. 
 
The only statistically significant different outcome between the groups was in rates of 
induction of labour for hypertension, with lower rates in the group with revealed results 
(25.5% vs 49%, p=0.015). This is consistent with the hypothesis underpinning this work, that 
ABPM would avoid unnecessary rates of intervention. The decreased rate of induction for 
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hypertension could be explained by reassuring results of 24 hour blood pressure monitoring 
(compared to conventional measurements), which were not available in the concealed group.   
 
When analyzing the overall induction rate, it was still lower in Group A compared to Group 
B (37.3% vs 49%). However, this difference was not statistically significant (p=0.236). 
When the inductions of labour in the Group B (concealed) group were analysed, all 24 were 
done for the indication of hypertension. In the women in the Group A (revealed) group, 13 of 
the 19 inductions were done for raised BP. The remainder were for post-term (n=4), pre-
labour ruptured membranes (n=1) and maternal choice (n=1). These results do suggest that 
there is a trend for clinicians to be reassured by ABPM results and allow pregnancies to 
continue for longer without induction of labour for hypertension. This premise is supported 
by the fact that more women who were induced in Group A delivered at a gestation of ≥40 
weeks than in Group B (42% vs 16%). 
 
An alternative explanation for the results on induction might be that clinicians chose to 
record the indication for induction in Group B (concealed) as hypertension in preference to 
other reasons. The higher rates of induction for hypertension in Group B would then simply 
reflect a raised risk of „labelling‟ women as hypertensive and documenting this as the main 
reason for their decision to intervene. However, this would actually support our hypothesis 
that ABPM would decrease intervention by detecting women with white coat hypertension, 
reassuring clinicians who would not label the pregnancies as hypertensive. The information 
on gestation at delivery in women who were induced is of interest, as women in Group B 
were generally induced before 40 weeks. This suggests clinicians were not simply „re-
labelling‟ women being induced at post-term as hypertensive, and that the recorded 
indication for induction is a true representation of the clinician‟s decision. 
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There was no significant increase in the rates of adverse perinatal outcomes examined: rates 
of preterm delivery, low birth weight and neonatal admission did not differ between the two 
groups (Table 4.5). 
 
In any trial of an intervention the experience of the participants should be assessed. Previous 
authors have published rates of complication and patient acceptability of ABPM devices. In a 
study of 219 non-pregnant patients, only four had complications; in all cases this was 
petechiae distal to the cuff.
239
 In an evaluation of the SpaceLabs 90207 monitor in 120 
pregnant and postpartum women, over half reported sleep disturbance and significant 
discomfort.
240
 The device was judged „acceptable‟ by 74% at first use. The same monitor 
was evaluated by 110 women in a 2004 report, and problems with sleep were a major cause 
of dissatisfaction: 79% of patients reported a degree of sleep disturbance. 
241
  
 
In our patients, the results in Table 4.7 show similar findings, with only 24% reporting that 
their sleep was not disturbed, and 14% describing disturbance as „severe‟. Limitation of daily 
activities was reported to some degree by 69% of patients. There were a similar number of 
questionnaires returned for each group. It is notable that more patients in Group B 
(concealed) than Group A (revealed) entered comments (16 vs 9), and that 50% of these 
were negative compared to 22% of the Group A comments. The patients were aware of their 
group allocation once ABPM was complete. The group with concealed results did not gain 
personally from the test, which might increase the chance of negative feedback.  However, 
there was still comment from Group B participants on being happy to take part in research, 
and 7 of 13 (54%) of all positive comments were from this group. Overall, free text 
comments were more positive than negative, with a good understanding of potential 
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advantages of the technique. A willingness to repeat ABPM if recommended in future 
pregnancy was reported by 89% of the participants.  
 
The literature published so far in the field of ABPM in pregnancy has been extensively 
reviewed in Chapter 1. There are no randomized trials with which to compare this work. 
However, the findings are consistent with previous authors who report that ABPM is useful 
particularly in assessing women who may have white coat hypertension, which would not 
warrant obstetric intervention but is only diagnosed if ABPM is performed. The consultants 
in our hospital were familiar with the use of ABPM and interpretation of results, and should 
be experienced at taking the results into account when deciding on management. In other 
settings, education would be needed for clinicians particularly on the normal ranges of 
ABPM in the different trimesters of pregnancy.  
 
When designing a randomized study of a diagnostic test such as blood pressure monitoring 
several factors need to be considered. Firstly, it is not possible to blind the patient or staff to 
the fact that the test is being performed. We therefore blinded the staff and patient to the 
group allocation until the investigation was complete, and blinded clinicians and participant 
to the result in the concealed group. Secondly, we deliberately performed the ABPM in both 
groups of patients. This was to avoid the confounding effect of two attendances at hospital at 
the day unit (for application and downloading of the monitoring) as an opportunity for staff 
to assess a patient. If ABPM was found to be helpful one could argue that the extra 
attendance, not the monitoring itself, was responsible. However, in our study all patients 
attended for monitoring. Finally, it was also an ethical consideration, as very raised results 
were to be communicated regardless of the group allocation.  
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We were guided by the CONSORT statement for reporting randomized trials in documenting 
our results, and were able to conform to the standards set.
238
 However, the intervention in our 
randomized trial is unusual because it is a diagnostic test, rather than a treatment or 
management strategy. The level of blood pressure on ABPM is a means of diagnosing 
hypertensive disorder and contributing to allocation of risk. It also is directly related to 
detection of the complications of worsening hypertension (such as superimposed pre-
eclampsia in chronic hypertension), a diagnosis which can also be seen as an outcome. We 
used concrete outcomes to assess the use of ABPM such as induction of labour, caesarean 
section and birth weight of the baby. This provides a separation between the randomized 
„intervention‟ of the ABPM result and outcomes to be assessed. It also prioritises outcomes 
which are of most interest to clinicians and their patients. 
 
In a series of papers on the evidence base of clinical diagnosis in the BMJ, the authors of the 
introductory article (Knottnerus et al) state that „the methodology of diagnostic research lags 
behind that for evaluating treatment.‟ 242 Diagnostic investigations have the following 
objectives: increasing certainty of presence or absence of disease, supporting clinical 
management, assessing prognosis, monitoring clinical course and measuring fitness. All the 
first four objectives apply to ABPM. The choice of study design in diagnostic research varies 
with the aims of that study. For example, to assess the diagnostic accuracy of a test, cross 
sectional studies with reference to the „gold standard‟ are needed. This has been described in 
the studies of ABPM in pregnancy, outlined in Section 1.4.3 above, which compare it to the 
use of conventional mercury BP devices, using techniques such as sensitivity and specificity, 
and the area under a receiver operator characteristic curve.  
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The most important evaluation of a diagnostic test involves the health outcomes after 
management informed by the test.
243
 To study the impact of a test on decision-making and 
outcomes, the standard method is quoted as the randomized controlled trial. This method is 
superior to an observational cohort study, where both groups may not be comparable at 
baseline entry. The value of the test under investigation can be assessed (in comparison to 
either the usual procedure or no test), in providing potential improvements in diagnostic 
accuracy, management and prognosis. Knottnerus et al describe a „variant‟ where the index 
test is used on all subjects, with randomized disclosure of the results to the clinical team 
caring for the patient (if ethical). The authors describe this as an „ideal placebo procedure‟ 
for the patient. This is the design of our research study. 
 
To complement the CONSORT statement for reporting randomized trials, the STARD 
(Standards for Reporting of Diagnostic Accuracy) Initiative was published in 2003.
244
 A 
checklist and flow diagram was produced, but these are particularly relevant to reporting 
studies of diagnostic accuracy such as laboratory tests. The randomized controlled trial we 
conducted was more suited to the CONSORT guideline, 
 
The main limitations of our study relate to the power calculations and number of patients 
recruited. We did not enroll as many people in the trial as recommended by the power 
calculations. Unfortunately the other participating centre withdrew due to logistical 
problems. A significant decrease in rates of induction of labour for hypertension was seen in 
the group with revealed ABPM results. Although overall rates of induction were also 
reduced in this group, this did not reach statistical significance. The lack of adverse effects of 
perinatal outcomes may be secondary to the small sample size and should be interpreted with 
caution.  
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We also recruited a deliberately heterogeneous population with broad inclusion criteria. 
Women with various disorders at different gestations were included, and this may have 
placed ABPM at a disadvantage. Other research has suggested that ABPM has a greater 
benefit in women with chronic hypertension. This is also consistent with findings in the non-
pregnant population, where ABPM confers the greatest benefit in predicting cardiovascular 
disease in later life. Chronic hypertension is a particularly high-risk state in pregnancy, 
possibly due to early end-organ damage and/or increased vascular resistance. ABPM, as a 
better predictor of cardiovascular outcome, may be most useful in assessing this group of 
patients during pregnancy. In view of the positive findings of observational studies of ABPM 
in women with suspected hypertension in early pregnancy
190
, a randomized trial in this group 
would provide useful evidence on the use of ABPM, particularly relating to identification of 
white coat hypertension.  
 
Another reason for the lack of an effect might be the elements of ABPM reported to 
clinicians in the study, ie daytime, night-time and 24-hour means for systolic, diastolic and 
mean arterial pressure, along with raw data. No further modeling of the data was performed. 
Other measures described in section 1.4.3, such as blood pressure load, might be more 
powerful measures when predicting outcomes in pregnancy. Finally, the clinicians in the 
study, although familiar with the technique of ABPM, may not have used these results in the 
most effective way. 
 
In summary, we have shown that it is feasible to conduct a randomized controlled trial of the 
diagnostic technique of ABPM, and report here the first such trial of ABPM in pregnancy. 
Although patient acceptability is good, rates of sleep disturbance and discomfort cannot be 
disregarded, and it is important to establish in pragmatic practice the potential advantage of 
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decreasing rates of intervention without adversely affecting outcomes. Further studies with a 
similar design and larger numbers of participants in specified diagnostic groups should 
provide the answer to these questions, with the option of combining results in a meta-
analysis for robust evidence in this important area of obstetric practice. 
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CHAPTER 5: 
CONCLUSIONS AND RECOMMENDATIONS 
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5.1  SUMMARY OF FINDINGS  
This thesis begins with a review of blood pressure measurement outlining the history of the 
technique, along with potential sources of inaccuracies inherent in conventional 
measurement, including device faults and human error. The incidence and implications of 
high blood pressure in pregnancy are discussed in section 1.3. There are now established 
clinical and research definitions which should aid work in the field. The importance of this 
common pregnancy complication and its role in relation to outcomes such as maternal 
mortality and morbidity, perinatal loss, preterm delivery and growth restriction in the fetus is 
emphasised. However, there are significant gaps in knowledge of the pathophysiology of the 
hypertensive disorders of pregnancy which hamper efforts to improve clinical care.  
 
The potential of ambulatory blood pressure monitoring (ABPM) to provide more reliable 
measurements, predicting outcomes more effectively and thus improving allocation of risk, 
is discussed in section 1.4. There is increasing evidence supporting the use of ABPM in non-
pregnant individuals, especially in assessment of patients suspected of having white coat 
hypertension. Improved prediction of outcomes such as end-organ damage is now evident 
from large-scale trials. These findings mirror the relevant areas in obstetric practice of 
improved diagnosis and identifying high risk pregnancy. 
 
To provide reliable readings in pregnancy formal validation of devices is advised. This is 
reviewed in section 1.4.2. There is proven need for caution in severe pre-eclampsia, as 
several studies revealed unreliable results for ABPM in these women. An exhaustive search 
and review of the literature has revealed only eight papers publishing ten validation studies 
using recommended protocols in pregnancy, and only two devices passed. One of these 
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devices, the SpaceLabs 90207, was used in the research in this thesis. It is not unusual for 
studies of ABPM in pregnancy to quote validation studies in which the device actually fails. 
However, the relevance of a small number of readings at rest compared to mercury device 
readings, in a monitor designed to be used for multiple readings while a patient is ambulatory 
over 24 hours, can be questioned. The practical applications of use in the clinical situation 
and the potential for improving patient care and outcomes are the ultimate test of the 
technique.  
 
This is examined in section 1.4.3 with a review of the literature available on the use of 
ABPM in pregnancy (Table 1.4). All studies are observational, cohort or case-controlled 
studies; no randomized trials were identified. The normal values and patterns of ABPM in 
normotensive and hypertensive pregnancy have been established.  Early hopes for screening 
normal pregnancies for risk of hypertension in pregnancy or pre-eclampsia using patterns 
such as loss of nocturnal „dip‟ were not confirmed, as studies showed disappointing positive 
predictive values. Some authors have shown reasonable prediction of hypertensive outcomes 
using ABPM either in combination with indices in high risk women (such as uterine artery 
Doppler), or with complex computerised assessment, or in diabetic women. However, the 
results are inconsistent.  
 
When assessing a hypertensive population for prediction of specific outcomes such as poor 
fetal growth, proteinuria, preterm delivery, and severe hypertension, ABPM has compared 
favourably to conventional BP measurement. It also has a continuous inverse relationship 
with fetal birth weight in the general obstetric population. It is in the area of white coat and 
chronic hypertension that the most interesting results emerge, with initial scepticism in some 
authors giving way to good evidence that in suspected essential hypertension in early 
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pregnancy, a third of women can be identified as having white coat hypertension. There are 
better outcomes in this group with potential for reducing interventions such as anti-
hypertensive medication. The reviews and guidelines (Table 1.5) of ABPM in the literature 
echo the above findings. 
 
In Chapter 2, outcomes of pregnancies in hypertensive women attending a specialist 
antenatal clinic were examined, with particular reference to 317 women with chronic 
hypertension. Compared to the hospital population, all hypertensive women had a 
significantly increased rate of Caesarean section and (with the exception of those with 
gestational hypertension) a baby born preterm or small for gestational age. Perinatal 
mortality rates were very high, and were increased in Black women, and significantly raised 
in Asian compared to White women (83.3:1000 vs 28.0:1000). In chronic hypertension, 
stillbirth rates were raised in Asian vs White women (102:1000 vs 11:1000). Superimposed 
pre-eclampsia raised perinatal mortality rate significantly to 115.9:1000.  
 
Mean gestation at birth of stillborn babies in chronic hypertensive pregnancies was 28 
weeks, and 88.2% were growth-restricted. Nearly one in five Asian women with chronic 
hypertension booked after 20 weeks gestation, suggesting lack of early pregnancy care might 
contribute to worse outcomes in this group. In conclusion, this study confirms poor outcomes 
particularly in chronic hypertension, which are worse in women of Black and Asian 
ethnicity. Fetal growth restriction is an important risk and is linked to intra-uterine death. 
Reports in the literature of outcomes in hypertension in Asian women are very limited; work 
from this database is important in publicising these figures.  
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Any mechanism of improving these outcomes deserves investigation. To this end, Chapter 3 
assesses the predictive value of ABPM for important outcomes. Using regression analysis to 
compare it to conventional BP measurement, ABPM predicted development of proteinuria, 
gestation and weight at birth with greater accurately. This confirms previous research 
findings. This work also found that the technique of ABPM was viable in our District 
General Hospital setting. Following this initial assessment of ABPM, we undertook the first 
randomized controlled trial of ABPM in pregnancy. 
 
In section 4.5 the area of diagnostic research is reviewed. Randomized controlled trials are 
recommended to assess diagnostic techniques as they are used in the clinical area. One 
proposed study design is the „ideal placebo procedure‟ of using the „test‟ on all subjects with 
randomized disclosure of results. This design is used in our study, which showed that a 
pragmatic prospective randomized controlled trial of ABPM in hypertensive pregnancies is 
possible. We randomized 100 women to either revealed or concealed ABPM result. In the 
women with the revealed result, induction of labour for hypertension significantly decreased 
by 23%. Although overall rates of induction were also reduced in this group, this did not 
reach statistical significance. There were no other differences in other outcomes between the 
groups. A patient questionnaire showed good understanding of the potential advantages of 
the technique, and 89% would be willing to undergo ABPM in a future pregnancy. However, 
there are issues with self-reported sleep disturbance and discomfort, emphasising the need 
for good evidence behind the request for women to undergo this monitoring. 
 
The hypothesis underlying the trial was that identification of women with white coat 
hypertension might reassure clinicians and limit intervention to those women with genuinely 
raised BP in pregnancy. The reduced rate of inductions for hypertension would support this. 
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Unfortunately we did not recruit the numbers of women needed according to the power 
calculations. There was also a heterogeneous population of women within the trial which 
might „dilute‟ the possible effect of ABPM on outcomes. 
5.2 RECOMMENDATIONS FOR FUTURE RESEARCH 
The lack of robust validation of ABPM devices in common usage is of concern. Relevant 
bodies such as the International Society for the Study of Hypertension in Pregnancy and the 
British Hypertension Society should advise on processes for validation and testing of these 
devices, with investigation of the possibility of testing the devices during normal use.  
 
The very high perinatal mortality rates found in the review of the database of hypertensive 
pregnancies and outcomes are at least equivalent to those in maternal diabetes. The 
Confidential Enquiry into Maternal and Child Health (CEMACH) has conducted a 
confidential enquiry into the care of diabetic women and published recommendations in this 
field. We propose that management of women with chronic hypertension in pregnancy 
would be a suitable topic for a further enquiry, with particular focus on women from Black 
and Asian ethnic backgrounds. 
 
There is good potential for the use of ABPM in chronic hypertension, particularly to identify 
women with white coat hypertension in early pregnancy, who have better outcomes and can 
safely have less intervention. We have shown that randomized trials of ABPM are viable; a 
study of pregnant women with hypertension at first presentation, especially with uncertain 
diagnosis, would confirm this, while ensuring that there are no adverse effects of the 
monitoring.  
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APPENDIX 1: LITERATURE SEARCH 
A formal systematic search was also conducted with the aid of a clinical librarian as outlined 
below, with the aim of identifying studies of ABPM in pregnancy, and general reviews of 
hypertension in pregnancy to identify recent advances and important studies. 
 
 
 
 
 
 
 
 
Saved Searches 
 
You have the following Saved Searches. 
To run a Saved Search, select it and click the Run Search button. 
Click Delete to delete a Saved Search. 
 
Name   Search strategy 
 
    
GENERAL HT SEARCH 
MEDLINE 21 09 
 
1. SEARCH: HYPERTENSION.TI.   
2. SEARCH: HYPERTENSION.W..MJ.   
3. SEARCH: HYPERTENSION-
PREGNANCY-INDUCED.MJ. 
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4. SEARCH: 1 OR 2 OR 3   
5. SEARCH: PREECLAMP$4.TI.   
6. SEARCH: PRE-ECLAMP$4.TI.   
7. SEARCH: (PRE ADJ ECLAMP$4).TI.   
8. SEARCH: PRE-ECLAMPSIA.MJ.   
9. SEARCH: 5 OR 6 OR 7 OR 8   
10. SEARCH: 4 OR 9   
11. SEARCH: PREGNAN$5.TI,AB.   
12. SEARCH: PREGNANCY.W..MJ.   
13. SEARCH: 11 OR 12   
14. SEARCH: 10 AND 13   
15. SEARCH: 14 AND LG=EN   
16. SEARCH: 15 AND REVIEW=YES   
17. SEARCH: 15 AND PT=META-ANALYSIS   
18. SEARCH: 15 AND (CLINICAL-TRIALS# 
OR PT=CLINICAL-TRIAL#) 
  
19. SEARCH: 16 OR 17 OR 18   
 
HYPERTENSION GENERAL 
EMBASE 21 09 
 
1. SEARCH: HYPERTENSION.TI.   
2. SEARCH: HYPERTENSION.W..MJ.   
3. SEARCH: MATERNAL-
HYPERTENSION.MJ. 
  
4. SEARCH: 1 OR 2 OR 3   
5. SEARCH: PREECLAMP$4.TI.   
6. SEARCH: PRE-ECLAMP$4.TI.   
7. SEARCH: (PRE ADJ ECLAMP$4).TI.   
8. SEARCH: PREECLAMPSIA.W..MJ.   
9. SEARCH: 5 OR 6 OR 7 OR 8   
10. SEARCH: 4 OR 9   
11. SEARCH: PREGNAN$5.TI,AB.   
12. SEARCH: PREGNANCY.W..MJ.   
13. SEARCH: 11 OR 12   
14. SEARCH: 10 AND 13   
15. SEARCH: 14 AND LG=EN   
16. SEARCH: 15 AND REVIEW=YES   
17. SEARCH: 15 AND PT=META-ANALYSIS   
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18. SEARCH: 15 AND (CLINICAL-TRIALS# 
OR PT=CLINICAL-TRIAL#) 
  
19. SEARCH: 16 OR 17 OR 18   
 
HYPERTENSION IN 
PREGNANCY GENERAL 20 09 
07 
 
1. SEARCH: HYPERTENSION.TI.   
2. SEARCH: HYPERTENSION.W..MJ.   
3. SEARCH: HYPERTENSION-
PREGNANCY-INDUCED.MJ. 
  
4. SEARCH: 1 OR 2 OR 3   
5. SEARCH: PREECLAMP$4.TI.   
6. SEARCH: PRE-ECLAMP$4.TI.   
7. SEARCH: (PRE ADJ ECLAMP$4).TI.   
8. SEARCH: PRE-ECLAMPSIA.MJ.   
9. SEARCH: 5 OR 6 OR 7 OR 8   
10. SEARCH: 4 OR 9   
11. SEARCH: PREGNAN$5.TI,AB.   
12. SEARCH: PREGNANCY.W..MJ.   
13. SEARCH: 11 OR 12   
14. SEARCH: 10 AND 13   
15. SEARCH: 14 AND LG=EN   
16. SEARCH: 15 AND REVIEW=YES   
17. SEARCH: 15 AND PT=META-ANALYSIS   
18. SEARCH: 15 AND (CLINICAL-TRIALS# 
OR PT=CLINICAL-TRIAL#) 
  
19. SEARCH: 16 OR 17 OR 18   
 
    
ABPM SEARCH 20 09 07  
1. SEARCH: ABPM.TI,AB. [MEDL] 
2. SEARCH: (AMBULATORY ADJ 
BLOOD ADJ 
PRESSURE).TI,AB. 
[MEDL] 
3. SEARCH: BLOOD-PRESSURE-
MONITORING-
AMBULATORY.MJ. 
[MEDL] 
4. SEARCH: PREGNAN$4.TI,AB. [MEDL] 
5. SEARCH: PREGNANCY.W..MJ. [MEDL] 
6. SEARCH: 1 OR 2 OR 3 [MEDL] 
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7. SEARCH: 4 OR 5 [MEDL] 
8. SEARCH: 6 AND 7 [MEDL] 
9. SEARCH: 8 AND LG=EN [MEDL] 
10. SEARCH: ABPM.TI,AB. [EMED] 
11. SEARCH: (AMBULATORY ADJ 
BLOOD ADJ 
PRESSURE).TI,AB. 
[EMED] 
12. SEARCH: BLOOD-PRESSURE-
MONITORING-
AMBULATORY.MJ. 
[EMED] 
13. SEARCH: PREGNAN$4.TI,AB. [EMED] 
14. SEARCH: PREGNANCY.W..MJ. [EMED] 
15. SEARCH: 10 OR 11 OR 12 [EMED] 
16. SEARCH: 13 OR 14 [EMED] 
17. SEARCH: 15 AND 16 [EMED] 
18. SEARCH: 17 AND LG=EN [EMED] 
 
HYPERTENSION IN 
PREGNANCY GENERAL 
EMBASE 20 09 07 
 
1. SEARCH: HYPERTENSION.TI. [MEDL] 
2. SEARCH: HYPERTENSION.W..MJ. [MEDL] 
3. SEARCH: HYPERTENSION-
PREGNANCY-
INDUCED.MJ. 
[MEDL] 
4. SEARCH: 1 OR 2 OR 3 [MEDL] 
5. SEARCH: PREECLAMP$4.TI. [MEDL] 
6. SEARCH: PRE-ECLAMP$4.TI. [MEDL] 
7. SEARCH: (PRE ADJ ECLAMP$4).TI. [MEDL] 
8. SEARCH: PRE-ECLAMPSIA.MJ. [MEDL] 
9. SEARCH: 5 OR 6 OR 7 OR 8 [MEDL] 
10. SEARCH: 4 OR 9 [MEDL] 
11. SEARCH: PREGNAN$5.TI,AB. [MEDL] 
12. SEARCH: PREGNANCY.W..MJ. [MEDL] 
13. SEARCH: 11 OR 12 [MEDL] 
14. SEARCH: 10 AND 13 [MEDL] 
15. SEARCH: 14 AND LG=EN [MEDL] 
16. SEARCH: 15 AND REVIEW=YES [MEDL] 
17. SEARCH: 15 AND PT=META-
ANALYSIS 
[MEDL] 
18. SEARCH: 15 AND (CLINICAL- [MEDL] 
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TRIALS# OR 
PT=CLINICAL-TRIAL#) 
19. SEARCH: 16 OR 17 OR 18 [MEDL] 
20. SEARCH: HYPERTENSION.TI. [EMED] 
21. SEARCH: HYPERTENSION.W..MJ. [EMED] 
22. SEARCH: MATERNAL-
HYPERTENSION.MJ. 
[EMED] 
23. SEARCH: 20 OR 21 OR 22 [EMED] 
24. SEARCH: PREECLAMP$4.TI. [EMED] 
25. SEARCH: PRE-ECLAMP$4.TI. [EMED] 
26. SEARCH: (PRE ADJ ECLAMP$4).TI. [EMED] 
27. SEARCH: PREECLAMPSIA.W..MJ. [EMED] 
28. SEARCH: 24 OR 25 OR 26 OR 27 [EMED] 
29. SEARCH: 23 OR 28 [EMED] 
30. SEARCH: PREGNAN$5.TI,AB. [EMED] 
31. SEARCH: PREGNANCY.W..MJ. [EMED] 
32. SEARCH: 30 OR 31 [EMED] 
33. SEARCH: 29 AND 32 [EMED] 
34. SEARCH: 33 AND LG=EN [EMED] 
35. SEARCH: 34 AND REVIEW=YES [EMED] 
36. SEARCH: 34 AND PT=META-
ANALYSIS 
[EMED] 
37. SEARCH: 34 AND (CLINICAL-
TRIALS# OR 
PT=CLINICAL-TRIAL#) 
[EMED] 
38. SEARCH: 35 OR 36 OR 37 [EMED] 
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APPENDIX 2: PROFORMA FOR CHAPTER 3 
ABPM PROFORMA         
NUMBER 
 
CASE NO: 
DOB G    P    + AGE RACE CIGS/D ALC/W HT WT BMI 
PREVIOUS HISTORY: 
CHILD DOB 
1. 
GEST 
 
W M PIH 
Y/N 
PET 
Y/N 
MEDICAL PROBLEMS 
1. 
BP PRE PREG 
2.    Y/N Y/N 2. DRUGS AT 
CONCEPTN 
3.    Y/N Y/N 3. METANEPH 
4.    Y/N Y/N 4. IVP USS 
INDEX PREGNANCY: 
LMP 
      /         /         
EDD 
     /        /        US/MP  
BOOKING BP 
      /             @      /40 
BOOKING 
URINE 
ALB/BLD/GLU 
LOC DAT G BP PR PR24 PL UA ALT ALB DRUGS 
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DU ATTENDANCES ABPM MEAN: 
1                        /     / 
 
2                        /     / 
 
3             /     / 
NO OF ADMISSIONS FOR BP TOTAL DAYS INPATIENT 
DATE ADMITTED GESTATION STAY (DAYS) NOTES 
1    
2    
3    
4    
5    
6    
7    
OUTCOMES 
IUGR  Y / N 
         /       / 
ABSENT EDF  Y / N 
        /        / 
REVERSE EDF  Y /N 
       /       / 
OLIGO     Y / N 
       /        / 
ECLAMPSIA  Y / N 
       /        / 
DIC    
Y / N         
    MAG  
   Y / N  
HDU      Y / N 
NO OF DAYS: 
 
LABOUR: 
IOL:  
Y / N 
DOB 
    /      / 
GESTATION MODE INDICATION 
BABY DATA: 
APGAR 1 5 WEIGHT (G) SEX 
M / F 
ALIVE 
Y / N 
NNU:    Y / N 
STAY: 
POSTNATAL: 
6 WKS P/N BP: DRUGS AT 6 WKS FURTHER INFO 
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APPENDIX 3: POSTER FOR TRIAL  
ABPM TRIAL STARTS ON MARCH 11, 2002! 
Who is eligible? 
 Pregnant women aged 16 or over: outpatients or inpatients 
 Diastolic BP of 90 mmHg or more (two readings at least 4 hours apart) 
 No history of diabetes or renal disease 
 Not needing delivery in the next 24 hours 
Why are we doing the study? 
 Ambulatory blood pressure monitoring (ABPM) may give a better assessment of 
BP. This might decrease unnecessary interventions and may also identify women 
at higher risk of poor outcomes. 
What is the study design? 
 All women will have ABPM. Half will be randomized to revealing the results to 
the Obstetric team and half will have results concealed. 
What do I do? 
 Find the purple file in ANC, on the day unit or on wards 4 & 5 
 Give out the patient information leaflet and answer questions 
 If declines, record patient details and reason 
 If agrees, contact Cathy Rhodes to consent the woman for the study 
 Contact the Day Unit to organise ABPM 
 Put purple sticker on outside of hospital notes 
 For every woman put in the study and for any queries, contact:  
Cathy Rhodes, research fellow for ABPM trial 
[Bleep]/[Phone] 
 
THANK YOU VERY MUCH FOR HELPING WITH THIS STUDY! 
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APPENDIX 4: DAY UNIT STAFF: DETAILED 
INSTRUCTIONS FOR ABPM TRIAL PATIENTS 
Patient is eligible if:   
 Any stage of pregnancy, diastolic BP 90 mmHg or more on two readings at least 4 
hours apart 
 Never had ABPM 
 Over 16 years old and no diabetes/renal disease 
 Doesn‟t need delivery in next 24 hours 
Give information sheet (patient to keep this) and answer questions. If doesn‟t agree to take 
part, record name, hospital number and reason for declining. 
 
If agrees to take part:  
 Inform Dr C Rhodes (research fellow) to complete 3 consent forms: one each to 
patient, hospital notes and trial records 
 Allocate patient identification number (PIN) for the trial  
 Note in trial log the date, PIN, name, hospital number, and consultant 
 Put trial sticker on hospital and hand-held notes  
 Arrange ABPM, ideally immediately 
GROUP A (REVEALED): 
 Dr Rhodes will give ABPM results and letter to consultant 
 ABPM results to be filed in notes to ensure this is seen by all; one copy to research 
fellow 
 Can have ABPM again if clinicians wish, organise as normal. 
GROUP B (CONCEALED):   
 Dr Rhodes will contact Consultant by letter to inform 
 Results are kept where no-one will have access. 
 Care continues as normal but not to have ABPM again during pregnancy. 
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APPENDIX 5: PATIENT INFORMATION SHEET 
PATIENT INFORMATION SHEET 
1. Title of study  
„A randomized comparison of ambulatory blood pressure monitoring versus conventional 
office blood pressure measurement in the management of pregnant hypertensive women‟  
 
2. Invitation to take part 
You are being invited to take part in a research study to test a new method of measuring 
blood pressure in pregnant hypertensive women, which means women with high blood 
pressure in pregnancy. Before you decide it is important that you understand why the 
research is done and what it involves. Please read this sheet carefully. Do ask us if anything 
is not clear or if you want to know more. Thank you for reading this.  
 
3. What is the study about? 
Good Hope Hospital wants to try to improve care for pregnant women suffering from high 
blood pressure. High blood pressure affects about one in ten of all pregnant women. They are 
seen more often in clinics and have more admissions to hospital. Some of these women may 
not have high blood pressure at home or under normal conditions and do not need this extra 
care. 
 
Women who truly have high blood pressure can be admitted to hospital for long periods. A 
better way of assessing their blood pressure and the risk to them and their baby would be 
helpful. This might mean less time in hospital for these women.  
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4. What new technique is being studied? 
The new technique we are looking at is called Ambulatory Blood Pressure Monitoring. 
Ambulatory blood pressure monitors are worn on a belt or shoulder strap like a portable tape 
recorder. They automatically measure blood pressure while a woman is at home or work 
during her daily routine, or up and about in hospital. This can give a more realistic record of 
blood pressure. Care in pregnancy may be improved, based on these results. 
 
This method of measuring blood pressure may lead to less interference in the pregnancies of 
some women. This could reduce the number of procedures such as caesarean sections or 
induction of labour (starting labour off using drugs or „breaking the waters‟). In order to test 
this idea, we are doing a research study of ambulatory blood pressure monitoring in 
pregnancy. 
 
5. Why have I been chosen? 
You have been chosen because your blood pressure measurement is raised. If your hospital 
doctor thinks you need to be treated for high blood pressure and delivered in the next 24 
hours you will not take part in the study. 
 
6. Do I have to take part? 
It is up to you to decide. If you do not want to take part your doctors and midwives will 
manage you in the usual way. It will not affect the quality of care you will receive. 
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7. What will happen to me if I take part? 
You will have 24 hours of blood pressure monitoring using the ambulatory monitors.  As we 
don‟t yet know which way of measuring blood pressure is best, we need to make 
comparisons between the current standard blood pressure measurement and the use of the 
new technique. We will do this by dividing women taking part into two groups. 
 
For one group, the doctor will be given the results of the patient‟s ambulatory blood pressure 
recording, which he or she can then use in planning the patient‟s care. For the second group, 
the doctor will not be given the results of the patient‟s ambulatory blood pressure recording.  
In this second group of women, the doctor will only have the clinic blood pressure readings 
to use in planning the patient‟s care. This is the current way of making a blood pressure 
assessment.  
 
After you have had your baby, you will be sent a short questionnaire at home. This is so we 
can get your views about the monitoring. As you are the person undergoing the monitoring it 
is very important for us to have your opinions. 
 
8. How will you decide which group I will be in? 
Which group you are in will be decided by chance, like the toss of a coin, so you will not be 
able to choose a particular group. At the end of the study the results will be analysed to see if 
the new technique does save women from extra interference during their pregnancy. 
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9. What are the benefits and risks? 
The reason for the study is to see if the technique is helpful. As yet we do not know if it is. 
We only think that it may be. The risks are very few. The monitors themselves sometimes 
cause discomfort in the arm when the cuff is blown up to take a measurement. If this 
becomes too uncomfortable then the cuff can be removed. 
 
Your doctors will have all the usual information from the clinic and ward blood pressures to 
look after you. For half of the women entered into the study the hospital doctor will have the 
extra information from the monitoring to base decisions on. Any change in your care will be 
based on extra information and not less. 
 
You may have a worryingly high blood pressure on the ambulatory blood pressure 
monitoring and be in the group where results are not given to your doctor. If this happens 
you will be taken out of the study and the results of the monitoring will be sent to your 
hospital doctor. 
 
10. What happens to the information? 
Your notes and your baby‟s notes will be reviewed as part of the study. The information 
collected for the study will be held in one place. Only your hospital number will identify 
you. All the information will be absolutely confidential and not released to anyone else. 
When the study and its written reports are complete the information will be destroyed. If you 
wish to see your own information at any time this can be sent to you when you ask for it in 
writing. At the end of the study written reports will be sent for publication in the scientific 
medical press. Summary copies will be made available to you if you request them. 
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11. What if something goes wrong?  
If something goes wrong your right to compensation is not affected. You may make any 
complaints in the usual manner through the NHS complaints procedure. 
 
12. What happens now if I decide to take part? 
If you do decide to take part in the study we will ask you to sign a consent form. 
Arrangements will then be made for you to have the ambulatory blood pressure monitoring. 
You will be given a copy of this sheet and a signed consent form to keep. 
 
13. What happens if I change my mind? 
You can change your mind at any time and withdraw from the study. It will not affect your 
care at all, which will carry on in the same way as before the study. All women will receive 
the highest standard of care possible at all times. 
 
14. What if I have more questions? 
If you have more questions then please contact Dr Rhodes, research fellow with Mr D 
Churchill at Good Hope Hospital.  
Contacts and telephone numbers 
Research Fellow at Good Hope Hospital:  
Dr Cathy Rhodes 
Telephone:  0121 378 2211 Ext: 3084, or ask switchboard to page Dr Rhodes 
If you are able to co-operate with this study your help would be most appreciated.  
Thank you for taking time to read this and consider being in the study. 
 
 
Date information sheet completed: 30/8/02 (Version 2) 
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APPENDIX 6: PATIENT CONSENT FORM 
Patient Identification Number for this trial: 
 
CONSENT FORM 
A RANDOMIZED COMPARISON OF AMBULATORY BLOOD PRESSURE 
MONITORING VERSUS CONVENTIONAL OFFICE BLOOD PRESSURE 
MEASUREMENT IN THE MANAGEMENT OF 
PREGNANT HYPERTENSIVE WOMEN 
          Please initial box 
1. I confirm that I have read and understand the information sheet    
dated 30/08/02 for the above study and have had the chance to ask questions. 
2. I understand that my taking part is voluntary and I am free to  
withdraw at any time, without giving any reason, without my medical care  
or legal rights being affected. 
3. I understand that sections of my and my baby‟s medical notes may  
be looked at by medical, midwifery and regulatory authority staff where  
it is relevant to my taking part in research. I give permission for these  
individuals to have access to these records. 
4. I agree to take part in the above study.    
 
_______________________  _______________  _______________ 
Name of patient    Date    Signature 
 
_______________________  _______________  _______________ 
Name of person taking consent   Date    Signature 
(if not researcher) 
 
_______________________  _______________  _______________ 
Researcher    Date    Signature 
 
A signed copy each to patient, researcher and hospital notes. 
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APPENDIX 7: CONSULTANT LETTERS 
 
 
 
 
 
 
 
 
date 
 
Dear  
 
Name  no 
 
The above patient consented to be in the ambulatory blood pressure monitoring study. She 
was allocated to Group A, where her result is revealed. The result is enclosed for your 
information and to be filed with this letter in her hospital notes. If you wish her to have 
further ABPM recordings these would be arranged in the usual way and the results filed in 
her notes routinely. 
 
Thank you very much for your help. 
 
Yours sincerely, 
 
 
 
Dr Cathy Rhodes MRCOG 
Research Fellow  
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Date 
 
Dear  
 
Name  Reg No 
 
The above patient consented to be in the ambulatory blood pressure monitoring study. She 
was randomized to Group B, where her result is concealed. Please file this letter in the 
hospital notes. 
 
Thank you very much for your help. 
 
Yours sincerely, 
 
 
 
Dr Cathy Rhodes MRCOG 
Research Fellow 
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APPENDIX 8: PROFORMA FOR CHAPTER 4 
ABPM TRIAL PROFORMA       CASE NO: 
NUMBER  
 
HOSPITAL DOB AGE ETH 
GRAV PARITY  HT WT BMI CIGS/D CON 
PREVIOUS HISTORY:                                  MEDICAL PROBLEMS 
CHILD DOB 
1. 
GEST 
 
W M PIH 
Y/N 
PET 
Y/N 
1. DRUGS AT 
CONCEPTN 
2.    Y/N Y/N 2. 
3.    Y/N Y/N 3. BOOKING BP 
4.    Y/N Y/N 4. GESTATION 
BOOKED 
INDEX PREGNANCY:                                    No of fetuses: 1 / 2 
LMP 
      /         /         
EDD 
           /           /         
BASIS EDD 
USS / LMP / BOTH 
BOOKING 
URINE 
ALB/BLD/GLU 
MARK TRIAL ENTRY WITH A ‘T’ GROUP ALLOCATION:  A / B 
LOC DAT G BP PR PR24 PL UA ALT ALB DRUGS/SX/ 
NOTES 
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LOC DAT G BP PR PR24 PL UA ALT ALB DRUGS/SX/ 
NOTES 
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
 
NO OF COMMUNITY CLINIC ATTENDANCES 
 
WERE EXTRA CMW VISITS NEEDED FOR BP CHECKS? Y / N 
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 DU 
ATTENDANCES 
ABPM MEAN: 
1                        /     / 
 
2                    /     / 
 
3                       /     
/ 
NO OF ADMISSIONS FOR BP: TOTAL DAYS INPATIENT: 
DATE  
ADM 
DATE 
DISCH 
STAY GEST  NOTES: REASON FOR ADMISSION 
 BLOODS/MAX BP/UR/SX/DRUGS 
1     
2     
3     
4     
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OUTCOMES 
IUGR  Y / N 
         /       / 
ABSENT EDF  Y / N 
        /        / 
REVERSE EDF  Y /N 
       /       / 
OLIGO     Y / N 
       /        / 
ECLAMPSIA  Y / N 
       /        / 
ABRUPT 
Y / N 
DIC 
Y / N 
MAG 
Y / N 
RENAL 
Y / N 
HDU      Y / N 
NO OF DAYS: 
PPH Y / N TRANSFN  Y / N INFECTN  Y / N 
 
LABOUR: ANALGESIA: NIL/NO/PETH/EPID/SPIN 
IOL:  
Y / N 
INDICN METHOD DOB 
    /      / 
GEST MODE INDICATION 
BABY DATA: 
APGAR 
Baby 1 
Baby 2 
1 5 WEIGHT (G) HC LENGTH SEX M / F 
ABG:       pH        BE 
Baby 1 
 
Baby 2 
VBG:     pH           BE 
Baby 1 
 
Baby 2 
ALIVE 
 
NNU:   1       2   
Y/N: 
STAY: 
ITU: 
NNU: 
VENT:1       2 
Y/N: 
DAYS: 
COMPLICATIONS: RDS / NEC / IVH / NEONATAL DEATH 
DATE MOTHER DISCHARGED          
              /          / 
DRUGS @ DISCHARGE 
DATE BABY DISCHARGED           
Baby 1:               /         / 
Baby 2:               /         /      
POSTNATAL:    HOSPITAL / GP 
6 WKS P/N BP: DRUGS AT 6 WKS FURTHER INFO 
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APPENDIX 9: PATIENT QUESTIONNAIRE & LETTER 
 
 
 
 
Date: 
 
Dear  
 
I am writing to thank you again for agreeing to take part in the study on 24-hour ambulatory 
blood pressure monitoring in pregnancy at Good Hope Hospital. Your contribution to this 
research work is greatly appreciated.  
 
We feel it is important that we assess your experience of the monitoring. To do this, we 
would be very grateful if you would take a few minutes to complete the questionnaire 
enclosed with this letter. A stamped addressed envelope is enclosed for your reply. 
 
Thank you again for your help. 
 
Yours sincerely, 
 
 
 
Dr Cathy Rhodes MRCOG 
Research Fellow to Mr Churchill 
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AMBULATORY BLOOD PRESSURE MONITORING QUESTIONNAIRE 
PIN:      
Please circle one answer for each question. 
1. How was the use of your arm while wearing the blood pressure cuff?  
No limits to use / Slightly limited / Moderately limited / Severely limited 
 
2. How did the blood pressure cuff feel on your arm? 
No discomfort / Slight discomfort / Moderate discomfort / Severe discomfort 
 
3. Could you perform normal daily activities during the monitoring? 
No limits to activities / Slightly limited / Moderately limited / Severely limited 
 
4. Did the noise of the monitor disturb you? 
No / Slightly / Moderately / Severely 
 
5. How was your sleep pattern during monitoring? 
Not disturbed / Slightly disturbed / Moderately disturbed / Severely disturbed 
 
6. If 24-hour blood pressure monitoring became a part of routine pregnancy care, would 
you be willing to have it again in a future pregnancy? 
Yes / No 
 
PLEASE USE THE SPACE BELOW TO ADD ANY FURTHER COMMENTS: 
 
 
 
 
Thank you for completing this questionnaire. Please return it in the stamped addressed 
envelope. 
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APPENDIX 10: ETHICAL APPROVAL  
See next two pages. 
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APPENDIX 11: CONSORT STATEMENT 2001 CHECKLIST:  
ITEMS TO INCLUDE WHEN REPORTING A RANDOMIZED TRIAL.      
PAPER 
SECTION 
And topic 
ITEM 
Descriptor Reported on 
Page # 
TITLE & 
ABSTRACT 
1 How participants were allocated to interventions (e.g., 
"random allocation", "randomized", or "randomly 
assigned"). 
Title p 126 
Abstract p 127 
INTRODUCTION 
Background 
2 Scientific background and explanation of rationale. Background in 
Introduction p 128 
Also refers to 
Section 1.4  
METHODS 
Participants 
3 Eligibility criteria for participants and the settings and 
locations where the data were collected. 
Participants p 128 
onwards: Inclusion 
& exclusion 
criteria, setting 
Interventions 4 Precise details of the interventions intended for each 
group and how and when they were actually administered. 
Intervention p 129 
onwards, full 
details  
Objectives 5 Specific objectives and hypotheses. Hypothesis and 
objective 
described p 127 
(Abstract), p 128 
(Background) 
Outcomes 6 Clearly defined primary and secondary outcome measures 
and, when applicable, any methods used to enhance the 
quality of measurements (e.g., multiple observations, 
training of assessors). 
Outcome measures 
in Table 4.1 (p 
133) 
Sample size 7 How sample size was determined and, when applicable, 
explanation of any interim analyses and stopping rules. 
Power calculations 
in Table 4.2 (p 
136) 
Randomization -- 
Sequence 
generation 
8 Method used to generate the random allocation sequence, 
including details of any restrictions (e.g., blocking, 
stratification) 
Described in 
randomization 
section (p 129 on) 
Randomization -- 
Allocation 
concealment 
9 Method used to implement the random allocation 
sequence (e.g., numbered containers or central telephone), 
clarifying whether the sequence was concealed until 
interventions were assigned. 
Described in 
randomization 
section (p 129 on), 
was concealed 
until intervention 
assigned. 
Randomization -- 
Implementation 
10 Who generated the allocation sequence, who enrolled 
participants, and who assigned participants to their 
groups. 
Described in 
randomization 
section (p 129 on) 
Blinding 
(masking) 
11 Whether or not participants, those administering the 
interventions, and those assessing the outcomes were 
blinded to group assignment. If done, how the success of 
blinding was evaluated. 
Described in 
randomization 
section (p 129 on). 
All blinded until 
intervention 
complete as per 
protocol. 
Statistical methods 12 Statistical methods used to compare groups for primary 
outcome(s); Methods for additional analyses, such as 
subgroup analyses and adjusted analyses. 
In statistics section 
p 135. One 
subgroup analysis: 
overall induction 
of labour. 
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PAPER 
SECTION 
And topic 
ITEM 
Descriptor Reported on 
Page # 
RESULTS 
Participant flow 
 
13 Flow of participants through each stage (a diagram is 
strongly recommended). Specifically, for each group 
report the numbers of participants randomly assigned, 
receiving intended treatment, completing the study 
protocol, and analyzed for the primary outcome. Describe 
protocol deviations from study as planned, together with 
reasons. 
Figure 4.2 (p 138) 
shows flow 
diagram of 
participants 
through trial. Text 
p 137, no protocol 
violations. 
Recruitment 14 Dates defining the periods of recruitment and follow-up. Results: p 137 for 
recruitment dates. 
Outcome measures 
ended at delivery. 
6 week follow up 
attempted but poor 
attendance (p 142) 
Baseline data 15 Baseline demographic and clinical characteristics of each 
group. 
Table 4.3 p 139 
Numbers analyzed 16 Number of participants (denominator) in each group 
included in each analysis and whether the analysis was by 
"intention-to-treat". State the results in absolute numbers 
when feasible (e.g., 10/20, not 50%). 
All tables include 
number in 
denominator, 
absolute numbers 
given, page 136 
stated „intention-to 
treat‟. 
Outcomes and 
estimation 
17 For each primary and secondary outcome, a summary of 
results for each group, and the estimated effect size and its 
precision (e.g., 95% confidence interval). 
Tables 4.4, 4.5, 4.6 
summarise groups 
separately, effect 
size with 
confidence 
intervals. 
Ancillary analyses 18 Address multiplicity by reporting any other analyses 
performed, including subgroup analyses and adjusted 
analyses, indicating those pre-specified and those 
exploratory. 
Overall inductions 
analysed (not 
prespecified). No 
other analyses. 
Adverse events 19 All important adverse events or side effects in each 
intervention group. 
Nil occurred. 
Results: p 137 
DISCUSSION 
Interpretation 
20 Interpretation of the results, taking into account study 
hypotheses, sources of potential bias or imprecision and 
the dangers associated with multiplicity of analyses and 
outcomes. 
Multiplicity p 145. 
Discussion 
includes induction  
including 
hypothesis. 
Limitations of 
study discussed. 
Generalizability 21 Generalizability (external validity) of the trial findings. In Statistics 
section p 135 
Discussion p 148 
mentioned issues 
of local staff 
familiarity with the 
technique 
Overall evidence 22 General interpretation of the results in the context of 
current evidence. 
In Discussion 
especially related 
to studies in 
chronic 
hypertension p 151 
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